U.S. patent application number 17/152543 was filed with the patent office on 2021-05-13 for systems and methods for growing cells in vitro.
This patent application is currently assigned to Hi-Tech Park, Edmond J. Safra Campus. The applicant listed for this patent is Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Invention is credited to Yaakov NAHMIAS.
Application Number | 20210139843 17/152543 |
Document ID | / |
Family ID | 1000005355383 |
Filed Date | 2021-05-13 |
![](/patent/app/20210139843/US20210139843A1-20210513\US20210139843A1-2021051)
United States Patent
Application |
20210139843 |
Kind Code |
A1 |
NAHMIAS; Yaakov |
May 13, 2021 |
SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO
Abstract
A system for growing cells comprising a bioreactor chamber for
growing the cells, a delivery system delivering a perfusion
solution to the bioreactor chamber for perfusion of the perfusion
solution through the cells, a dialysis system having a dialyzer, a
dialysate for performing a dialysis and a filter for reducing
ammonia content in said dialysate, and a controller that circulates
the perfusion solution through the dialyzer and the dialysate
through the filter.
Inventors: |
NAHMIAS; Yaakov; (Mevaseret
Zion, IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Yissum Research Development Company of the Hebrew University of
Jerusalem Ltd. |
Jerusalem |
|
IL |
|
|
Assignee: |
Hi-Tech Park, Edmond J. Safra
Campus
Jerusalem
IL
|
Family ID: |
1000005355383 |
Appl. No.: |
17/152543 |
Filed: |
January 19, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16316667 |
Jan 10, 2019 |
|
|
|
PCT/IL2017/050790 |
Jul 11, 2017 |
|
|
|
17152543 |
|
|
|
|
62360495 |
Jul 11, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12M 29/04 20130101;
C12N 2506/1307 20130101; C12M 29/10 20130101; C12N 5/0062 20130101;
C12M 21/00 20130101 |
International
Class: |
C12N 5/00 20060101
C12N005/00; C12M 1/00 20060101 C12M001/00 |
Claims
1. A method of generating a composition comprising a cultured fat
and a plant-derived protein matrix, the method comprising:
culturing an adipocyte cell in vitro to obtain the cultured fat;
and adding the plant-derived protein matrix to the cultured fat,
thereby generating the composition comprising cultured fat and a
plant-derived protein matrix.
2. The method according to claim 1, wherein the adipocyte cell is
generated from a fibroblast.
3. The method of claim 2, wherein the fibroblast is a spontaneously
immortalized fibroblast.
4. The method according to claim 1, wherein the culturing of the
adipocyte cell occurs in a suspension culture.
5. The method of according to claim 1, wherein the culturing of the
adipocyte cell is performed on a plant-derived protein matrix,
thereby generating the cultured fat on the plant-derived protein
matrix.
6. The method according to claim 3, further comprising generating
the adipocyte cell from a spontaneously immortalized fibroblast by
culturing a spontaneously immortalized fibroblast in a serum-free
medium comprising oleic acid and a peroxisome
proliferator-activated receptor gamma (PPAR-gamma) agonist or
activator.
7. The method of claim 6, wherein the PPAR-gamma agonist or
activator is rosiglitazone.
8. The method of claim 6, wherein the spontaneously immortalized
fibroblast is a chicken embryonic fibroblast.
9. The method according to claim 1, wherein the plant-derived
protein matrix comprises at least one plant-derived protein from
the legume (Fabaceae) family, the cereal family, or the
pseudocereal family.
10. The method according to claim 9, wherein the at least one
plant-derived protein is from the legume (Fabaceae) family and is
selected from the group consisting of alfalfa, pea, bean, lentil,
carob, soybean, and peanut proteins and combinations thereof.
11. The method according to claim 10, wherein the at least one
plant-derived protein is a soy protein or a pea protein.
12. The method according to claim 9, wherein the at least one
plant-derived protein is from the cereal family and is selected
from the group consisting of maize, rice, wheat, barely, sorghum,
millet, oats, rye, tritcale, and fonio proteins and combinations
thereof.
13. The method according to claim 9, wherein the at least one
plant-derived protein is from the pseudocereal family and is
selected from the group consisting of buckwheat, quinoa, and chia
proteins and combinations thereof.
14. The method according to claim 1, wherein the plant-derived
protein matrix comprises a soy protein or a pea protein.
15. A composition produced according to the method of claim 1,
wherein the composition is a meat substitute product.
16. A meat substitute product comprising: a cultured fat obtained
from culturing, in-vitro, an adipocyte cell; and a plant-derived
protein matrix.
17. The meat substitute product of claim 16, wherein the adipocyte
cell is generated from a fibroblast.
18. The meat substitute product of claim 17, wherein the fibroblast
is a spontaneously immortalized fibroblast.
19. The meat substitute product of claim 16, wherein the adipocyte
cell is cultured in a suspension medium.
20. The meat substitute product of claim 19, wherein the suspension
medium is a serum-free medium comprising oleic acid and a
peroxisome proliferator-activated receptor gamma (PPAR-gamma)
agonist or activator.
21. The meat substitute product of claim 16, wherein the
plant-derived protein matrix comprises at least one plant-derived
protein from the legume (Fabaceae) family, the cereal family, or
the pseudocereal family.
22. The meat substitute product of claim 21, wherein the at least
one plant-derived protein is from the legume (Fabaceae) family and
is selected from the group consisting of alfalfa, pea, bean,
lentils, carob, soybean, and peanut proteins and combinations
thereof.
23. The meat substitute product of claim 22, wherein the at least
one plant-derived protein is a soy protein or a pea protein.
24. The meat substitute product of claim 21, wherein the at least
one plant-derived protein is from cereal family and is selected
from the group consisting of maize, rice, wheat, barely, sorghum,
millet, oats, rye, tritcale, and fonio proteins and combinations
thereof.
25. The meat substitute product of claim 22, wherein the at least
one plant-derived protein is from the pseudocereal family and is
selected from the group consisting of buckwheat, quinoa, and chia
proteins and combinations thereof.
26. The meat substitute product of claim 16, wherein the
plant-derived protein matrix comprises a soy protein or a pea
protein.
27. The meat substitute product of claim 16, wherein the
spontaneously immortalized fibroblast is a chicken embryonic
fibroblast.
28. A composition for the in-vitro production of cultured fat, the
composition comprising an adipocyte cell; and a serum-free medium,
wherein the adipocyte cell generates the cultured fat.
29. The composition of claim 28, wherein the adipocyte cell is
generated from a spontaneously immortalized fibroblast.
30. The composition of claim 29, wherein the serum free medium
comprises oleic acid and PPAR-gamma agonist or activator.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/316,667, entitled "Systems and Methods for
Growing Cells In Vitro," filed Jan. 10, 2019, which is a 371 of PCT
Application Serial No. PCT/IL2017/050790, entitled "Systems and
Methods for Growing Cells In Vitro," filed Jul. 11, 2017, which
claims the benefit of priority of U.S. Provisional Patent
Application Ser. No. 62/360,495, entitled "Systems and Methods for
Growing Cells In Vitro," filed on Jul. 11, 2016. Each of these
applications is incorporated herein by reference in its
entirety.
SEQUENCE LISTING STATEMENT
[0002] The ASCII file, entitled 76441_ST25.txt, created on Jan. 10,
2019, comprising 29,718,555 bytes, submitted concurrently with the
filing of this application is incorporated herein by reference. The
sequence listing submitted herewith is identical to the sequence
listing forming part of the international application.
FIELD AND BACKGROUND OF THE INVENTION
[0003] The present invention, in some embodiments thereof, relates
to cell growth and, more particularly, but not exclusively, to a
system and a method for growing cells in vitro.
[0004] The current world population is over 7 billion and still
rapidly growing. In order to support the nutritional requirement of
this growing population, increasing amount of land is dedicated for
food production. The natural sources are insufficient to fulfill
the demand. This has led to famine in some parts of the world. In
other parts of the world the problem is being addressed by
large-scale production of animals in dense factory farms under
harsh conditions. This large-scale production is not only causing
great suffering to animals, but in addition, organoarsenic
compounds and antibiotics are used to increase food efficiency and
control infection, increasing arsenic levels and drug-resistance
bacteria in meat products. It can also increase the number of
diseases and the consequences thereof for both animals and humans.
Large scale slaughtering is currently required to fulfill the
current food requirements and as a consequence of large-scale
disease outbreaks such as the occurrence of porcine pestivirus and
mad cows disease. These diseases also result in loss of the meat
for human consumption thus completely denying the purpose for which
the animals were being bred in the first place. In addition the
large-scale production is reducing the flavor of the finished
product. A preference exists among those that can afford it for
non-battery laid eggs and non-battery produced meat. Not only it is
a matter of taste but also a healthier choice thereby avoiding
consumption of various feed additives such as growth hormones.
Another problem associated with mass animal production is the
environmental problem caused by the vast amounts of fecal mater the
animals produce and which the environment subsequently has to deal
with. Also the large amount of land currently required for animal
production or the production of feed for the animals which cannot
be used for alternative purposes such as growth of other crop,
housing, recreation, wild nature and forests.
[0005] Several approaches have been disclosed to address these
problems.
[0006] U.S. Pat. No. 685,390 discloses a non-human tissue
engineered meat product and a method for producing same. The meat
product comprises muscle cells that are grown ex-vivo and is used
for food consumption. The muscle cells may be grown and attached to
a support structure and may be derived from any non-human cells.
The meat product may also comprise other cells such as fat cells or
cartilage cells, or both, that are grown ex-vivo together with the
muscle cells.
[0007] U.S. Pat. No. 7,270,829 discloses a meat product containing
in-vitro produced animal cells in a three dimensional form and a
method for producing the meat product. The method comprises the
culturing in-vitro of animal cells in medium free of hazardous
substances for humans on an industrial scale thereby providing
three dimensional animal tissue suited for human consumption,
wherein the cells are muscle cells, somite cells or stem cells.
[0008] U.S. Pat. No. 8,703,216 discloses methods and engineered
meat products formed as a plurality of at least partially fused
layers, wherein each layer comprises at least partially fused
multicellular bodies comprising non-human myocytes and wherein the
engineered meat is comestible, and wherein the non-human myocytes
are adhered and/or cohered to one another; and the multicellular
bodies are arranged adjacently on a nutrient-permeable support
substrate and maintained in culture to allow the multicellular
bodies to at least partially fuse to form a substantially planar
layer for use in formation of engineered meat.
[0009] U.S. Patent application US2011/0091604 discloses examples of
methods, systems and computer accessible mediums related to
producing synthetic meat, with a substrate configured to support
cell growth, which can be seeded with cells. The seeded substrate
may be rolled through a bioreactor having a roll-to-roll mechanism,
thereby allowing nutrients and growth factors to interact with the
cells. The seeded substrate may be stretched to simulate muscle
action. The seeded substrate may be monitored for uniformity of
cell growth as it is rolled through the bioreactor. A film of
synthetic meat is obtained from the substrate.
[0010] U.S. Patent application US2011/0301249 discloses methods for
producing in-vitro cultured protein products that are enhanced with
stem cells, providing nutrients to an animal by feeding the animal
with the in-vitro cultured protein products.
[0011] WO 2015/066377 discloses methods for enhancing cultured meat
production, such as livestock-autonomous meat production, wherein
the meat can be any metazoan tissue or cell-derived comestible
product intended for use as a comestible food or nutritional
component by humans, companion animals, domesticated or captive
animals whose carcasses are intended for comestible use, service
animals, conserved animal species, animals used for experimental
purposes, or cell cultures.
[0012] U.S. Pat. No. 8,802,361 discloses a perfusion solution
comprising specific metabolic agents, antioxidant agents, and
membrane stabilizer agents that can help improve preservation,
organ viability, and in some cases recover organs that would
otherwise being unusable for transplantation, wherein the perfusion
solution can be used in combination with hypothermic machine
perfusion. It has been found that combination of the perfusion
solution and hypothermic machine perfusion can help prevent or
reduce further damage to the organ and restore the organ's
anti-oxidant system, stabilize the cellular cytoskeleton and
cellular membranes, inhibit arachidonic acid pathway, provide
oncotic support, reduce interstitial edema formation, and help
restore energy stores within the organ.
[0013] One of the main problems of the aforementioned techniques is
the relation between cost, time and quality of the product, with a
long time to produce, at extremely high costs with a mediocre
quality that cannot and will not replace the current meat derived
from livestock.
SUMMARY OF THE INVENTION
[0014] According to an aspect of some embodiments of the present
invention there is provided a system for growing cells, the system
comprising:
[0015] a bioreactor chamber for growing the cells;
[0016] a delivery system configured to deliver a perfusion solution
to the bioreactor chamber for perfusion of the perfusion solution
through the cells at a perfusion rate;
[0017] a dialysis system having a dialyzer and a dialysate for
performing a dialysis and a filter for reducing ammonia content in
the dialysate; and
[0018] a controller configured to circulate the perfusion solution
out of the bioreactor chamber through the dialyzer and back into
the bioreactor chamber, and to circulate the dialysate out of the
dialyzer through the filter and back into the dialyzer.
[0019] According to an aspect of some embodiments of the present
invention there is provided a method of growing cells, the method
comprising:
[0020] growing the cells in a bioreactor chamber;
[0021] delivering a perfusion solution to the bioreactor chamber
for perfusion of the perfusion solution through the cells;
[0022] circulating the perfusion solution out of the bioreactor
chamber through a dialyzer having a dialyzer therein and back into
the bioreactor chamber; and
[0023] circulating the dialysate out of the dialyzer, through a
filter selected for reducing ammonia content in the dialysate, and
back into the dialyzer.
[0024] According to an aspect of some embodiments of the present
invention there is provided a system for growing cells, the system
comprising:
[0025] a bioreactor chamber for growing the cells;
[0026] a delivery system configured to deliver a perfusion solution
to the bioreactor chamber for perfusion of the perfusion solution
through the cells at a perfusion rate;
[0027] a dialysis system having a dialyzer for performing a
dialysis; and
[0028] a controller configured to increase the perfusion rate with
time, and to circulate the perfusion solution out of the bioreactor
chamber, separately through the dialyzer and the delivery system,
and back into the bioreactor chamber;
[0029] wherein at least 90% of a volume of the perfusion solution
that exits the bioreactor chamber is circulated back into the
bioreactor chamber during an entire growth period of the cells.
[0030] According to an aspect of some embodiments of the present
invention there is provided a method of growing cells, the method
comprising:
[0031] growing the cells in a bioreactor chamber;
[0032] delivering by a delivery system a perfusion solution to the
bioreactor chamber for perfusion of the perfusion solution through
the cells at a perfusion rate that increases with time; and
[0033] circulating the perfusion solution out of the bioreactor
chamber separately through a dialyzer and the delivery system, and
back into the bioreactor chamber;
[0034] wherein at least 90% of a volume of the perfusion solution
that exits the bioreactor chamber is circulated back into the
bioreactor chamber during an entire growth period of the cells.
[0035] According to an aspect of some embodiments of the present
invention there is provided a system for growing a suspension cell
culture, the system comprising:
[0036] a bioreactor chamber for growing the suspension cell
culture;
[0037] a delivery system configured to deliver a perfusion solution
to the bioreactor chamber for perfusion of the perfusion solution
through the suspension cell culture at a perfusion rate;
[0038] a dialysis system having a dialyzer for performing a
dialysis; and
[0039] a controller configured to circulate the perfusion solution
out of the bioreactor chamber through the dialyzer and back into
the bioreactor chamber, while maintaining at least 95% of cells
forming the suspension cell culture in the bioreactor chamber
during the circulation.
[0040] According to an aspect of some embodiments of the present
invention there is provided a method of growing a suspension cell
culture, the method comprising:
[0041] growing the suspension cell culture in a bioreactor
chamber;
[0042] delivering a perfusion solution to the bioreactor chamber
for perfusion of the perfusion solution through the suspension cell
culture; and
[0043] circulating the perfusion solution out of the bioreactor
chamber through a dialyzer and back into the bioreactor chamber,
while maintaining at least 95% of cells forming the suspension cell
culture in the bioreactor chamber during the circulation.
[0044] According to an aspect of some embodiments of the present
invention there is provided an adipocyte obtainable according to
the methods of some embodiments of the invention.
[0045] According to an aspect of some embodiments of the present
invention there is provided a method of generating a cultured fat
on a protein matrix, comprising generating the adipocyte cell from
the fibroblast according to the method of some embodiments of the
invention, wherein the culturing is performed on a plant-derived
protein matrix, thereby generating the cultured fat on the protein
matrix.
[0046] According to an aspect of some embodiments of the present
invention there is provided an in-vitro method of generating an
adipocyte cell from a fibroblast, comprising culturing a
spontaneously immortalized fibroblast in a serum-free medium
comprising oleic acid and a PPAR-gamma agonist or activator,
thereby generating the adipocyte cell.
[0047] According to an aspect of some embodiments of the present
invention there is provided a cultured fat in a plant-derived
protein matrix.
[0048] According to an aspect of some embodiments of the present
invention there is provided an in-vitro method of generating a
myocyte from a fibroblast, comprising upregulating expression
within a spontaneously immortalized fibroblast of a polypeptide
selected from the group consisting of myoD1 and myogenin.
[0049] According to an aspect of some embodiments of the present
invention there is provided a myocyte obtainable according to the
methods of any one of claims 57-62.
[0050] According to an aspect of some embodiments of the present
invention there is provided an in-vitro method of screening for a
small molecule capable of producing a myocyte, comprising:
[0051] (a) transfecting a spontaneously immortalized fibroblast
with a nucleic acid construct comprising a nucleic acid sequence
encoding a reporter polypeptide under a transcriptional control of
a promoter specifically active in myocytes,
[0052] (b) contacting a transfected fibroblast resultant of step
(a) with at least one small molecule of a plurality of small
molecules, and
[0053] (c) detecting activity of the reporter polypeptide above a
pre-determined threshold in the transfected fibroblast following
step (b), wherein presence of the activity above the pre-determined
threshold is indicative that the at least one small molecule is
capable of converting the spontaneously immortalized fibroblast
into the myocyte.
[0054] According to an aspect of some embodiments of the present
invention there is provided an in-vitro method of generating an
edible meat, comprising culturing:
[0055] (a) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
an adipocyte, and/or
[0056] (b) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
a myocyte, thereby generating the edible meat.
[0057] According to an aspect of some embodiments of the present
invention there is provided an in-vitro method of generating an
edible meat, comprising culturing:
[0058] (a) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
an adipocyte, and/or
[0059] (b) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
a myocyte,
[0060] (c) an endothelial cell,
thereby generating the edible meat.
[0061] According to an aspect of some embodiments of the present
invention there is provided an edible meat obtainable from the
method of any one of claims 67-81.
[0062] According to an aspect of some embodiments of the present
invention there is provided a method of generating a spontaneously
immortalized fibroblast, comprising:
[0063] (a) culturing avian embryo cells in the presence of a
serum-containing medium under adherent culture conditions to
thereby obtain chicken embryonic fibroblasts,
[0064] (b) passaging the avian embryonic fibroblasts for at least
10-12 passages in the serum-containing medium under the adherent
conditions until culture collapse, wherein the culture collapse is
characterized by senescence and/or death of at least 90% of the
avian embryonic fibroblasts,
[0065] (c) isolating at least one colony which survived the culture
collapse in the serum-containing medium for at least additional 20
passages,
thereby generating the spontaneously immortalized fibroblast.
[0066] According to an aspect of some embodiments of the present
invention there is provided a spontaneously immortalized chicken
fibroblast obtainable by the method of some embodiments of the
invention.
[0067] According to some embodiments of the invention, at least 90%
of a volume of the perfusion solution that exits the bioreactor
chamber is circulated back into the bioreactor chamber during an
entire growth period of the cells
[0068] According to some embodiments of the invention, the cells
form a tissue.
[0069] According to some embodiments of the invention, the cells
form a cultured meat product.
[0070] According to some embodiments of the invention, the dialyzer
comprises a filter selected to reduce ammonia content of the
perfusion solution.
[0071] According to some embodiments of the invention, the
perfusion rate increases over time.
[0072] According to some embodiments of the invention, the
increment is exponential.
[0073] According to some embodiments of the invention, there is a
plurality of bioreactor chambers, all being in fluid communication
with the same dialyzer, and wherein the dialyzer applies the
dialysis to perfusion solutions circulated out of each of the
bioreactor chambers.
[0074] According to some embodiments of the invention, the dialyzer
is configured to ensure that at least one protein exiting the
bioreactor chamber with the perfusion solution is circulated back
into the bioreactor chamber.
[0075] According to some embodiments of the invention, the at least
one protein is albumin.
[0076] According to some embodiments of the invention, there is
from about 0.1 liters to about 10 liters of the perfusion solution
per one kilogram of cells in the bioreactor chamber.
[0077] According to some embodiments of the invention, there is
from about 0.1 liters to about one liter of the perfusion solution
per one kilogram of cells in the bioreactor chamber.
[0078] According to some embodiments of the invention, the delivery
of the perfusion solution is via a fluidic circuit constituted to
enrich the perfusion solution by a culture medium and oxygen.
[0079] According to some embodiments of the invention, the fluidic
circuit is constituted to enrich the perfusion solution also by
carbon dioxide.
[0080] According to some embodiments of the invention, the fluidic
circuit is constituted to trap or remove bubbles present in the
perfusion solution.
[0081] According to some embodiments of the invention, the fluidic
circuit is constituted to heat the perfusion solution.
[0082] According to some embodiments of the invention, the delivery
and the circulation is without discarding the perfusion solution
throughout the cell growth.
[0083] According to some embodiments of the invention, the cells
form a cultured meat product and wherein the bioreactor chamber is
at most 5 liters in volume.
[0084] According to some embodiments of the invention, the
bioreactor chamber is at most 5 liters in volume.
[0085] According to some embodiments of the invention, the
fibroblast is an avian fibroblast.
[0086] According to some embodiments of the invention, the avian is
selected from the group consisting of: chicken, duck, goose, and
quail.
[0087] According to some embodiments of the invention, the
fibroblast is a chicken embryonic fibroblast.
[0088] According to some embodiments of the invention, the
spontaneously immortalized fibroblast is non-genetically
modified.
[0089] According to some embodiments of the invention, the
PPAR-gamma agonist or activator is a small molecule.
[0090] According to some embodiments of the invention, the small
molecule is selected from the group consisting of
Thiazolidinedione, 3-Isobutyl-1-methylxanthine (IBMX), phenamil,
GW7845, RG14620, and Harmine.
[0091] According to some embodiments of the invention, the small
molecule is rosiglitazone.
[0092] According to some embodiments of the invention, the
serum-free medium is devoid of animal contaminants.
[0093] According to some embodiments of the invention, the
serum-free medium is devoid of human contaminants.
[0094] According to some embodiments of the invention, the
serum-free medium comprises insulin or a substitute thereof, and
basic fibroblast growth factor (bFGF) or a substitute thereof, and
at least one additional agent selected from the group consisting of
dexamethasone, transferrin, selenium, EGF or a substitute thereof,
and PGE2.
[0095] According to some embodiments of the invention, the
substitute of the insulin comprises IGF-1 or a stabilized Long R3
IGF-1
[0096] According to some embodiments of the invention, the
substitute of the EGF comprises an EGF-R agonist.
[0097] According to some embodiments of the invention, the EGF-R
agonist comprises NSC-228155 at a concentration of 5-50 ng/ml.
[0098] According to some embodiments of the invention, the
substitute of the bFGF is a small molecule or a synthetic agonist
of the FGF-signaling pathway.
[0099] According to some embodiments of the invention, the
synthetic agonist is C19-jun at a concentration of 10-20 ng/ml.
[0100] According to some embodiments of the invention, the
dexamethasone is provided at a concentration range of 0.01 nM-10
.mu.M.
[0101] According to some embodiments of the invention, the bFGF is
provided at a concentration range of 0.1-30 ng/ml.
[0102] According to some embodiments of the invention, the EGF is
provided at a concentration range of 0.1-30 ng/ml.
[0103] According to some embodiments of the invention, the PGE2 is
provided at a concentration range of 0.01 nM-10 .mu.M.
[0104] According to some embodiments of the invention, the
plant-derived protein matrix is from the legume (Fabaceae) family,
from the cereal family or from the pseudocereal family.
[0105] According to some embodiments of the invention, the
plant-derived protein matrix comprises a soy protein or a pea
protein.
[0106] According to some embodiments of the invention, the cultured
fat of some embodiments of the invention is obtainable by the
method of some embodiments of the invention.
[0107] According to some embodiments of the invention, the
upregulation is of the myoD1 and myogenin polypeptides.
[0108] According to some embodiments of the invention, the chicken
myoD1 polypeptide is encoded by a polynucleotide comprising the
nucleic acid sequence set forth by SEQ ID NO:5.
[0109] According to some embodiments of the invention, the chicken
myogenin polypeptide is encoded by a polynucleotide comprising the
nucleic acid sequence set forth by SEQ ID NO:7.
[0110] According to some embodiments of the invention, the chicken
myoD1 polypeptide is encoded by the nucleic acid construct set
forth by SEQ ID NO: 1 or 3.
[0111] According to some embodiments of the invention, the chicken
myogenin polypeptide is encoded by the nucleic acid construct set
forth by SEQ ID NO: 2.
[0112] According to some embodiments of the invention, the
serum-free medium comprises oleic acid and a PPAR-gamma
agonist.
[0113] According to some embodiments of the invention, the
endothelial cell is a spontaneously immortalized endothelial
cell.
[0114] According to some embodiments of the invention, the
endothelial cell is non-genetically modified.
[0115] According to some embodiments of the invention, step (a) and
step (b) are effected simultaneously in the same culture
system.
[0116] According to some embodiments of the invention, step (a) and
step (b) are effected in two distinct culture systems.
[0117] According to some embodiments of the invention, steps (a),
(b) and (c) are effected simultaneously in the same culture
system.
[0118] According to some embodiments of the invention, the
culturing is performed on a scaffold.
[0119] According to some embodiments of the invention, the
culturing is performed in a perfusion system.
[0120] According to some embodiments of the invention, the
culturing is performed on an edible hollow fiber cartridge.
[0121] According to some embodiments of the invention, the
culturing is performed on a vegetable-derived matrix.
[0122] According to some embodiments of the invention, the
vegetable-derived matrix is from a cereal family, legume (Fabaceae)
family or a pseudocereal family.
[0123] According to some embodiments of the invention, the legume
is soy or pea.
[0124] According to some embodiments of the invention, the
culturing is performed in a suspension culture devoid of substrate
adherence.
[0125] According to some embodiments of the invention, the
culturing is performed in the system of some embodiments of the
invention.
[0126] According to some embodiments of the invention, the edible
meat of some embodiments of the invention is in a form of a patty
or nugget with a density of about 200.times.10.sup.6
cells/gram.
[0127] According to some embodiments of the invention, the
serum-containing medium is a DMEM/F12 based medium.
[0128] According to some embodiments of the invention, the serum in
the medium comprises about 15% fetal bovine serum (FBS).
[0129] According to some embodiments of the invention, the chicken
embryo is obtained from a fertilized broiler chicken egg grown for
10-12 days.
[0130] According to some embodiments of the invention, the
spontaneously immortalized chicken fibroblast of some embodiments
of the invention being capable of a continuous passaging for at
least 30 passages.
[0131] According to some embodiments of the invention, the
spontaneously immortalized chicken fibroblast of some embodiments
of the invention being capable of at least 90 population
doublings.
[0132] Unless otherwise defined, all technical and/or scientific
terms used herein have the same meaning as commonly understood by
one of ordinary skill in the art to which the invention pertains.
Although methods and materials similar or equivalent to those
described herein can be used in the practice or testing of
embodiments of the invention, exemplary methods and/or materials
are described below. In case of conflict, the patent specification,
including definitions, will control. In addition, the materials,
methods, and examples are illustrative only and are not intended to
be necessarily limiting.
[0133] Implementation of the method and/or system of embodiments of
the invention can involve performing or completing selected tasks
manually, automatically, or a combination thereof. Moreover,
according to actual instrumentation and equipment of embodiments of
the method and/or system of the invention, several selected tasks
could be implemented by hardware, by software or by firmware or by
a combination thereof using an operating system.
[0134] For example, hardware for performing selected tasks
according to embodiments of the invention could be implemented as a
chip or a circuit. As software, selected tasks according to
embodiments of the invention could be implemented as a plurality of
software instructions being executed by a computer using any
suitable operating system. In an exemplary embodiment of the
invention, one or more tasks according to exemplary embodiments of
method and/or system as described herein are performed by a data
processor, such as a computing platform for executing a plurality
of instructions. Optionally, the data processor includes a volatile
memory for storing instructions and/or data and/or a non-volatile
storage, for example, a magnetic hard-disk and/or removable media,
for storing instructions and/or data. Optionally, a network
connection is provided as well. A display and/or a user input
device such as a keyboard or mouse are optionally provided as
well.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0135] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the Office
upon request and payment of the necessary fee.
[0136] Some embodiments of the invention are herein described, by
way of example only, with reference to the accompanying drawings.
With specific reference now to the drawings in detail, it is
stressed that the particulars shown are by way of example and for
purposes of illustrative discussion of embodiments of the
invention. In this regard, the description taken with the drawings
makes apparent to those skilled in the art how embodiments of the
invention may be practiced.
[0137] FIGS. 1A and 1B are schematic illustrations of a system
suitable for growing cells according to some embodiments of the
present invention.
[0138] FIGS. 2A-E demonstrate the derivation of a spontaneously
immortalized line of chicken embryonic fibroblasts. FIG.
2A--Broiler chicken embryo extracted from fertilized egg on day 11.
FIG. 2B--morphology of primary chicken embryonic fibroblasts (CEF)
after 1 population doubling ("PD 1"). FIG. 2C--Morphology of
spontaneously immortalized chicken fibroblasts (CSIF) post crisis
(after 90 population doublings ("PD 90"). FIG. 2D--Growth kinetics
of CSIF cultured in 15% serum (FBS, black curve), serum-free medium
as described in Example 5 of the Examples section which follows
("SFM", red curve) and commercially available TheraPEAK.TM. (LONZA
WALKERSVILLE, INC. Walkersville, Md., 217930127) medium ("T-PEAK",
green curve). FIG. 2E--Doubling time of CSIF cultured in 15% serum
(FBS, black column), serum-free medium as described in Example 6 of
the Examples section which follows ("SFM", red column) and
commercially available TheraPEAK.TM. (LONZA WALKERSVILLE, INC.
Walkersville, Md., 217930127) medium ("T-PEAK", green column). Note
that the immortalized chicken fibroblast cell line (CSIF) exhibit
the same growth kinetics and doubling time in the presence of
serum-free medium formulation uncovered by the present inventor (as
described in Example 6 of the Examples section which follows) when
compared to the serum-containing medium. Also note that the
commercially available TheraPEAK.TM. (LONZA WALKERSVILLE, INC.
Walkersville, Md., 217930127) failed to support the expansion of
the CSIF cells (FIG. 2D), and the cells cultured therein exhibit an
elongated doubling time of 40 hours as compared to less than 20
hours in either the serum-containing medium of the SFM of some
embodiments of the invention.
[0139] FIGS. 3A-F depict the development and identification of
serum-free medium for CSIF propagation. Shown are sulforhodamine B
stain (FIGS. 3A-E) and protein content quantification (FIG. 3F)
following 72 hours of culture with 15% serum ("FBS"), minimal
serum-free medium (MIN) alone (FIG. 3B) or with 10 ng/ml basic
Fibroblast Growth Factor (bFGF, FIG. 3C), 5 ng/ml Epidermal Growth
Factor (EGF, FIG. 3D), 0.01 .mu.M Prostaglandin E2 (PGE2, FIG. 3E),
or 10 ng/ml Growth Hormone. Serum-free medium (SFM) contained MIN
medium supplemented with bFGF (10 ng/ml), EGF (5 ng/ml), and PGE2
(0.01 M). "MIN" medium included: DMEM/F12, 0.1 .mu.M dexamethasone,
insulin, transferrin, and selenium (ITS), 12 .mu.M linoleic and
oleic acids, and L-Analyl-L-Glutamine. (GlutaMAX); Note that the
cells cultured in the SFM exhibit a similar cell mass (as
determined by protein content) as the cells cultured in a medium
supplemented with 15% FBS.
[0140] FIGS. 4A-D depict conversion of CSIF to adipocytes in
serum-free medium. FIGS. 4A-C. LipidTOX.TM. (Thermo Fisher
Scientific) neutral lipid stain of serum-free cultures of CSIF
exposed to either 400 .mu.M oleic acid (OA) alone (FIG. 4A) or with
0.5 mM IBMX (OA+IBMX, FIG. 4B), or 10 .mu.M Rosiglitazone (OA+TZD,
FIG. 4C) for 7 days. Both small molecules show strong adipogenesis
in the presence of OA. FIG. 4D--Normalized intracellular lipid
content (in arbitrary fluorescent units) of CSIF cultures treated
for 4 and 7 days as prescribed above. 400 .mu.M OA with small
molecules IBMX or TZD show optimal results.
[0141] FIGS. 5A-E depict conversion of CSIF to myocytes. FIG.
5A--Phase image of CSIF expressing Dox-inducible MyoD1 and Myogenin
(MYOG) for 6 days ("d6"). FIGS. 5B-C--CSIF expressing rat myosin
light chain COP-GFP reporter (rMLC3-GFP) following Dox-induced
MyoD1+MYOG expression for 11 days (FIG. 5B) or 30 days (FIG. 5C).
About 2-4% of the cultures become positive for MLC3 (Green). MLC3
positive myoblasts maintain elongated fiber morphology for over 30
days in vitro (FIG. 5C). FIG. 5D--Fluorescence staining using
phalloidin (F-Actin probe, green) showing multinucleated cells
(syncytia) as well as some striation following 7 days in culture.
Nuclei are stained with Hoechst (blue). FIG. 5E--Immunofluorescence
staining for .alpha.1-skeletal muscle actin (ACTA1, green) and
Troponin T (red) showing a clear muscle phenotype by day 7 of
induction. Nuclei are stained with Hoechst (blue).
[0142] FIG. 6 is a schematic illustration of the
pinducer-VP64-cMyoD1 nucleic acid construct used to express chicken
MyoD1 in a spontaneously immortalized fibroblast under
Dox-induction. Shown are the "central polypurine tract/central
termination sequence" (CPPT/CTS) element (in orange), which creates
a "DNA flap" that increases nuclear importation of the viral genome
during target cell infection and improves vector integration and
transduction efficiency); the tetracycline response element (in
pink); the VP64 transcriptional activator (in peach); the HA
epitope tag (in yellow); and the cMYOD1 coding sequence (in light
blue).
[0143] FIG. 7 is a schematic illustration of the
pInducer20-cMyogenin nucleic acid construct used to express the
chicken myogenin in a spontaneously immortalized fibroblast under
Dox-induction. Shown are the "central polypurine tract/central
termination sequence" (CPPT/CTS) element (in light peach), the
tetracycline response element (in Turquoise); the minimal CMV
promoter (white arrow head); and the cMyogenin coding sequence (in
light blue).
[0144] FIG. 8 is a schematic illustration of the rat MLC3
enhancer-promoter in pGreenFire lentiviral vector used to show the
conversion of a spontaneously immortalized fibroblast into a
myocyte. Shown are the central polypurine tract" (CPPTS) element
(in yellow); the rat MLC3 enhancer (in light blue); the rat MLC3
promoter (in orange) and the COP GFP coding sequence (in green). It
is noted that this vector can be used to screen for small molecules
capable of converting a spontaneously immortalized fibroblast into
a myocyte.
[0145] FIG. 9 is a schematic illustration of a system suitable for
growing cells as designed in a prototype design, according to some
embodiments of the present invention.
[0146] FIGS. 10A and 10B are graph showing the produce mass and
applied perfusion rates (FIG. 10A), and accumulated glucose
consumption (FIG. 10B), as obtained in experiments performed
according to some embodiments of the present invention.
[0147] FIGS. 11A-C depict tissue formation and vascularization.
FIG. 11A--Sulforhodamine B stain of 3D collagen scaffolds loaded
with 150.times.10.sup.6 spontaneously immortalized chicken
fibroblasts (CSIF) and 15.times.10.sup.6 spontaneously immortalized
rat microvascular endothelial cells (RCEC) per millimeter of
volume. FIG. 11B--Phase image of 3D scaffolds loaded with high
density of CSIF and RCEC co-culture following 11 days of perfusion
in a bioreactor. FIG. 11C--Confocal cross-section of 3D scaffolds
loaded with RCEC (red label) and iPS-derived cells (green) showing
vascular network formation and close cell-cell interactions
following 11 days of perfusion in a bioreactor.
[0148] FIG. 12 a schematic illustration of the pInducer20-cMyoD1
nucleic acid construct used to express the chicken MyoD1 in a
spontaneously immortalized fibroblast under Dox-induction. Shown
are the "central polypurine tract/central termination sequence"
(CPPT/CTS) element (in light peach), the tetracycline response
element (in Turquoise); the minimal CMV promoter (white arrow
head); and the cMyoD1 coding sequence (in orange).
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
[0149] The present invention, in some embodiments thereof, relates
to cell growth and, more particularly, but not exclusively, to a
system and a method for growing cells in vitro.
[0150] The present inventor has described a system for culturing
cells which can be used, in some embodiments of the present
invention, for generating edible meat.
[0151] Chicken meat has been a major source of dietary protein
since the dawn of the agricultural revolution. Production has
traditionally been local, with families and later small villages
growing their own grain-fed animals. However, rapid urbanization
and population growth driven by the industrial revolution led to
the development of intensive farming methods. Factory farms now
produce close to 9 billion chickens each year in the United States,
with animal growth and transportation producing 18% of current
greenhouse emissions. It was recognized by the present inventor
that large amount of chicken meat (e.g., over 70% in the United
States) contains unsafe levels of arsenic, and antibiotic resistant
bacteria. It was also recognized by the present inventor that
transportation and animal density lead to widespread fecal
contamination of chicken meat leading to increased salmonella
infection.
[0152] Laboratory-grown meat allows growing meat from animal cells
under sterile conditions. It was find by the present inventor that
it is possible to produce a sufficient amount of cells per unit
mass of meat product (e.g., from about 500 to about
200.times.10.sup.6 cells per gram), without the use of animal
products, such as fetal bovine serum. However, while many cell
culture techniques have been developed over the past 50 years for
biological research, the present inventor found that such culture
techniques are incredibly wasteful, requiring a large volume of
culture medium to produce a small mass of laboratory-grown meat.
For example, known techniques require a volume of about 230 liter
of to produce about 1 Kg of meat, translating to a cost of at least
$4,600 per Kg due to medium costs alone.
[0153] For purposes of better understanding some embodiments of the
present invention, the construction and operation of industrial
scale cell manufacturing techniques will be described.
[0154] Known in the art are several industrial scale cell
manufacturing techniques. These include a 10,000 liter fed-batch
process, and a 1,000 liter concentrated perfusion process. Typical
media cost at current prices is estimated at about $20 per liter L
for fed-batch processes and about $5 per liter for concentrated
perfusion processes. For ideal CHO cells, the fed-batch processes
allow achieving cell densities of about 25.times.10.sup.6 cells/ml,
and the concentrated perfusion processes allow achieving cell
densities of about 100.times.10.sup.6 cells/ml. These cell
densities mean that a 10,000 liter fed batch reactor can produce
1,250 kg mass every 19 days, while a 1,000 liter perfusion reactor
can produce 500 kg mass every 30 days. The fed batch process
consumes 12,500 liter medium including the seed train, while the
perfusion process consumes 2,120 liters medium. These numbers
translate to $200 per kg mass for fed batch process and $21 per kg
mass for perfusion process for the culture medium costs alone.
[0155] It is recognized that consumable costs are often less than a
third of the cost of good. One parameter is the capital costs.
10,000 liter fed batch facilities are known to cost of $50 million
or more, and 1,000 perfusion facilities are known to cost $30
million or more. Assuming a liberal 10% annual depreciation and
maintenance costs, an industrial scale 10,000 fed batch facility
can produce 24,000 kg per year at an annual maintenance cost of
about $5,000,000, resulting in a capital cost of $200 per kg mass
produced. An industrial scale 1,000 perfusion facility can produce
6,000 kg per year at an annual maintenance cost of about
$3,000,000, resulting in a capital cost of about $500 per kg mass
produced.
[0156] The present inventor devised a cell growing technique that
outperforms these conventional processes.
[0157] Before explaining at least one embodiment of the invention
in detail, it is to be understood that the invention is not
necessarily limited in its application to the details of
construction and the arrangement of the components and/or methods
set forth in the following description and/or illustrated in the
drawings and/or the Examples. The invention is capable of other
embodiments or of being practiced or carried out in various
ways.
[0158] FIGS. 1A and 1B are schematic illustrations of a system 1000
suitable for growing cells 302 according to some embodiments of the
present invention. System 1000 can be used form growing many types
of cells. In some embodiments of the present invention cells 302
form a suspension culture, useful, for example, for cellular
therapy or for protein or vaccine production, in some embodiments
of the present invention cells 302 form a tissue, useful, for
example, for tissue transplantation, and in some embodiments of the
present invention cells form a cultured meat.
[0159] System 1000 preferably comprises a bioreactor chamber 300
for growing the cells 302 therein, a delivery system 100 configured
to deliver a perfusion solution to bioreactor chamber 300 for
perfusion of the perfusion solution through the cells, and a
dialysis system 200 having a dialyzer 20 and a dialysate 22 for
performing a dialysis to exchange nutrient and byproduct.
Bioreactor chamber 300 can employ any technique for growing cells,
including, without limitation, a hollow fiber cartridge, a packed
bed, or a vascularized embedded tissue configuration. The perfusion
of the perfusion solution through the cells is optionally and
preferably continuous. In some embodiments of the present
invention, at the end of the growth cycle there are from about 0.1
liters to about 10 liters, e.g., 1 liter, of perfusion solution per
one kilogram of cells in the bioreactor chamber. Bioreactor chamber
300 can have any size but in preferred embodiments of the present
invention bioreactor chamber 300 is at most 5 liters, e.g., from
about 1 liter to about 5 liters, in volume. These embodiments are
particularly useful when system 1000 comprises a plurality of
bioreactor chambers as further detailed hereinbelow. Bioreactor
chamber 300 can typically facilitate growth of muscle tissue, from
an initial amount of about 20 mg to a consumable amount of at least
500 grams, e.g., 1000 grams or more.
[0160] System 1000 preferably operates in a generally closed loop
fluidic mode, wherein the perfusion solution exits bioreactor
chamber 300 through one or more outlet ports 308 into delivery
system 100 and dialysis system 200, treated in these systems and
then returns back into bioreactor chamber 300 through one or more
inlet ports 306. The operation is referred to as "a close loop
operation" in the sense that the perfusion solution itself is not
discarded. Thus, system 1000 is optionally and preferably devoid of
any mechanism for removing the perfusion solution out of system
1000 into an external waste removal device, and devoid of any
mechanism that increases the amount of perfusion solution during
the operation. It is to be understood, however, that the contents
of the perfusion solution are changed during operation by
interacting with systems 100 and 200. In various exemplary
embodiments of the invention wherein at least 90% or at least 92%
or at least 94% or at least 96% or at least 98% of a volume of the
perfusion solution that exits bioreactor chamber 300 (either to
system 100 or to system 200) is circulated back into bioreactor
chamber 300 at all times over a period of at least 4 days or at
least 5 days or at least 6 days or at least 7 days or at least 8
days or at least 9 days or at least 10 days or at least 12 days or
at least 14 days or at least 16 days or at least 18 days or at
least 20 days, or during the entire growth cycle of cells 302.
[0161] System 1000 optionally and preferably comprises a controller
304 for controlling delivery system 100, dialysis system 200 and/or
bioreactor chamber 300. Controller 304 optionally and preferably
comprises a circuit configured for performing the various
operations described herein. In some embodiments of the present
invention controller 304 is a computerized controller.
Representative control lines from controller are shown as dotted
lines. One of ordinary skills in the art, provided with the details
described herein would know how to construct control lines between
controller 304 and other controllable components of system
1000.
[0162] In some embodiments of the present invention controller 304
circulates the perfusion solution out of bioreactor chamber 300
through dialyzer 20 and back into bioreactor chamber 300. This can
be achieved by means of a pump 21 which is controlled by controller
304. In various exemplary embodiments of the invention the
circulation is executed while maintaining at least 95% or at least
96% or at least 97% of the cells 302 in bioreactor chamber 300
during the circulation. Preferably, dialyzer 20 is configured to
ensure that at least one protein (e.g., albumin), more preferably
all proteins, exiting bioreactor chamber 300 with the perfusion
solution is circulated back into bioreactor chamber 300. This can
be done for example, by providing a membrane dialyzer with a
membrane that ensures that the respective protein (such as, but not
limited to, albumin, with a molecular weight of about 66.5 kDa) is
circulated back to bioreactor chamber 300 without entering the
dialysate 22 of dialysis system 200. The advantage of this
embodiment is that albumin is a carrier protein of growth factors,
hormones, and fatty acids, and can therefore facilitate growth of
cells 302 for at least a period that equals its characteristic
half-life (about 20 days). This significantly reduces the
production cost of the cells since albumin, hormones, and growth
factors are the main cost driver of culture media.
[0163] In various exemplary embodiments of the invention a filter
is employed in dialysis system 200 to remove ammonia from the
portion of the perfusion solution that enters dialysis system 200.
This can be achieved by providing dialysis system 200 with a filter
24 selected for reducing ammonia content in dialysate 22. In these
embodiments, controller 304 optionally and preferably circulates
dialysate 22 out of dialyzer 20 through filter 24 and back into
dialyzer 22, for example, by controlling a pump 23 in dialysis
system 200. Ammonia is a product of peptide degradation and
glutamine breakdown. Ammonia become toxic and limits cell growth
when it reaches 5 mM concentration. The close loop operation of the
present embodiments preferably separates the protein-containing
medium from the protein-free dialysate that can be scrubbed of
ammonia without losing protein to non-specific absorption. Suitable
for the present embodiments are filters such as, but not limited
to, packed Zeolites particles or carbon meshes. Zeolite-based
oxygen concentrator systems are widely used to produce
medical-grade oxygen. The zeolite is used as a molecular sieve to
create purified oxygen from air using its ability to trap
impurities, in a process involving the adsorption of nitrogen,
leaving highly purified oxygen and clearing ammonia from the
solution.
[0164] System 1000 preferably operates in cycles, wherein the cell
growth is initiated at the beginning of the cycle, and the grown
cells are taken out of the chamber to provide a cellular product
(suspension culture, tissue, cultured meat) at the end of the
cycle. Typically, a 10 day cycle is employed but other cycle
durations are also contemplated. In some embodiments of the present
invention controller 304 ensures that the perfusion rate within
bioreactor chamber 300 increases over time during the operation
cycle. Preferably, the increment is exponential. The increment of
the perfusion rate need not to be continuous, albeit a continuous
increment of the perfusion rate is also contemplated. For example,
the perfusion rate can be increased intermittently at certain days
during the operation cycle. Typically, but not necessarily, the
first increment is effected several days after the beginning of the
cycle. At the end of the cycle, the perfusion rate is preferably at
least 20 ml/s or at least 25 ml/s or at least 30 ml/s or at least
35 ml/s, e.g., 36 ml/s or more.
[0165] Referring again to FIGS. 1A-B, the delivery of the perfusion
solution is optionally and preferably via a fluidic circuit 102,
which is optionally and preferably controlled by controller 304,
for example, by means of a pump 11 in delivery system 100, and is
constituted to enrich the perfusion solution by a culture medium
and one or more gaseous media, such as, but not limited to, oxygen,
carbon dioxide and nitrogen. This is optionally and preferably
achieved by means of a culture medium reservoir 10 that enriches
the perfusion solution by the culture medium, and a mass transfer
device 12 such as, but not limited to, an oxygenator or the like,
that enriches the perfusion solution by one or more gaseous media.
Typically, mass transfer device 12 provides a mixture of Oxygen
from about 21% to about 95%, Carbon dioxide from about 0% to about
10% and balanced to 100% by Nitrogen. Preferably, mass transfer
device 12 maintains a generally constant (e.g., with 10% or less
tolerance) pH. In a representative example, which is not to be
considered as limiting, mass transfer device 12 provides a mixture
of about 80% Oxygen about 5% Carbon dioxide and about 15%
Nitrogen.
[0166] Optionally, fluidic circuit 102 is constituted to trap or
remove bubbles present in the perfusion solution. This can be
achieved by means of a bubble handling device 12 that may include a
bubble trap and/or a debubbler. The advantage of trapping or
removing the bubbles is that bubbles that inadvertently introduced
into the bioreactor chamber 300 can negatively affect the operation
of system 1000 since bubbles are cytotoxic to cells and can
potentially rupture their cell membranes, and so trapping or
removing the bubbles can improves the performance of system 1000.
In some embodiments of the present invention fluidic circuit 102 is
also constituted to heat the perfusion solution, optionally and
preferably before the perfusion solution enters the bioreactor
chamber 300.
[0167] System 1000 can comprise more than one bioreactor chamber
300. This preferred embodiment is illustrated in FIG. 1B. Shown are
several bioreactor chambers, each being optionally and preferably
similar to bioreactor chamber 300 as described herein, and several
delivery systems, each being optionally and preferably similar to
delivery system 100 as described herein, wherein each delivery
system circulates, for example, by means of pump 11, the perfusion
solution through one of the bioreactor chambers.
[0168] A portion of the perfusion solution also exits the
bioreactor chambers for dialysis as further detailed hereinabove.
In the illustrated embodiments, which is not to be considered as
limiting, portions of the perfusion solutions from all the
bioreactor chambers enter a main circulation channel 1002
circulating the perfusion solutions into the same dialysis system,
which is optionally and preferably similar to dialysis system 200
as described herein. Thus, in these embodiments, System 1000
comprises a plurality of bioreactor chambers, a respective
plurality of delivery systems, and a shared dialysis system which
apply dialysis to perfusion solutions of all the bioreactor
chambers.
[0169] The bioreactor chambers, delivery systems and dialysis
system are optionally and preferably controlled by controller 304
as further detailed hereinabove.
[0170] The number of bioreactor chambers (and of respective
delivery systems) in system 1000 is preferably selected such that
the aggregate volumes of the perfusion solutions in the bioreactor
chambers can be dialyzed by the dialysis system. Typically, there
are from about 10 to about 500, e.g., about 100 bioreactor chambers
in system 1000. For example, when the dialysis system is
constructed to dialyze about V liters of perfusion solution, and
each of the bioreactor chambers has about v liters of perfusion
solution, the number of bioreactor chambers in system 1000 is V/v.
As a representative example which is not to be considered as
limiting, V can be about 500 and v can be about 5, so that V/v is
about 100. The advantage of having a plurality of relatively small
bioreactor chambers is that it allows having a relatively high
perfusion rate.
[0171] Following is a more detailed description of system 1000,
according to some embodiments of the present invention.
[0172] Dialyzer 20 can be, for example, hollow fiber dialyzer, such
as, but not limited to, the hollow fiber dialyzer that is
commercially distributed by Rancho Spectrum Labs (Rancho Dominguez,
Calif.). The dialyzer can include membrane having an area of from
about 500 to about 1000, e.g., about 790 cm.sup.2, and a molecular
weight cutoff of from about 20 to about 40, e.g., about 30 kDa. A
fraction of the perfusion solution can be diverted using a pump 21,
such as, but not limited to, a peristaltic pump, to system 200
through dialyzer 20. The dialyzer 20 dialyzes the perfusion
solution by counter-flow exposure to a protein-free dialysate 22,
recirculated through a filter 24, such as, but not limited to, an
ammonia filter 24, an additional pump 23, such as, but not limited
to, a peristaltic pump. Temperature within system 1000 is
optionally and preferably maintained at a physiological range
selected based on the type of animal cell 302 being grown. For
chicken, for example, the temperature can be from about 38 to about
42.degree. C., for beef cow the temperature can be from about 36.7
to about 39.degree. C., for pig the temperature can be from about
38 to about 39.degree. C., etc.
Bioreactor Chamber
[0173] In some embodiments of the present invention, the chamber
300 has a volume and internal dimensions that are configured and
arranged to receive the growing cells and retain the cells within
its volume while a sufficient amount of perfusion solution
continuously circulates through the growing cells. The chamber 300
is optionally and preferably specifically adapted to the type of
cells in it, in order to provide the adequate environment for the
cells to grow and minimize mechanical damage or physical stress
that can block vascular supply of oxygen and nutrients to the
growing cells.
[0174] Peristaltic Pumps
[0175] Peristaltic pumps are known in the art. In order to provide
any person skilled in the art with the required information to
perform the present invention a brief explanation will be provided.
A peristaltic pump is a type of positive displacement pump used for
pumping a variety of fluids
(www.en.dot.wikipedia.dot.org/wiki/Peristaltc_pump, incorporated
herein as reference). The fluid is contained within a flexible tube
fitted inside a circular pump casing (though linear peristaltic
pumps have been made). A rotor with a number of "rollers", "shoes",
"wipers", or "lobes" attached to the external circumference of the
rotor compresses the flexible tube. As the rotor turns, the part of
the tube under compression is pinched closed (or "occludes") thus
forcing the fluid to be pumped to move through the tube.
Additionally, as the tube opens to its natural state after the
passing of the cam ("restitution" or "resilience") fluid flow is
induced to the pump. This process is called peristalsis and is used
in many biological systems such as the gastrointestinal tract.
Typically, there will be two or more rollers, or wipers, occluding
the tube, trapping between them a body of fluid. The body of fluid
is then transported, at ambient pressure, toward the pump outlet.
Peristaltic pumps may run continuously, or they may be indexed
through partial revolutions to deliver smaller amounts of
fluid.
[0176] Peristaltic pumps are typically used to pump clean/sterile
or aggressive fluids because cross contamination with exposed pump
components cannot occur. Some common applications include pumping
IV fluids through an infusion device, aggressive chemicals, high
solids slurries and other materials where isolation of the product
from the environment, and the environment from the product, are
critical. It is also used in heart-lung machines to circulate blood
during a bypass surgery as the pump does not cause significant
hemolysis.
[0177] Peristaltic pumps are also used in a wide variety of
industrial applications. Their unique design makes them especially
suited to pumping abrasives and viscous fluids.
[0178] The minimum gap between the roller and the housing
determines the maximum squeeze applied on the tubing. The amount of
squeeze applied to the tubing affects pumping performance and the
tube life--more squeezing decreases the tubing life dramatically,
while less squeezing can cause the pumped medium to slip back,
especially in high pressure pumping, and decreases the efficiency
of the pump dramatically and the high velocity of the slip back
typically causes premature failure of the hose. Therefore, this
amount of squeeze becomes an important design parameter.
[0179] The term "occlusion" is used to measure the amount of
squeeze. It is either expressed as a percentage of twice the wall
thickness, or as an absolute amount of the wall that is
squeezed.
[0180] Let y denote an occlusion, g denote minimum gap between the
roller and the housing, and t denote wall thickness of the tubing.
Then y=2t-g, when expressed as the absolute amount of squeeze, and
y=(2t-g)/(2t).times.100, when expressed as a percentage of twice
the wall thickness. The occlusion is typically 10 to 20%, with a
higher occlusion for a softer tube material and a lower occlusion
for a harder tube material.
[0181] Thus for a given pump, the most critical tubing dimension
becomes the wall thickness. An interesting point here is that the
inside diameter of the tubing is not an important design parameter
for the suitability of the tubing for the pump. Therefore, it is
common for more than one ID be used with a pump, as long as the
wall thickness remains the same.
[0182] Inside diameter: for a given rpm of the pump, a tube with
larger inside diameter (ID) will give higher flow rate than one
with a smaller inside diameter. Intuitively the flow rate is a
function of the cross section area of the tube bore.
[0183] The flow rate in a peristaltic pump is determined by many
factors, such as the tube internal diameter (ID), where higher flow
rate are obtained with larger ID, the pump head's outer diameter
(OD), where higher flow are obtained with larger OD, and the pump
head's rotation speed, where higher flow rate are obtained with
higher rotation speed. It is recognized that increasing the number
of rollers typically does not increase the flow rate. Rather it
typically decreases the flow rate by reducing the effective
(fluid-pumping) circumference of the head. Increasing rollers
typically decreases the amplitude of the fluid pulsing at the
outlet by increasing the frequency of the pulsed flow.
[0184] The length of tube (measured from initial pinch point near
the inlet to the final release point near the outlet) does not
affect the flow rate. However, a longer tube implies more pinch
points between inlet and outlet, increasing the pressure that the
pump can generate.
[0185] The present embodiments contemplate any of several
variations of peristaltic pumps. Hose pumps can typically operate
against up to 16 bar in continuous service, use shoes (rollers only
used on low pressure types) and have casings filled with lubricant
to prevent abrasion of the exterior of the pump tube and to aid in
the dissipation of heat, and use reinforced tubes, often called
"hoses". This class of pump is often called a "hose pump". The
advantage with the hose pumps over the roller pumps is the high
operating pressure of up to 16 bar. With rollers max pressure can
arrive up to 12 Bar. Tube pumps are typically lower pressure
peristaltic pumps having dry casings and use rollers along with
non-reinforced, extruded tubing. This class of pump is sometimes
called a "tube pump" or "tubing pump". These pumps employ rollers
to squeeze the tube. Except for the 360.degree. eccentric pump
design as described below, these pumps have a minimum of 2 rollers
180.degree. apart, and may have as many as 8, or even 12 rollers.
Increasing the number of rollers increase the pressure pulse
frequency of the pumped fluid at the outlet, thereby decreasing the
amplitude of pulsing.
[0186] The present embodiments contemplate any of several
variations of roller designs. In a fixed occlusion pump, the
rollers have a fixed locus as it turns, keeping the occlusion
constant as it squeezes the tube. In spring-loaded rollers, the
rollers in this pump are mounted on a spring. This design helps
overcome the variations in the tube wall thickness over a broader
range. Regardless of the variations, the roller imparts the same
amount of stress on the tubing that is proportional to the spring
constant, making this a constant stress operation. The spring is
selected to overcome not only the hoop strength of the tubing, but
also the pressure of the pumped fluid.
[0187] The operating pressure of these pumps is determined by the
tubing and by the motor's ability to overcome the hoop strength of
the tubing and the fluid pressure.
[0188] While the embodiments above are described with a particular
emphasis to peristaltic pumps, it is to be understood that other
pumps, such as, but not limited to, positive displacement pumps,
impulse pumps, velocity pumps, gravity pumps, steam pumps and
valveless pumps, can be employed.
[0189] Medium Perfusate
[0190] Depending on the type of cell source grown in the device of
the present invention a specific medium perfusate is used.
[0191] Cell culture medium often contains fetal bovine serum (FBS)
that provides attachment factors, fatty acids, growth factors,
hormones, and albumin. FBS can usually be replaced with serum
replacement (e.g. KO-serum) that is composed of amino acids,
vitamins, and trace elements in addition to transferrin, insulin,
and lipid-rich bovine serum albumin. While both transferrin and
insulin are produced in bacteria using recombinant technology,
albumin is usually animal derived. However, plant and
bacteria-derived recombinant human albumin (e.g. Cellastim.TM.) are
available through several companies, including Sigma-Aldrich (St.
Louis, Mo.).
[0192] Chicken embryonic fibroblast (CEF) medium is traditionally
composed of M199 or DMEM/F12 medium supplemented with 15% FBS, and
glutamine. However, serum-free medium for the growth of mammalian
fibroblasts is now readily available. Medium is for mammalian cells
(e.g. cow, pig) is composed of M199 supplemented with 0.5 mg/mL
albumin, 0.6 .mu.M linoleic acid, 0.6 .mu.g/mL lecithin, 5 ng/mL
bFGF, 5 ng/mL EGF, 30 pg/mL TGF.beta.1, 7.5 mM glutamine, 1
.mu.g/mL hydrocortisone, 50 .mu.g/mL ascorbic acid, and 5 .mu.g/mL
insulin. This medium PCS-201-040 is available from ATCC (Manassas,
Va.) and is reported to support 4-fold faster proliferation of
human fibroblasts. Under some conditions, insulin could be replaced
with IGF-1, or the stabilized Long R3 IGF-1 (Sigma). EGF can be
replaced with the EGF-R agonist NSC-228155 (Sakanyan et al. Sci.
Reports. 2014). FGF can similarly be replaced with a small molecule
or synthetic agonist such as C19-jun (Ballinger et al. Nature.
Biotech. 1999). Chicken hepatocytes are similarly supported by a
serum-free culture medium designed for human and mouse hepatocytes.
Medium is composed of Williams E basal medium supplemented with
albumin, insulin, transferrin, and hydrocortisone (1).
[0193] Oxygenator
[0194] An oxygenator is a medical device that is capable of
exchanging oxygen and carbon dioxide in the blood of human patient
during surgical procedures that may necessitate the interruption or
cessation of blood flow in the body, a critical organ or great
blood vessel. These organs can be the heart, lungs or liver, while
the great vessels can be the aorta, pulmonary artery, pulmonary
veins or vena cava. An oxygenator is typically utilized by a
perfusionist in cardiac surgery in conjunction with the heart-lung
machine. However, oxygenators can also be utilized in
extracorporeal membrane oxygenation in neonatal intensive care
units by nurses (www.en.dot.wikipedia.dot.org/wiki/Oxygenator,
incorporated hereinafter as reference).
For most cardiac operations such as coronary artery bypass
grafting, the cardiopulmonary bypass is performed using a
heart-lung machine (or cardiopulmonary bypass machine). The
heart-lung machine serves to replace the work of the heart during
the open bypass surgery. The machine replaces both the heart's
pumping action and the lungs' gas exchange function. Since the
heart is stopped during the operation, this permits the surgeon to
operate on a bloodless, stationary heart.
[0195] One component of the heart-lung machine is the oxygenator.
The oxygenator component serves as the lung, and is designed to
expose the blood or perfusion medium to oxygen and remove carbon
dioxide. It is disposable and contains about 2-4 m.sup.2 of a
membrane permeable to gas but impermeable to blood, in the form of
hollow fibers. Blood flows on the outside of the hollow fibers,
while oxygen flows in the opposite direction on the inside of the
fibers. As the blood passes through the oxygenator, the blood comes
into intimate contact with the fine surfaces of the device itself.
Gas containing oxygen and medical air is delivered to the interface
between the blood and the device, permitting the blood cells to
absorb oxygen molecules directly.
[0196] In some embodiments of the present invention, an oxygenator
is provided as mass transfer device 12 to exchange of gases in the
medium used to grow the cells.
[0197] In various embodiments of the present invention the gases
are selected from a group consisting of oxygen (O.sub.2), carbon
dioxide (CO.sub.2), nitrogen (N.sub.2) and any combination
thereof.
[0198] In a preferred embodiment of the present invention the
ratio:percentage of each gas that need to be maintained is of
O.sub.2 from about 21% to about 95%, CO.sub.2 from about 0% to
about 10% and N.sub.2 from about 0% to about 80%.
[0199] In a preferred embodiment of the present invention the
ratio:percentage of each gas that need to be maintained is O.sub.2
at about 80%, CO.sub.2 at about 5% and N.sub.2 at about 15%.
[0200] Bubble Trap
[0201] Unwanted bubbles inadvertently introduced into a
microfluidic system can negatively affect device operation and
experimental outcome. This is especially true for microfluidic
perfusion culture systems, which typically require sterilization
and pre-conditioning of the surface prior to cell seeding, time to
allow for cell attachment, and then take several days to observe
the growth rate and cell morphologies. Bubbles can form at the
connection between the device and tubing or can be introduced when
unplugging connections to transfer the device between the
microscope and incubator. The bubbles are cytotoxic to the cells
and can potentially rupture their cell membranes.
[0202] One solution to mitigate bubble-based device failure is to
integrate microfluidic features to prevent bubbles from entering
critical areas of a device. There are, in general, two different
approaches: trapping versus debubbling. A bubble trap is a
structure integrated into the flow system that halts further
progress of a bubble through a device. It has been demonstrated a
simple, easily implemented bubble trap by making a chamber at the
connection point between external tubing and their device. This
approach has the advantage that device operation is maintained
while the bubbles are trapped. The alternative is to actively
remove the bubbles from the system. This is advantageous since the
bubble trap does not remove bubbles from the system, so that when
the bubble trap completely fills with bubbles, any additional
bubbles would be sent through the system. Active bubble removal can
be achieved based on gas permeability of the material forming the
fluidic circuit 102 (e.g., PDMS). In these embodiments, positive
pressure is applied to force bubbles out of fluidic circuit
102.
[0203] In an embodiment of the present invention, the system
comprises a dedicated part for the removal of bubbles selected from
the group consisting of: bubble trap, debubbler, and any
combination thereof.
[0204] Heat Exchanger
[0205] A heat exchanger is a device used to transfer heat between
one or more fluids. The fluids may be separated by a solid wall,
such as plastic or metal tubing, to prevent mixing or they may be
in direct contact. They are widely used in space heating,
refrigeration, air conditioning, power stations, chemical plants,
petrochemical plants, petroleum refineries, natural-gas processing,
and sewage treatment. The classic example of a heat exchanger is
found in an internal combustion engine in which a circulating fluid
known as engine coolant flows through radiator coils and air flows
past the coils, which cools the coolant and heats the incoming air
(www.en.dot.wikipedia.dot.org/wiki/Heat_exchanger#Fluid_heat_exchangers---
incorporated herein as reference).
[0206] Flow arrangement: There are three primary classifications of
heat exchangers according to their flow arrangement. In
parallel-flow heat exchangers, the two fluids enter the exchanger
at the same end, and travel in parallel to one another to the other
side. In counter-flow heat exchangers the fluids enter the
exchanger from opposite ends. The counter current design is the
most efficient, in that it can transfer the most heat from the heat
(transfer) medium per unit mass due to the fact that the average
temperature difference along any unit length is higher. See
countercurrent exchange. In a cross-flow heat exchanger, the fluids
travel roughly perpendicular to one another through the
exchanger.
[0207] For efficiency, heat exchangers are designed to maximize the
surface area of the wall between the two fluids, while minimizing
resistance to fluid flow through the exchanger. The exchanger's
performance can also be affected by the addition of fins or
corrugations in one or both directions, which increase surface area
and may channel fluid flow or induce turbulence.
[0208] The driving temperature across the heat transfer surface
varies with position, but an appropriate mean temperature can be
defined. In most simple systems this is the "log mean temperature
difference" (LMTD). Sometimes direct knowledge of the LMTD is not
available and the Number of Transfer Units (NTU) method is
used.
[0209] Types: Double pipe heat exchangers are the simplest
exchangers used in industries. On one hand, these heat exchangers
are cheap for both design and maintenance, making them a good
choice for small industries. On the other hand, their low
efficiency coupled with the high space occupied in large scales,
has led modern industries to use more efficient heat exchangers
like shell and tube or plate. However, since double pipe heat
exchangers are simple, they are used to teach heat exchanger design
basics to students as the fundamental rules for all heat exchangers
are the same. To start the design of a double pipe heat exchanger,
the first step is to calculate the heat duty of the heat exchanger.
It must be noted that for easier design, it's better to ignore heat
loss to the environment for initial design.
[0210] Shell and tube heat exchanger: shell and tube heat
exchangers consist of series of tubes. One set of these tubes
contains the fluid that must be either heated or cooled. The second
fluid runs over the tubes that are being heated or cooled so that
it can either provide the heat or absorb the heat required. A set
of tubes is called the tube bundle and can be made up of several
types of tubes: plain, longitudinally finned, etc. Shell and tube
heat exchangers are typically used for high-pressure applications
(with pressures greater than 30 bar and temperatures greater than
260.degree. C.). This is because the shell and tube heat exchangers
are robust due to their shape.
[0211] Several thermal design features must be considered when
designing the tubes in the shell and tube heat exchangers: There
can be many variations on the shell and tube design. Typically, the
ends of each tube are connected to plenums (sometimes called water
boxes) through holes in tubesheets. The tubes may be straight or
bent in the shape of a U, called U-tubes.
[0212] Tube diameter: Using a small tube diameter makes the heat
exchanger both economical and compact. However, it is more likely
for the heat exchanger to foul up faster and the small size makes
mechanical cleaning of the fouling difficult. To prevail over the
fouling and cleaning problems, larger tube diameters can be used.
Thus to determine the tube diameter, the available space, cost and
fouling nature of the fluids must be considered.
[0213] Tube thickness: The thickness of the wall of the tubes is
usually determined to ensure:
[0214] There is enough room for corrosion
[0215] That flow-induced vibration has resistance
[0216] Axial strength
[0217] Availability of spare parts
[0218] Hoop strength (to withstand internal tube pressure)
[0219] Buckling strength (to withstand overpressure in the
shell)
[0220] Tube length: heat exchangers are usually cheaper when they
have a smaller shell diameter and a long tube length. Thus,
typically there is an aim to make the heat exchanger as long as
physically possible whilst not exceeding production capabilities.
However, there are many limitations for this, including space
available at the installation site and the need to ensure tubes are
available in lengths that are twice the required length (so they
can be withdrawn and replaced). Also, long, thin tubes are
difficult to take out and replace.
[0221] Tube pitch: when designing the tubes, it is practical to
ensure that the tube pitch (i.e., the centre-centre distance of
adjoining tubes) is not less than 1.25 times the tubes' outside
diameter. A larger tube pitch leads to a larger overall shell
diameter, which leads to a more expensive heat exchanger.
[0222] Tube corrugation: this type of tubes, mainly used for the
inner tubes, increases the turbulence of the fluids and the effect
is very important in the heat transfer giving a better
performance.
[0223] Tube Layout: refers to how tubes are positioned within the
shell. There are four main types of tube layout, which are,
triangular (30.degree.), rotated triangular (60.degree.), square
(90.degree.) and rotated square (45.degree.). The triangular
patterns are employed to give greater heat transfer as they force
the fluid to flow in a more turbulent fashion around the piping.
Square patterns are employed where high fouling is experienced and
cleaning is more regular.
[0224] Baffle Design: baffles are used in shell and tube heat
exchangers to direct fluid across the tube bundle. They run
perpendicularly to the shell and hold the bundle, preventing the
tubes from sagging over a long length. They can also prevent the
tubes from vibrating. The most common type of baffle is the
segmental baffle. The semicircular segmental baffles are oriented
at 180 degrees to the adjacent baffles forcing the fluid to flow
upward and downwards between the tube bundle. Baffle spacing is of
large thermodynamic concern when designing shell and tube heat
exchangers. Baffles must be spaced with consideration for the
conversion of pressure drop and heat transfer. For thermo economic
optimization it is suggested that the baffles be spaced no closer
than 20% of the shell's inner diameter. Having baffles spaced too
closely causes a greater pressure drop because of flow redirection.
Consequently, having the baffles spaced too far apart means that
there may be cooler spots in the corners between baffles. It is
also important to ensure the baffles are spaced close enough that
the tubes do not sag. The other main type of baffle is the disc and
doughnut baffle, which consists of two concentric baffles. An
outer, wider baffle looks like a doughnut, whilst the inner baffle
is shaped like a disk. This type of baffle forces the fluid to pass
around each side of the disk then through the doughnut baffle
generating a different type of fluid flow. Fixed tube liquid-cooled
heat exchangers especially suitable for marine and harsh
applications can be assembled with brass shells, copper tubes,
brass baffles, and forged brass integral end hubs.
[0225] Plate heat exchangers: another type of heat exchanger is the
plate heat exchanger. These exchangers are composed of many thin,
slightly separated plates that have very large surface areas and
small fluid flow passages for heat transfer. Advances in gasket and
brazing technology have made the plate-type heat exchanger
increasingly practical. In HVAC applications, large heat exchangers
of this type are called plate-and-frame; when used in open loops,
these heat exchangers are normally of the gasket type to allow
periodic disassembly, cleaning, and inspection. There are many
types of permanently bonded plate heat exchangers, such as
dip-brazed, vacuum-brazed, and welded plate varieties, and they are
often specified for closed-loop applications such as refrigeration.
Plate heat exchangers also differ in the types of plates that are
used, and in the configurations of those plates. Some plates may be
stamped with "chevron", dimpled, or other patterns, where others
may have machined fins and/or grooves.
When compared to shell and tube exchangers, the stacked-plate
arrangement typically has lower volume and cost. Another difference
between the two is that plate exchangers typically serve low to
medium pressure fluids, compared to medium and high pressures of
shell and tube. A third and important difference is that plate
exchangers employ more countercurrent flow rather than cross
current flow, which allows lower approach temperature differences,
high temperature changes, and increased efficiencies.
[0226] Plate and shell heat exchanger: A third type of heat
exchanger is a plate and shell heat exchanger, which combines plate
heat exchanger with shell and tube heat exchanger technologies. The
heart of the heat exchanger contains a fully welded circular plate
pack made by pressing and cutting round plates and welding them
together. Nozzles carry flow in and out of the platepack (the
`Plate side` flowpath). The fully welded platepack is assembled
into an outer shell that creates a second flowpath (the `Shell
side`). Plate and shell technology offers high heat transfer, high
pressure, high operating temperature, uling and close approach
temperature. In particular, it does completely without gaskets,
which provides security against leakage at high pressures and
temperatures.
Adiabatic wheel heat exchanger: a fourth type of heat exchanger
uses an intermediate fluid or solid store to hold heat, which is
then moved to the other side of the heat exchanger to be released.
Two examples of this are adiabatic wheels, which consist of a large
wheel with fine threads rotating through the hot and cold fluids,
and fluid heat exchangers. Plate fin heat exchanger: this type of
heat exchanger uses "sandwiched" passages containing fins to
increase the effectiveness of the unit. The designs include
crossflow and counterflow coupled with various fin configurations
such as straight fins, offset fins and wavy fins.
[0227] Plate and fin heat exchangers are usually made of aluminum
alloys, which provide high heat transfer efficiency. The material
enables the system to operate at a lower temperature difference and
reduce the weight of the equipment. Plate and fin heat exchangers
are mostly used for low temperature services such as natural gas,
helium and oxygen liquefaction plants, air separation plants and
transport industries such as motor and aircraft engines.
[0228] Advantages of Plate and Fin Heat Exchangers:
[0229] High heat transfer efficiency especially in gas
treatment
[0230] Larger heat transfer area
[0231] Approximately 5 times lighter in weight than that of shell
and tube heat exchanger.
[0232] Able to withstand high pressure
Disadvantages of Plate and Fin Heat Exchangers:
[0233] Might cause clogging as the pathways are very narrow
[0234] Difficult to clean the pathways
[0235] Aluminum alloys are susceptible to Mercury Liquid
Embrittlement Failure
[0236] Pillow plate heat exchanger: a pillow plate exchanger is
commonly used in the dairy industry for cooling milk in large
direct-expansion stainless steel bulk tanks. The pillow plate
allows for cooling across nearly the entire surface area of the
tank, without gaps that would occur between pipes welded to the
exterior of the tank.
[0237] The pillow plate is constructed using a thin sheet of metal
spot-welded to the surface of another thicker sheet of metal. The
thin plate is welded in a regular pattern of dots or with a
serpentine pattern of weld lines. After welding the enclosed space
is pressurized with sufficient force to cause the thin metal to
bulge out around the welds, providing a space for heat exchanger
liquids to flow, and creating a characteristic appearance of a
swelled pillow formed out of metal.
[0238] Fluid heat exchangers: this is a heat exchanger with a gas
passing upwards through a shower of fluid (often water), and the
fluid is then taken elsewhere before being cooled. This is commonly
used for cooling gases whilst also removing certain impurities,
thus solving two problems at once. It is widely used in espresso
machines as an energy-saving method of cooling super-heated water
to use in the extraction of espresso.
[0239] Waste heat recovery units: a Waste Heat Recovery Unit (WHRU)
is a heat exchanger that recovers heat from a hot gas stream while
transferring it to a working medium, typically water or oils. The
hot gas stream can be the exhaust gas from a gas turbine or a
diesel engine or a waste gas from industry or refinery.
[0240] Big systems with high volume and temperature gas streams,
typical in industry, can benefit from Steam Rankine Cycle (SRC) in
a WHRU, but these cycles are too expensive for small systems. The
recovery of heat from low temperature systems requires different
working fluids than steam.
[0241] An Organic Rankine Cycle (ORC) WHRU can be more efficient at
low temperature range using Refrigerant that boil at lower
temperatures than water. Typical organic refrigerants are Ammonia,
Pentafluoropropane (R-245fa and R-245ca), and Toluene.
[0242] The refrigerant is boiled by the heat source in the
Evaporator to produce super-heated vapor. This fluid is expanded in
the turbine to convert thermal energy to kinetic energy, which is
converted to electricity in the electrical generator. This energy
transfer process decreases the temperature of the refrigerant that,
in turn, condenses. The cycle is closed and completed using a pump
to send the fluid back to the evaporator.
[0243] Dynamic scraped surface heat exchanger: another type of heat
exchanger is called "(dynamic) scraped surface heat exchanger".
This is mainly used for heating or cooling with high-viscosity
products, crystallization processes, evaporation and high-fouling
applications. Long running times are achieved due to the continuous
scraping of the surface, thus avoiding fouling and achieving a
sustainable heat transfer rate during the process.
[0244] Phase-change heat exchangers: In addition to heating up or
cooling down fluids in just a single phase, heat exchangers can be
used either to heat a liquid to evaporate (or boil) it or used as
condensers to cool a vapor and condense it to a liquid. In chemical
plants and refineries, reboilers used to heat incoming feed for
distillation towers are often heat exchangers.
[0245] Distillation set-ups typically use condensers to condense
distillate vapors back into liquid.
[0246] Power plants that use steam-driven turbines commonly use
heat exchangers to boil water into steam. Heat exchangers or
similar units for producing steam from water are often called
boilers or steam generators.
[0247] In the nuclear power plants called pressurized water
reactors, special large heat exchangers pass heat from the primary
(reactor plant) system to the secondary (steam plant) system,
producing steam from water in the process. These are called steam
generators. All fossil-fueled and nuclear power plants using
steam-driven turbines have surface condensers to convert the
exhaust steam from the turbines into condensate (water) for
re-use.
[0248] To conserve energy and cooling capacity in chemical and
other plants, regenerative heat exchangers can transfer heat from a
stream that must be cooled to another stream that must be heated,
such as distillate cooling and reboiler feed pre-heating.
[0249] This term can also refer to heat exchangers that contain a
material within their structure that has a change of phase. This is
usually a solid to liquid phase due to the small volume difference
between these states. This change of phase effectively acts as a
buffer because it occurs at a constant temperature but still allows
for the heat exchanger to accept additional heat. One example where
this has been investigated is for use in high power aircraft
electronics.
[0250] Heat exchangers functioning in multiphase flow regimes may
be subject to the Ledinegg instability.
[0251] Direct contact heat exchangers: Direct contact heat
exchangers involve heat transfer between hot and cold streams of
two phases in the absence of a separating wall. Thus such heat
exchangers can be classified as:
[0252] Gas--liquid
[0253] Immiscible liquid--liquid
[0254] Solid-liquid or solid--gas
[0255] Most direct contact heat exchangers fall under the
Gas--Liquid category, where heat is transferred between a gas and
liquid in the form of drops, films or sprays.
[0256] Such types of heat exchangers are used predominantly in air
conditioning, humidification, industrial hot water heating, water
cooling and condensing plants.
TABLE-US-00001 TABLE 1 Continuous Driving Change of Phases phase
force phase Examples Gas- Gas Gravity No Spray columns, packed
Liquid columns Yes Cooling towers, falling droplet evaporators
Forced No Spray coolers/quenchers Liquid Yes Spray condensers/ flow
evaporation, jet condensers Liquid Gravity No Bubble columns,
perforated tray columns Yes Bubble column condensers Forced No Gas
spargers Gas flow Yes Direct contact evaporators, submerged
combustion
[0257] Microchannel heat exchangers: Micro heat exchangers,
Micro-scale heat exchangers, or microstructured heat exchangers are
heat exchangers in which (at least one) fluid flows in lateral
confinements with typical dimensions below 1 mm. The most typical
such confinement are microchannels, which are channels with a
hydraulic diameter below 1 mm. Microchannel heat exchangers can be
made from metal, ceramic, and even low-cost plastic. Microchannel
heat exchangers can be used for many applications including:
[0258] high-performance aircraft gas turbine engines
[0259] heat pumps
[0260] air conditioning
[0261] heat recovery ventilators
[0262] Helical-coil heat exchangers: Although double-pipe heat
exchangers are the simplest to design, the better choice in the
following cases would be the helical-coil heat exchanger
(HCHE):
[0263] The main advantage of the HCHE, like that for the SHE, is
its highly efficient use of space, especially when it's limited and
not enough straight pipe can be laid.
[0264] Under conditions of low flowrates (or laminar flow), such
that that the typical shell-and-tube exchangers have low
heat-transfer coefficients and becoming uneconomical.
[0265] When there is low pressure in one of the fluids, usually
from accumulated pressure drops in other process equipment.
[0266] When one of the fluids has components in multiple phases
(solids, liquids, and gases), which tends to create mechanical
problems during operations, such as plugging of small-diameter
tubes. Cleaning of helical coils for these multiple-phase fluids
can prove to be more difficult than its shell and tube counterpart;
however the helical coil unit would require cleaning less
often.
[0267] These have been used in the nuclear industry as a method for
exchanging heat in a sodium system for large liquid metal fast
breeder reactors since the early 1970s, using an HCHE device
invented by Charles E. Boardman and John H. Germer. There are
several simple methods for designing HCHE for all types of
manufacturing industries, such as using the Ramachandra K. Patil
(et al.) method from India and the Scott S. Haraburda method from
the United States.
[0268] However, these are based upon assumptions of estimating
inside heat transfer coefficient, predicting flow around the
outside of the coil, and upon constant heat flux. Yet, recent
experimental data revealed that the empirical correlations are
quite in agreement for designing circular and square pattern HCHEs.
During studies published in 2015, several researchers found that
the boundary conditions of the outer wall of exchangers were
essentially constant heat flux conditions in power plant boilers,
condensers and evaporators; while convective heat transfer
conditions were more appropriate in food, automobile and process
industries.
[0269] In an embodiment of the present invention, the system
comprises a dedicated part for the heat conservancy of the medium
in a form of a heat exchanger selected from the group consisting
of: shell and tube heat exchanger, plate heat exchanger, plate and
shell heat exchanger, adiabatic wheel heat exchanger, plate fin
heat exchanger, pillow plate heat exchanger, fluid heat exchanger,
waste heat recovery units, dynamic scraped surface heat exchanger,
phase-change heat exchanger, direct contact heat exchanger,
microchannel heat exchanger, helical-coil heat exchanger, spiral
heat exchanger, and any combination thereof.
[0270] Dialyzer
[0271] A dialyzer is a machine equipped with a semipermeable
membrane and used for performing dialysis. Dialysis is the process
of diffusion of solutes through a semipermeable membrane from a
liquid with higher solute concentration on one side of the membrane
to a liquid with a lower concentration on the other side. The
membranes are semipermeable because they allow some molecules to
pass while preventing others from passing. The process has long
been used for the molecular separation of small molecules from
macromolecules (www.dot.spectrumlabs.dot.com/lit/abc.dot.pdf,
incorporated hereinafter as reference) and for extracorporeal
support (kidney dialysis,
www.en.dot.wikipedia.dot.org/wiki/Dialysis, incorporated
hereinafter as reference).
[0272] Common dialysis applications utilize tubular forms of
membranes and involve placing a "sample" inside the membrane and a
"buffer" outside the membrane. The process is run until the desired
degree of separation is attained. Molecules smaller than the pores
will eventually be equally distributed between the two solutions.
Usually, a very large volume of buffer is chosen so that the
permeable species are greatly diluted and therefore reduced-to very
small concentrations in the remaining sample solution. Commonly,
dialysis processes require several hours to complete.
[0273] Dialysis Membranes: advances in dialysis membrane
development were made as a result of research to provide relief
from renal disease by means of hemodialysis, a pressure driven
rather than concentration gradient driven process. Greater membrane
permeability was achieved through the use of cellulose ester. These
solutions could be formulated to yield a wider range of pore sizes.
Cellulose ester membranes are now widely used for clinical and
laboratory dialysis. Membranes used for dialysis have pore sizes
ranging from 100 to 300,000 Daltons (1 to 300 kDa). Sample volumes
have also been greatly reduced to allow dialysis of small
quantities of precious samples, particularly where maintaining
enzyme activity is desired.
[0274] Factors that Affect the Rate of Dialysis
[0275] Molecular Weight Cut Off and Selectivity: dialysis membranes
are characterized by molecular weight cut off (MWCO). MWCO is
determined by testing the degree of permeability for several
solutes of different molecular weights. The MWCO rating for the
membrane is the molecular weight of the smallest solute that is 90%
retained in a 17-hour dialysis test. Molecular weight cut off
ratings are used as a guide and not an absolute prediction of
performance with every type of solute. A membrane MWCO size rating
should be chosen as high as possible in order to achieve the
maximum dialysis rate while still preventing the loss of the
desired solute. Plotting the results of a MWCO test in the form of
retention versus the solute molecular weight would ideally produce
a sigmoid curve. The steepness of the curve is a measure of the
selectivity of the membrane.
Flux and Permeation Rate: the driving force for laboratory dialysis
is the concentration difference across the membrane. The flux (or
permeation rate) is directly proportional to the concentration
difference, i.e. the greater the difference, the greater the rate.
However, the dialysis rate is also influenced by other variables
such as:
[0276] Diffusion coefficient: different size molecules pass through
a membrane at different rates. Larger molecules have a smaller
coefficient and a lower rate of diffusion across the membrane.
[0277] Molecular shape and charge: linear molecules permeate faster
than globular molecules. The pH and ionic strength also affect the
rate of dialysis.
[0278] Concentration polarization: As molecules diffuse across a
membrane, they first move through the bulk of the sample solution
to the surface of the membrane. The thin region next to the
membrane has a higher concentration of solutes than the bulk
solution. This build up is termed "concentration polarization" and
is caused by depletion of small molecules at the surface of the
membrane. This polarized layer causes resistance to the movement of
molecules across the membrane. Finally, after passing through the
membrane, the molecule often meets a thin layer of concentration
higher than the bulk solution, further slowing the passage. These
layers which form on either side of the membrane are called "fluid
boundary layers" or "gel layers".
[0279] Flow direction and agitation of the solution: sample and
buffer that flow perpendicular (or normal) might cause the membrane
to plug. Sample and buffer mixing during dialysis can reduce this
phenomenon. Mixing can be achieved by either stirring or by passing
the sample parallel (or tangential) to the membrane. Parallel flow
promotes higher permeation rates. The higher the stirring rate, the
higher the dialysis rates (Concentration polarization is reduced by
increased stirring rates).
[0280] Temperature: higher temperatures promote more rapid
molecular movement and therefore increase diffusion rate.
[0281] Membrane thickness: membrane properties effect the dialysis
rate. Thicker membranes will require a longer time for molecules to
pass through.
[0282] Membrane surface area: the larger the membrane area, the
faster the dialysis rate.
[0283] Hydrodynamic properties: viscosity of the fluid and the
membrane porosity affect the permeation rate. Low viscosity and
high porosity are ideal for higher rates.
MWCO Selection: selecting of the correct molecular weight cut off
(MWCO) of the membrane is based on the size of the molecular weight
of the macromolecules to be retained inside the membrane and the
molecular weight of the molecules to be removed. The ratio of the
two molecular weights should be a minimum 25 to 1 to achieve the
maximum 90% retention.
[0284] Tubular Membrane "flat width" Selection: smaller tubing will
dialyze more quickly than larger tubing. The latter will dialyze
more slowly due to the longer diffusion distances involved.
[0285] Albumin is the main carrier protein of growth factors,
hormones and fatty acids, and a major cost driver of liquid medium.
The system of the present invention is optionally and preferably
designed to retain albumin (MW about 66.4 kDa), achievable with a
target MWCO of 30 kDa.
[0286] In an embodiment of the present invention, the system
comprises a dialyzer with surface ranging from 15 to 20,000
cm.sup.2 membrane area and a molecular weight cutoff ranging from
10 to 60 kDa.
[0287] Dialysate
[0288] Dialysate or diffusate is the fluid and solutes in a
dialysis process that passes through the membrane in dialysis.
[0289] In an embodiment of the present invention, the system
comprises a dialysate containing glucose, insulin and growth
factors in serum-free medium. Depending on the type of cells being
grown in the chamber, a different content of dialysate is prepared
in order to respond to the specific needs of the growing cells.
[0290] Filtering
[0291] Filtering can be effected according to some embodiments of
the present invention by any type of filter that can remove
contaminants and impurities. Representative examples including,
without limitation, carbon filtering and zeolite filtering.
[0292] Carbon filtering is a method of filtering that uses a bed of
activated carbon to remove contaminants and impurities, using
chemical adsorption
(www.en.dot.wikipedia.dot.org/wiki/Carbon_filtering, incorporated
hereinafter as reference).
[0293] Each particle/granule of carbon provides a large surface
area/pore structure, allowing contaminants the maximum possible
exposure to the active sites within the filter media. One pound
(454 g) of activated carbon contains a surface area of
approximately 100 acres (40 Hectares).
[0294] Activated carbon works via a process called adsorption,
whereby pollutant molecules in the fluid to be treated are trapped
inside the pore structure of the carbon substrate. Carbon filtering
is commonly used for water purification, in air purifiers and
industrial gas processing, for example the removal of siloxanes and
hydrogen sulfide from biogas. It is also used in a number of other
applications, including respirator masks, the purification of
sugarcane and in the recovery of precious metals, especially gold.
Active charcoal carbon filters are most effective at removing
chlorine, sediment, volatile organic compounds (VOCs), taste and
odor from water. They are not effective at removing minerals,
salts, and dissolved inorganic compounds.
[0295] Typical particle sizes that can be removed by carbon filters
range from 0.5 to 50 micrometres. The particle size will be used as
part of the filter description. The efficacy of a carbon filter is
also based upon the flow rate regulation. When the water is allowed
to flow through the filter at a slower rate, the contaminants are
exposed to the filter media for a longer amount of time.
[0296] There are 2 predominant types of carbon filters used in the
filtration industry: powdered block filters and granular activated
filters. In general, carbon block filters are more effective at
removing a larger number of contaminants, based upon the increased
surface area of carbon. Many carbon filters also use secondary
media such as silver to prevent bacteria growth within the filter.
Alternatively, the activated carbon itself may be impregnated with
silver to provide this bacteriostatic property.
Factors that affect the performance of activated carbon are
(www.dot.watertreatmentguide.dot.com/activated_carbon_filtration.dot.htm,
incorporated hereinafter as reference):
[0297] Molecular weight: as the molecular weight increases, the
activated carbon adsorbs more effectively because the molecules are
lea soluble in water. However, the pore structure of the carbon
must be large enough to allow the molecules to migrate within. A
mixture of high and low molecular weight molecules should be
designed for the removal of the more difficult species.
[0298] pH: most organics are less soluble and more readily adsorbed
at a lower pH. As the pH increases, removal decreases. A rule of
thumb is to increase the size of the carbon bed by twenty percent
for every pH unit above neutral (7.0).
[0299] Contaminant concentration: the higher the contaminant
concentration, the greater the removal capacity of activated
carbon. The contaminant molecule is more likely to diffuse into a
pore and become adsorbed. As concentrations increase, however, so
do effluent leakages. The upper limit for contaminants is a few
hundred parts per million. Higher contaminant concentration may
require more contact time with the activated carbon. Also, the
removal of organics is enhanced by the presence of hardness in the
water, so whenever possible, place activated carbon units upstream
of the ion removal units. This is usually the case anyway since
activated carbon is often used upstream of ion exchange or
membranes to remove chlorine.
[0300] Particle size: activated carbon is commonly available in 8
by 30 mesh (largest), 12 by 40 mesh (most common), and 20 by 50
mesh (finest). The finer mesh gives the best contact and better
removal, but at the expense of higher pressure drop. A rule of
thumb here is that the 8 by 30 mesh gives two to three times better
removal than the 12 by 40, and 10 to 20 times better kinetic
removal than the 8 by 30 mesh.
[0301] Flow rate: generally, the lower the flow rate, the more time
the contaminant will have to diffuse into a pore and be adsorbed.
Adsorption by activated carbon is almost always improved by a
longer contact time. Again, in general terms, a carbon bed of 20 by
50 mesh can be run at twice the flow rate of a bed of 12 by 40
mesh, and a carbon bed of 12 by 40 mesh can be run at twice the
flow rate of a bed of 8 by 30 mesh.
[0302] Temperature: higher water temperatures decrease the solution
viscosity and can increase die diffusion rate, thereby increasing
adsorption. Higher temperatures can also disrupt the adsorptive
bond and slightly decrease adsorption. It depends on the organic
compound being removed, but generally, lower temperatures seem to
favor adsorption. In an embodiment of the present invention, the
system comprises a carbon filter adapted to clean toxins from
present in the dialysate.
[0303] When zeolite filtering is employed, the portion of the
perfusion solution that enters system 200 is passed through zeolite
to absorb the ammonia in the solution. Preferably, granular zeolite
is employed. The term zeolite is intended to encompass hydrated
aluminosilicate minerals that have a micro-porous structure.
Natural zeolites are formed where volcanic rocks and ash layers
react with alkaline ground water. Granular zeolites suitable for
use in the present invention can, for example, be sourced from
Zeolite Australia Pty Ltd (PO Box 6 Werris Creek NSW 2341,
Australia).
[0304] Sensors
[0305] In a preferred embodiment of the present invention, system
1000 comprises one or more active sensors (not shown in FIGS. 1A-B,
see FIG. 9) that allow continuous monitoring of the cells growing
therein. Some examples of sensors comprise, but are not limited to,
temperature sensors, pH sensor, volume sensor, video apparatuses,
flow sensor, optical sensors, weight sensor, glucose sensor, and
protein content sensor.
[0306] In a preferred embodiment of the present invention, the
system is connected to a main computer, having a non-transitory
computer readable medium (CRM), that operates automatically all the
daily necessities of the system and provides real-time alarms to
dedicated operators. The main computer can be connected and
operated remotely via internet/cloud services. In a second
embodiment the system is self-contained, with data from sensors
analyzed by a local central processing unit (CPU), which changes
input parameters such a nutrient, flow, pressure or temperature to
adjust cell growth and sensor signal to within desired parameter
set, maintaining growth homeostasis.
[0307] In a preferred embodiment of the present invention, the
system comprises a Closed-loop perfusion circuit composed of a
primary perfusion circuit and a secondary dialysis circuit for
nutrient and toxin exchange. The primary circuit includes culture
medium perfusate that is recirculated using a peristaltic pump
through a jacketed cell growth chamber, a membrane oxygenator, a
heat exchanger, and a bubble trap. The oxygenator is gassed with a
mixture of 80% O.sub.2/5% CO.sub.2/15% N.sub.2 maintaining constant
pH. A fraction of the perfusate is diverted to secondary circuit
through a dialyzer with a 2200 cm.sup.2 membrane area and a 30 kDa
molecular weight cutoff at a rate of 3 mL/min/gram cells. The
secondary circuit dialyzed the perfusate by counter-current
exposure to protein-free dialysate, recirculated through a carbon
filter using a third peristaltic pump. Temperature within the
system is maintained at 37.degree. C. All the system
[0308] Cell Types
[0309] Several types of cells can be grown in the closed-loop
perfusion circuit disclosed in the present invention.
[0310] Primary Cell Source
[0311] Chicken embryonic fibroblasts are widely used for the
production of viruses and vaccines. Together with chicken embryonic
liver cells they are produced from specific pathogen-free (SPF)
embryos and sold by Charles River Laboratories (Wilmington, Mass.)
and other companies. While chicken liver cells show limited
proliferation in culture, like their mammalian counterparts,
chicken fibroblasts can undergo over 30 population doublings,
producing about 2.6 ton of cells before spontaneously immortalizing
without becoming tumorigenic. Spontaneously transformed chicken
fibroblasts, such as the CSIF cell line generated by the present
inventor (e.g., as described in Example 5 of the Examples section
which follows), UMNSAH/DF-1 (CRL-12203) can be bought directly from
ATTC (Manassas, Va.). While the growth potential of fibroblast is
excellent, the cells primarily form inedible connective tissue.
[0312] Chicken embryonic endothelium can be easily isolated but
their growth potential is unknown and can be organ specific. Mouse
micro-vascular cells can undergo 30 population doublings, while
human cells seldom pass 12 population doublings. Chicken embryonic
muscle cells (myocytes) can be similar isolated but have a very
limited growth potential. Mouse and human cells seldom pass 12
population doublings. Myogenesis, the formation of new muscle
tissue, is uncommon past the neonatal stage of life in most
species. Small molecules can conceptually be used to modulate this
behavior.
[0313] Pluripotent Stem Cell Source
[0314] Numerous groups produced chicken embryonic stem cells (cESC)
over the last decade (3). Cells are isolated from fertilized
chicken eggs and are essentially immortal. Chicken induced
pluripotent stem cells (ciPSC) were produced from quail embryonic
fibroblasts by reprogramming factors OCT4, NANOG, SOX2, LIN28,
KLF4, and C-MYC (4) and more recently chicken fibroblasts using
OCT4, KLF4, and C-MYC (5). Cells are essentially immortal but are
genetically engineered.
Recently, mouse pluripotent stem cells were induced from
fibroblasts using small molecules (6) permitting the
differentiation of multiple cell types, including myocytes,
hepatocytes, and endothelial cells as well as complex embryoid
bodies. Chemical induction of ciPSC offers an alternative approach
to convert fibroblasts to other cell types.
[0315] Small Molecule-Based Reprogramming
[0316] Chemical compounds offer an attractive alternative to growth
factors and genetic engineering that are generally used to support
cell growth, or to switch one cell type to another through
reprogramming or differentiation. Small molecules are less
expensive, have lower lot-to-lot variability, are non-immunogenic
and are much more stable. In one study, Shan and colleagues used a
high content screen to identify FPH1 and FPH2, small molecules that
promoted proliferation of primary human hepatocytes (7). This
approach is appealing, as small molecules could replace growth
factors serum-free medium formulations, dramatically reducing costs
while increasing safety.
[0317] In a more recent study, Cao and colleagues identified a
combination of 9 compounds that induced human fibroblasts to turn
into cardiomyocytes (8), while others used a 7 compound combination
to transform mouse cells (9). Considering many of the signaling
pathways are conserved, a relatively similar combination could be
used to transform chicken fibroblasts into myocytes.
[0318] Animal Product Free Culture Medium
[0319] As mentioned above, cell culture medium often contains fetal
bovine serum (FBS) that provides attachment factors, fatty acids,
growth factors, hormones, and albumin. FBS can usually be replaced
with serum replacement (e.g. KO-serum) that is composed of amino
acids, vitamins, and trace elements in addition to transferrin,
insulin, and lipid-rich bovine serum albumin. While both
transferrin and insulin are produced in bacteria using recombinant
technology, albumin is usually animal derived. However, plant and
bacteria-derived recombinant human albumin (e.g. Cellastim.TM.) are
available through several companies, including Sigma-Aldrich (St.
Louis, Mo.).
[0320] Chicken fibroblast medium is traditionally composed of M199
medium supplemented with 10% FBS, tryptose phosphate and glutamine.
However, serum-free medium for the growth of mammalian fibroblasts
is now readily available. Medium is composed of M199 supplemented
with 0.5 mg/mL albumin, 0.6 .mu.M linoleic acid, 0.6 .mu.g/mL
lecithin, 5 ng/mL bFGF, 5 ng/mL EGF, 30 pg/mL TGF131, 7.5 mM
glutamine, 1 .mu.g/mL hydrocortisone, 50 .mu.g/mL ascorbic acid,
and 5 .mu.g/mL insulin. This medium PCS-201-040 is available from
ATCC (Manassas, Va.) and is reported to support 4-fold faster
proliferation of human fibroblasts. Chicken hepatocytes are
similarly supported by a serum-free culture medium designed for
human and mouse hepatocytes. Medium is composed of Williams E basal
medium supplemented with albumin, insulin, transferrin, and
hydrocortisone.
[0321] Perfused culture medium can also include an oxygen carrier.
Hemoglobin based oxygen carriers
(www.en.dot.wikipedia.dot.org/wiki/Haemoglobin-based_oxygen_carriers,
incorporated hereinafter as reference) include hemoglobin
derivatives either recombinant or chemically modified, encapsulated
hemoglobin or modified (e.g. cross-linked) red blood cells.
Alternatives include Perfluorocarbon based alternatives such as
those developed in Nahmias et al. (11)
(www.en.dot.wikipedia.dot.org/wiki/Blood_substitute#Current
therapeutics, incorporated hereinafter as reference)
[0322] The present inventor has uncovered that a spontaneously
immortalized fibroblast, such as chicken fibroblast, can be used to
generate fat and muscle cells in-vitro for the generation of edible
meat. In addition, the present inventor has uncovered that primary
or spontaneously immortalized endothelial cell can be co-cultured
with the muscle and fat cells in order to form an edible meat with
vascular-like network (tissue vessels) in which the endothelial
cells serve as vessels for transfer of nutrients and gasses, such
as glucose and oxygen. Example 5 of the Examples section which
follows demonstrates the isolation and generation of a
spontaneously immortalized chicken embryonic fibroblast cell line
having a doubling time of 18.+-.2 hours and at least 90 population
doublings (PDs) (FIG. 2E). In addition, as is further described in
Example 6 of the Examples section which follows, the present
inventor has generated, following laborious experimentations, a
serum-free culture medium which can maintain the spontaneously
immortalized chicken fibroblast cell line under conditions devoid
of any animal and/or human contaminants, while maintaining the
fibroblasts in a proliferative state for at least 90 population
doublings (FIGS. 3B-F). The present inventor has further envisaged
that small molecules can substitute at least some of the components
included in the serum-free medium (Examples 2, 3 and 6 of the
Examples section which follows). The present inventor was able to
successfully generate fully functional adipocyte cells,
characterized by a compact (not elongated) shape and the
accumulation of neutral lipid content from the spontaneously
immortalized chicken embryonic fibroblast cell line in a defined
serum-free culture medium which includes oleic acid and a small
molecule which activates PPAR-gamma such as IBMX or Rosiglitazone
(FIGS. 4A-D, Example 7). The present inventor further generated
myocyte cells by upregulating the expression level and activity of
the MyoD1 and/or Myogenin polypeptides within the spontaneously
immortalized chicken embryonic fibroblast cell line (Examples 3 and
8, FIGS. 6-8, 12 and 5A-E). In addition, as shown in described in
Examples 3 and 8 of the Examples section which follows, the present
inventor describes a screen for small molecules capable of
converting the spontaneously immortalized chicken embryonic
fibroblast cell line into myocytes using the rat myosin light
chain-3 promoter-enhancer reporter construct (rMLC3-GFP; FIG. 8).
Furthermore, the present inventor shows that spontaneously
immortalized endothelial cells (e.g., reaching at least 120
population doublings; Example 11), which were co-cultured in
serum-free and antibiotic-free culture medium with the
spontaneously immortalized fibroblast cell line (Example 12) formed
vascular network formation and close cell-cell interactions (FIGS.
11A-C). Furthermore, the present inventor describes a hybrid
plant-based meat substitute product with in-vitro generated fat
(Example 9), and patty or nuggets from the cultured fibroblasts
which were induced towards differentiation into muscle and/or fat
cells in a suspension culture devoid of microcarriers (Example
10).
[0323] According to an aspect of some embodiments of the invention,
there is provided an in-vitro method of generating an adipocyte
cell from a fibroblast, comprising culturing a spontaneously
immortalized fibroblast in a serum-free medium comprising oleic
acid and a peroxisome proliferator-activated receptor gamma
(PPAR-gamma) agonist or activator thereof, thereby generating the
adipocyte cell.
[0324] As used herein the phrase "spontaneously immortalized
fibroblast" refers to a fibroblast cell which is capable of
undergoing unlimited cell division, and preferably also cell
expansion, without being subjected to man-induced mutation e.g.,
genetic manipulation, causing the immortalization.
[0325] It should be noted that normally, primary fibroblast cells
are capable of a limited cell division, and thus undergo cellular
senescence after about 30 population doublings (e.g., 10 passages).
Methods of generating immortalized fibroblastoid cell lines include
genetic manipulation by introduction of a telomerase gene, or SV40,
or HPVE6/E7 gene using known methods.
[0326] According to some embodiments of the invention, the
fibroblast is an avian fibroblast.
[0327] According to some embodiments of the invention, the avian is
selected from the group consisting of: chicken, duck, goose, and
quail.
[0328] According to some embodiments of the invention, the
fibroblast is a chicken embryonic fibroblast.
[0329] According to some embodiments of the invention, the
spontaneously immortalized fibroblast is non-genetically
modified.
[0330] As used herein the phrase "non-genetically modified" refers
to not being subject to man-made genetic manipulation (e.g.,
transformation) of the cell.
[0331] PPAR is subfamily of the nuclear receptor superfamily of
transcription factors, plays important roles in lipid and glucose
metabolism, and has been implicated in obesity-related metabolic
diseases such as hyperlipidemia, insulin resistance, and coronary
artery disease.
[0332] PPAR.gamma. (peroxisome proliferator-activated receptor
gamma) is a fatty acid-activated member of the PPAR subfamily. It
is expressed at low levels in most physiological systems, including
the central nervous system (CNS), endocrine system,
gastrointestinal system, reproductive system, cardiopulmonary
system and metabolic tissues, but is most highly expressed in brown
and white adipose tissue (Elbrecht A, et al. 1996; "Molecular
cloning, expression and characterization of human peroxisome
proliferator activated receptors gamma 1 and gamma 2". Biochem.
Biophys. Res. Commun. 224 431-7 V).
[0333] As used herein the phrase "PPAR-gamma activator" refers to
an agent which induces the signaling pathway of PPAR-gamma leading
to activation of PPAR-gamma.
[0334] According to some embodiments of the invention, an activator
of PPAR-gamma does not need to directly bind the ligand-binding
domain of PPAR-gamma, but can induce the PPAR-gamma signaling
pathway leading to activation of PPAR-gamma by endogenous
ligand(s).
[0335] For example, a PPAR-gamma activator can be PPAR-gamma
agonist.
[0336] As used herein the phrase "PPAR-gamma agonist" refers to an
agent which binds to the ligand-binding domain of PPAR-gamma.
[0337] It should be noted that upon binding of the agonist to the
ligand-binding domain of PPAR-gamma, the PPAR-gamma protein
undergoes a conformational change resulting in activation of
PPAR-gamma.
[0338] For example, activation of PPAR-gamma (a transcription
factor) can be detected by monitoring expression of PPAR-gamma
target genes.
[0339] Methods of qualifying agonists or activators of PPAR-gamma
include, but are not limited to using a GAL4-PPAR-gamma reporter, a
LanthaScreen TR-FRET competitive binding assay (ThermoFisher,
PV4894), using a GFP-reporter driven by PPAR response element
(PPRE), or by checking the expression of target genes, essentially
as described in Goldwasser et al. PLoS One 2010, Volume 5, Issue 8,
e12399, which is fully incorporated herein by reference).
[0340] Non-limiting examples of PPAR.gamma. (gamma) target genes,
include genes related to adipogenesis (e.g., ADIPOQ, LPL, NR1H3,
and UCP1); genes related to fatty Acid Metabolism (e.g., ACADL,
ACADM, ACOX1, ACOX3, ACSL1, ACSL3, ACSL4, ACSL5, CPT1A, CPT1B,
CPT2, CYP27A1, CYP4A11, CYP7A1, EHHADH, FADS2, GK, and SCD); genes
related to lipid transport (e.g., ADIPOQ, ANGPTL4, APOE, DGAT1,
LPL, NR1H3, and OLR1); genes related to cell proliferation (e.g.,
CLU, ELN, HSPD1, and TXNIP); genes related to insulin signaling
(e.g., CPT1A, DGAT1, PCK1, and SORBS1) and other genes such as MMP9
and PCK1.
[0341] According to some embodiments of the invention, the
PPAR-gamma agonist or activator is a small molecule.
[0342] According to some embodiments of the invention, the small
molecule is selected from the group consisting of
Thiazolidinedione, 3-Isobutyl-1-methylxanthine (IBMX), phenamil,
GW7845, RG14620, and Harmine.
[0343] Thiazolidinediones (also known as "Glitazones") are a class
of medications that act by activating PPARs (peroxisome
proliferator-activated receptors), with greatest specificity for
PPAR.gamma. (PPAR-gamma, PPARG). The endogenous ligands for these
receptors are free fatty acids (FFAs) and eicosanoids.
[0344] According to some embodiments of the invention, the
Thiazolidinedione is provided at a concentration in the range of
about 20 nM to about 120 .mu.M, e.g., from 50 nM to 100 .mu.M,
e.g., from 100 nM to 50 .mu.M, e.g., from 1 .mu.M to 50 .mu.M,
e.g., in the range of 0.5-30 .mu.M, e.g., in the range of 0.5-25
.mu.M, e.g., about 0.5 .mu.M, about 1 .mu.M, about 5 .mu.M, about
10 .mu.M, about 15 .mu.M.
[0345] According to some embodiments of the invention, the
Thiazolidinedione is selected from the group consisting of
Pioglitazone (Actos), Rosiglitazone (Avandia), Lobeglitazone
(Dulie), Troglitazone (Rezulin), Ciglitazone, Darglitazone,
Englitazone, Netoglitazone, and Rivoglitazone.
[0346] According to some embodiments of the invention, the small
molecule is rosiglitazone.
[0347] According to some embodiments of the invention, the
concentration of rosiglitazone is between 1-10 .mu.M, e.g., about 5
.mu.M.
[0348] According to some embodiments of the invention, the
concentration of troglitazone is between 0.5-10 .mu.M, e.g., about
0.5-5 .mu.M, e.g., about 1 .mu.M.
[0349] According to some embodiments of the invention, the
PPAR-gamma agonist or activator is selenium.
[0350] Oleic acid is a naturally-occurring fatty acid, classified
as monounsaturated omega-9 fatty acid, abbreviated with a lipid
number of 18:1 cis-9.
[0351] According to some embodiments of the invention, the
concentration of oleic acid which is used in the serum-free medium
of some embodiments of the invention is from about 50 .mu.M to
about 1000 .mu.M, e.g., between 200-400 .mu.M.
[0352] According to some embodiments of the invention, the
culturing of the fibroblast is for at least 4 days, e.g., for at
least 5, 6, 7, 8, 9, 10, 15, 20 or more days.
[0353] It should be noted that for generation of a cultured edible
meat the medium used in the method of generating an adipocyte cell
should be well-defined, and serum-free. Well-defined culture medium
can be prepared by using recombinant, and/or synthetically and/or
purified agents. Since serum is obtained from a living organism,
e.g., a human being or an animal, it is subject to batch-to-batch
variations, and may further include animal or human contaminants,
such as bacterial, viral or fungal infections. Accordingly, it is
preferred to use a serum-free medium.
[0354] According to some embodiments of the invention, the
serum-free medium is devoid of animal contaminants.
[0355] According to some embodiments of the invention, the
serum-free medium is devoid of human contaminants.
[0356] According to some embodiments of the invention, the
serum-free medium is devoid any antibiotic drug.
[0357] According to some embodiments of the invention, for the
adipocyte differentiation the serum-free medium can include
insulin, and optionally also bFGF.
[0358] According to some embodiments of the invention, for the
adipocyte differentiation the serum-free medium can include
selenium, and optionally also insulin.
[0359] According to some embodiments of the invention, the
serum-free medium for culturing the spontaneously immortalized
chicken fibroblasts comprises insulin or a substitute thereof, and
basic fibroblast growth factor (bFGF) or a substitute thereof, and
at least one additional agent selected from the group consisting of
dexamethasone, transferrin, selenium, epidermal growth factor (EGF)
or a substitute thereof, and Prostaglandin E2 (PGE2).
[0360] As used herein the term "insulin" refers to the mature
insulin polypeptide having A chain and B chain, which are
covalently linked via two disulfide bonds. Also known as CAS Number
11061-68-0; EC Number 234-279-7; MDL number MFCD00131380. The
precursor polypeptide preproinsulin is cleaved to remove the
precursor signal peptide, and then the proinsulin is
post-translationally cleaved into three peptides: the B chain and A
chain peptides, which are covalently linked via two disulfide bonds
to form insulin, and C-peptide. Binding of insulin to the insulin
receptor (INSR) stimulates glucose uptake. There are 4 polypeptide
variants, encoding the same protein: variant 1 [GenBank Accession
No. NM_000207.2 (SEQ ID NO: 13), GenBank Accession No. NP_000198.1
(SEQ ID NO: 14)], variant 2 [GenBank Accession No. NM_001185097.1
(SEQ ID NO: 15), GenBank Accession No. NP_001172026.1 (SEQ ID NO:
16)]; variant 3 [GenBank Accession No. NM_001185098.1 (SEQ ID NO:
17), GenBank Accession No. NP_001172027.1 (SEQ ID NO: 18)]; and
variant 4 [GenBank Accession No. NM_001291897.1 (SEQ ID NO: 19),
GenBank Accession No. NP_001278826.1 (SEQ ID NO: 20)]. Insulin can
be provided from various suppliers such as Sigma-Aldrich (e.g.,
recombinant human insulin Catalogue Number 91077C).
[0361] According to some embodiments of the invention, the insulin
substitute comprises IGF-1 (Sigma 1146) or a stabilized Long R3
IGF-1 (Sigma I1271) According to some embodiments of the invention,
the insulin is provided at a concentration of 2.5.times.10.sup.-5
IU/mL to 1 IU/mL, e.g., between 0.1 IU/mL to about 0.5 IU/mL, e.g.,
about 0.24-0.3 IU/mL. It should be noted that IU/mL is an
abbreviation of "International Units Per Millilitre
(milliliter)".
[0362] Dexamethasone is a corticosteroid medication which can be
obtained from various suppliers such as Ark Pharm, Inc.,
Sigma-Aldrich, Parchem, and AvaChem Scientific.
[0363] According to some embodiments of the invention, the
dexamethasone is provided at a concentration of about 0.01 nM to
about 100 .mu.M, e.g., from about 0.01 nM to about 10 .mu.M, e.g.,
from 4 nM to about 10 .mu.M, e.g., between 70-120 nM, e.g., about
100 nM (0.1 .mu.M).
[0364] According to some embodiments of the invention, the medium
includes Basic fibroblast growth factor (bFGF) or a substitute
thereof, such as a small molecule or a synthetic agonist of the
FGF-signaling pathway.
[0365] Basic fibroblast growth factor (also known as bFGF, FGF2 or
FGF-.beta.) is a member of the fibroblast growth factor family.
BFGF [(e.g., human bFGF polypeptide GenBank Accession No.
NP_001997.5 (SEQ ID NO:21); human bFGF polynucleotide GenBank
Accession No. NM_002006.4 (SEQ ID NO: 22)] can be obtained from
various commercial sources such as Cell Sciences.RTM., Canton,
Mass., USA (e.g., Catalogue numbers CRF001A and CRF001B),
Invitrogen Corporation products, Grand Island N.Y., USA (e.g.,
Catalogue numbers: PHG0261, PHG0263, PHG0266 and PHG0264),
ProSpec-Tany TechnoGene Ltd. Rehovot, Israel (e.g., Catalogue
number: CYT-218), and Sigma, St Louis, Mo., USA (e.g., catalogue
number: F0291).
[0366] According to some embodiments of the invention, the bFGF is
provided at a concentration of 0.1-100 ng/ml, e.g., about 0.1-30
ng/ml, e.g., about 0.2-80 ng/ml, e.g., about 0.4-70 ng/ml. e.g.,
about 0.5-60 ng/ml, e.g., about 0.8-50 ng/ml, e.g., between about 1
ng/ml to about 40 ng/ml, e.g., about 1-20 ng/ml, e.g., about 2-20
ng/ml, e.g., about 3-20 ng/ml, e.g., about 4-15 ng/ml. e.g., about
10 ng/ml.
[0367] According to some embodiments of the invention, the
synthetic agonist of the FGF signaling is C19-jun.
[0368] According to some embodiments of the invention, the C19-jun
is provided at a concentration of about 1 ng/ml to about 50 ng/ml,
e.g., in the range of 10-20 ng/ml.
[0369] According to some embodiments of the invention, the
transferrin is provided at a concentration of about 0.1 ng/ml to
about 55 .mu.g/ml, e.g., from about 10 ng/ml to about 10 .mu.g/ml,
e.g., between 1-10 .mu.g/ml, e.g., 5.5 .mu.g/ml transferrin.
[0370] According to some embodiments of the invention, the selenium
is provided at a concentration of about 0.1 ng/ml to about 6000
.mu.g/ml. For example, in order to support fibroblast cell growth
the selenium can be provided at a concentration of about 1-10 ng/ml
(e.g., about 5 ng/ml of selenium to support cell growth).
Alternatively, to induce adipogenesis from a fibroblast cell the
selenium can be used at higher concentrations such as 200-1000
.mu.g/ml, e.g., about 500-800 .mu.g/ml, e.g., about 600 .mu.g/ml to
induce adipogenesis from a fibroblast cell.
[0371] The epidermal growth factor superfamily of proteins act as
potent mitogenic factors that play an important role in the growth,
proliferation and differentiation of numerous cell types. EGF can
be purchased from Peprotech (IL, e.g., Catalogue Number
AF10015).
[0372] According to some embodiments of the invention, the
epidermal growth factor (EGF) is provided at a concentration of
0.1-30 ng/ml, e.g., 0.5-20 ng/ml, e.g., 1-10 ng/ml, e.g., about 5
ng/ml.
[0373] According to some embodiments of the invention, the
substitute of EGF comprises an EGF-R agonist.
[0374] According to some embodiments of the invention, the EGF-R
agonist comprises NSC-228155.
[0375] According to some embodiments of the invention, the
NSC-228155 is provided at a concentration of about 1 ng/ml to about
100 ng/ml, e.g., about 5-50 ng/ml.
[0376] According to some embodiments of the invention, the
Prostaglandin E2 (PGE2) is provided at a concentration of 0.01
nM-10 .mu.M, e.g., from about 0.1 nM to about 1 .mu.M, e.g., from
about 10 nM to about 0.5 .mu.M, e.g., from about 50 .mu.M to about
0.5 .mu.M, e.g., about 0.01 .mu.M.
[0377] Any of the proteinaceous factors used by the method of some
embodiments of the invention (e.g., the insulin, bFGF, EGF, PGE2)
can be recombinantly expressed or biochemically synthesized. In
addition, naturally occurring proteinaceous factors such as bFGF
can be purified from biological samples (e.g., from human serum,
cell cultures) using methods well known in the art. It should be
noted that for the preparation of an animal contaminant-free
culture medium the proteinaceous factor is preferably purified from
a human source or is recombinantly expressed.
[0378] Biochemical synthesis of the proteinaceous factors of the
present invention (e.g., the insulin, bFGF, EGF, PGE2) can be
performed using standard solid phase techniques. These methods
include exclusive solid phase synthesis, partial solid phase
synthesis methods, fragment condensation and classical solution
synthesis.
[0379] Recombinant expression of the proteinaceous factors of the
present invention can be generated using recombinant techniques
such as described by Bitter et al., (1987) Methods in Enzymol.
153:516-544, Studier et al. (1990) Methods in Enzymol. 185:60-89,
Brisson et al. (1984) Nature 310:511-514, Takamatsu et al. (1987)
EMBO J. 6:307-311, Coruzzi et al. (1984) EMBO J. 3:1671-1680,
Brogli et al., (1984) Science 224:838-843, Gurley et al. (1986)
Mol. Cell. Biol. 6:559-565 and Weissbach & Weissbach, 1988,
Methods for Plant Molecular Biology, Academic Press, NY, Section
VIII, pp 421-463.
[0380] Methods of synthesizing the fatty acids, small molecules
such as Thiazolidinediones (TZD) are known in the art.
[0381] According to some embodiments of the invention, the method
is performed in-vitro.
[0382] Thus, the method of some embodiments of the invention result
in the conversion of a fibroblast cell to an adipocyte cells.
[0383] Without being bound by any theory, the conversion may occur
by transdifferentiation.
[0384] The adipocyte which is formed by the in-vitro method of some
embodiments of the invention, by culturing the spontaneously
immortalized fibroblast exhibit the characteristics of a
naturally-occurring adipocyte, e.g., having a compact shape (not
elongated), stains positive with Oil-O-Red, and exhibits lipid
droplets with a neutral lipid stain (e.g., as shown in FIGS.
4A-D).
[0385] According to an aspect of some embodiments of the invention
there is provided an adipocyte cell which is obtainable according
to the method of some embodiments of the invention.
[0386] According to an aspect of some embodiments of the invention
there is provided a method of generating a cultured fat on a
protein matrix, comprising generating the adipocyte cell generated
from the fibroblast according to the method of some embodiments of
the invention, wherein the culturing is performed on a
plant-derived protein matrix, thereby generating the cultured fat
on the protein matrix.
[0387] According to some embodiments of the invention, the
plant-derived protein matrix is from the legume (Fabaceae) family,
from the cereal family or from the pseudocereal family.
[0388] According to some embodiments of the invention, the
plant-derived protein matrix is from the legume, Fabaceae, family
such as alfalfa, peas, beans, lentils, carob, soybeans,
peanuts.
[0389] According to some embodiments of the invention, the
plant-derived protein matrix is from the cereal family such as
maize, rice, wheat, barley, sorghum, millet, oats, rye, tritcale,
fonio.
[0390] According to some embodiments of the invention, the
plant-derived protein matrix is selected the pseudocereal family
including buckwheat, quinoa, or chia
[0391] According to some embodiments of the invention, the
plant-derived protein matrix comprises a soy protein or a pea
protein.
[0392] According to some embodiments of the invention, the
plant-derived protein matrix is from a soy protein or a pea
protein.
[0393] According to an aspect of some embodiments of the invention
there is provided a cultured fat in a plant-derived protein
matrix.
[0394] According to some embodiments of the invention, the cultured
fat in the plant-derived protein matrix includes about 1-1000
million cells per gram.
[0395] According to some embodiments of the invention, the cultured
fat of some embodiments of the invention is obtainable by the
method of some embodiments of the invention.
[0396] According to an aspect of some embodiments of the invention
there is provided an in-vitro method of generating a myocyte from a
fibroblast, comprising upregulating expression within a
spontaneously immortalized fibroblast of a polypeptide selected
from the group consisting of myoD1 and myogenin.
[0397] Methods of upregulating a level of expression and/or
activity of a polypeptide are well known in the art and include
recombinant DNA techniques and/or genome editing methods as is
further described hereinunder.
[0398] According to some embodiments of the invention, the
upregulation is of the myoD1 and myogenin polypeptides.
[0399] According to some embodiments of the invention, the chicken
myoD1 polypeptide is encoded by a polynucleotide comprising the
nucleic acid sequence set forth by SEQ ID NO:5.
[0400] According to some embodiments of the invention, the chicken
myogenin polypeptide is encoded by a polynucleotide comprising the
nucleic acid sequence set forth by SEQ ID NO:7.
[0401] According to some embodiments of the invention, the chicken
myoD1 polypeptide is encoded by the nucleic acid construct set
forth by SEQ ID NO: 1 or 3.
[0402] According to some embodiments of the invention, the chicken
myogenin polypeptide is encoded by the nucleic acid construct set
forth by SEQ ID NO: 2.
[0403] According to an aspect of some embodiments of the invention
there is provided a myocyte obtainable according to the methods of
some embodiments of the invention.
[0404] According to an aspect of some embodiments of the invention
there is provided an in-vitro method of screening for a small
molecule capable of producing a myocyte, comprising:
[0405] (a) transfecting a spontaneously immortalized fibroblast
with a nucleic acid construct comprising a nucleic acid sequence
encoding a reporter polypeptide under a transcriptional control of
a promoter specifically active in myocytes,
[0406] (b) contacting a transfected fibroblast resultant of step
(a) with at least one small molecule of a plurality of small
molecules, and
[0407] (c) detecting activity of the reporter polypeptide above a
pre-determined threshold in the transfected fibroblast following
step (b), wherein presence of the activity above the pre-determined
threshold is indicative that the at least one small molecule is
capable of converting the spontaneously immortalized fibroblast
into the myocyte.
[0408] According to some embodiments of the invention, the
fibroblast is an avian fibroblast.
[0409] According to some embodiments of the invention, the avian is
selected from the group consisting of: chicken, duck, goose, and
quail.
[0410] Non-limiting examples of reporter polypeptides include, the
green fluorescent protein (GFP), blue fluorescent protein (BFP),
red fluorescent protein (RFP) or yellow fluorescent protein
(YFP).
[0411] According to some embodiments of the invention the reporter
polypeptide is the COP-GFP (e.g., as shown in FIG. 8). For example,
the coding sequence of the COP-GFP can be the nucleic acid sequence
set forth by SEQ ID NO: 12.
[0412] Fluorescence detection methods which can be used to detect
the reporter polypeptide include for example, fluorescence
activated flow cytometry (FACS), immunofluorescence confocal
microscopy, fluorescence in-situ hybridization (FISH) and
fluorescence resonance energy transfer (FRET).
[0413] It should be noted that the spontaneously immortalized
fibroblasts can be also used in screening without genetic
modification (e.g., visually for instance), for example with an
antibody or a dye.
[0414] According to an aspect of some embodiments of the invention
there is provided an n-vitro method of generating an edible meat,
comprising culturing:
[0415] (a) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
an adipocyte, and/or
[0416] (b) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
a myocyte,
[0417] thereby generating the edible meat.
[0418] According to an aspect of some embodiments of the invention
there is provided an in-vitro method of generating an edible meat,
comprising culturing:
[0419] (a) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
an adipocyte, and; or
[0420] (b) a spontaneously immortalized fibroblast in a serum-free
medium under conditions suitable for converting the fibroblast into
a myocyte,
[0421] (c) an endothelial cell,
thereby generating the edible meat.
[0422] According to some embodiments of the invention, the step (a)
and step (b) are effected simultaneously in the same culture
system.
[0423] According to some embodiments of the invention, the step (a)
and step (b) are effected in two distinct (e.g., separated) culture
systems.
[0424] According to some embodiments of the invention, the steps
(a), (b) and (c) are effected simultaneously in the same culture
system.
[0425] According to some embodiments of the invention, the
serum-free medium comprises oleic acid and a PPAR-gamma
agonist.
[0426] According to some embodiments of the invention, the
endothelial cell is a spontaneously immortalized endothelial
cell.
[0427] According to some embodiments of the invention, the
endothelial cell is non-genetically modified.
[0428] According to some embodiments of the invention, the
culturing is performed on a scaffold.
[0429] According to some embodiments of the invention, the cells
attach to the scaffold.
[0430] Non-limiting examples of scaffolds include, but are not
limited to various sponges, matrices, hydrogels or beads;
[0431] Examples of suitable sponges include, but are not limited
to, polylactic acid, polyglycolic acid, or poly(lactic-co-glycolic
acid) (PLGA, Sigma P2191, P2066, P1941, 430471, 764868, 790214,
900289), Variotis.TM. (Biometic, AU), Cellusponge.TM.
(hydroxypropyl cellulose. Bio-Byblos Catalogue No. Z741057).
[0432] According to some embodiments of the invention, the scaffold
is biodegradable.
[0433] According to some embodiments of the invention, the
culturing is performed in a perfusion system.
[0434] According to some embodiments of the invention, the
culturing is performed in the perfusion system of some embodiments
of the invention.
[0435] According to some embodiments of the invention, the
culturing is performed on an edible hollow fiber cartridge, where
nutrient supply is homogenously distributed in the absence of an
integrated vascular network. For example, the fibers of the
cartridge are made from edible natural or synthetic polymers, such
as cellulose (FiberCell, #C3008), cellulose acetate and the cells
form a mass surrounding the fibers. Cellulose is FDA approved as
GRAS, and used to control moisture and stabilizer shredded cheese,
bread, and various sauces.
[0436] According to some embodiments of the invention, the
culturing is performed on a vegetable-derived matrix.
[0437] According to some embodiments of the invention, the
vegetable-derived matrix is from a cereal, gluten, or legume.
[0438] According to some embodiments of the invention, the
vegetable-derived matrix is selected from the legume, Fabaceae,
family, such as alfalfa, peas, beans, lentils, carob, soybeans,
peanuts; or from the cereal family, such as maize, rice, wheat,
barley, sorghum, millet, oats, rye, tritcale, fonio; and/or from
the pseudocereal family including buckwheat, quinoa, or chia.
[0439] According to some embodiments of the invention, the legume
is soy or pea.
[0440] According to some embodiments of the invention, the
culturing is performed in a suspension culture devoid of substrate
adherence, without any adherence of the cells to the scaffold,
matrix, sponge, or any carrier such as micro-carrier beads.
[0441] According to an aspect of some embodiments of the invention
there is provided an edible meat obtainable from the method of some
embodiments of the invention.
[0442] According to some embodiments of the invention, the edible
meat is in a form of a patty of nugget with a density in the range
of about 100.times.10.sup.6 cells/gram to about 500.times.10.sup.6
cells/gram, e.g., about 200.times.10.sup.6 cells/gram.
[0443] According to an aspect of some embodiments of the invention
there is provided a method of generating a spontaneously
immortalized fibroblast, comprising:
[0444] (a) culturing avian embryo cells in the presence of a
serum-containing medium under adherent culture conditions to
thereby obtain chicken embryonic fibroblasts,
[0445] (b) passaging the avian embryonic fibroblasts for at least
10-12 passages in the serum-containing medium under the adherent
conditions until culture collapse, wherein the culture collapse is
characterized by senescence and/or death of at least 90% of avian
embryonic fibroblasts,
[0446] (c) isolating at least one colony which survived the culture
collapse in the serum-containing medium for at least additional 20
passages,
[0447] thereby generating the spontaneously immortalized
fibroblast.
[0448] As used herein the phrase "culture collapse" refers to a
cell culture in which the majority of the cells have undergone
senescence (i.e., stop cell division) or cell
apoptosis/necrosis.
[0449] According to some embodiments of the invention, the
serum-containing medium is a DMEM/F12 based medium.
[0450] According to some embodiments of the invention, the serum in
the medium comprises 15% FBS (fetal bovine serum).
[0451] According to some embodiments of the invention, the
serum-containing medium further comprises L-Analyl-L-Glutamine.
[0452] According to some embodiments of the invention, the chicken
embryo is obtained from a fertilized broiler chicken egg grown for
10-12 days.
[0453] According to an aspect of some embodiments of the invention
there is provided a spontaneously immortalized chicken fibroblast
obtainable by the method of some embodiments of the invention.
[0454] According to some embodiments of the invention, the
spontaneously immortalized chicken fibroblast is capable of a
continuous passaging for at least about 15, about 20, about 25,
about 30, about 35, about 40 passages.
[0455] According to some embodiments of the invention, the
spontaneously immortalized chicken fibroblast is capable of at
least about 40, about 45, about 50, about 55, about 60, about 65,
about 70, about 75, about 80, about 85, about 90 or more population
doublings.
[0456] Upregulation of myoD1 and/or myogenin in a cell (e.g., a
spontaneously immortalized fibroblast) can be effected at the
genomic level (i.e., activation of transcription via promoters,
enhancers, regulatory elements), at the transcript level (i.e.,
correct splicing, polyadenylation, activation of translation) or at
the protein level (i.e., post-translational modifications,
interaction with substrates and the like).
[0457] Following is a list of agents capable of upregulating the
expression level and/or activity of myoD1 and/or myogenin.
[0458] An agent capable of upregulating expression of a myoD1
and/or myogenin may be an exogenous polynucleotide sequence
designed and constructed to express at least a functional portion
of the myoD1 and/or myogenin. Accordingly, the exogenous
polynucleotide sequence may be a DNA or RNA sequence encoding a
myoD1 and/or myogenin molecule, capable of converting the
fibroblast to a myocyte cell.
[0459] To express exogenous myoD1 and/or myogenin in avian cells, a
polynucleotide sequence encoding myoD1 and/or myogenin is
preferably ligated into a nucleic acid construct suitable for avian
cell expression. Such a nucleic acid construct includes a promoter
sequence for directing transcription of the polynucleotide sequence
in the cell in a constitutive or inducible manner.
[0460] It will be appreciated that the nucleic acid construct of
some embodiments of the invention can also utilize myoD1 and/or
myogenin homologues which exhibit the desired activity (e.g.,
capable of converting the fibroblast to a myocyte cell). Such
homologues can be, for example, at least 80%, at least 81%, at
least 82%, at least 83%, at least 84%, at least 85%, at least 86%,
at least 87%, at least 88%, at least 89%, at least 90%, at least
91%, at least 92%, at least 93%, at least 94%, at least 95%, at
least 96%, at least 97%, at least 98%, at least 99% or 100%
identical to SEQ ID NO:5 or 7, as determined using the BestFit
software of the Wisconsin sequence analysis package, utilizing the
Smith and Waterman algorithm, where gap weight equals 50, length
weight equals 3, average match equals 10 and average mismatch
equals -9.
[0461] Constitutive promoters suitable for use with some
embodiments of the invention are promoter sequences which are
active under most environmental conditions and most types of cells
such as the cytomegalovirus (CMV) and Rous sarcoma virus (RSV).
Inducible promoters suitable for use with some embodiments of the
invention include for example the tetracycline-inducible promoter
(Zabala M, et al., Cancer Res. 2004, 64(8): 2799-804).
[0462] The nucleic acid construct (also referred to herein as an
"expression vector") of some embodiments of the invention includes
additional sequences which render this vector suitable for
replication and integration in prokaryotes, eukaryotes, or
preferably both (e.g., shuttle vectors). In addition, a typical
cloning vectors may also contain a transcription and translation
initiation sequence, transcription and translation terminator and a
polyadenylation signal. By way of example, such constructs will
typically include a 5' LTR, a tRNA binding site, a packaging
signal, an origin of second-strand DNA synthesis, and a 3' LTR or a
portion thereof.
[0463] The nucleic acid construct of some embodiments of the
invention typically includes a signal sequence for secretion of the
peptide from a host cell in which it is placed. Preferably the
signal sequence for this purpose is a mammalian signal sequence or
the signal sequence of the polypeptide variants of some embodiments
of the invention.
[0464] Eukaryotic promoters typically contain two types of
recognition sequences, the TATA box and upstream promoter elements.
The TATA box, located 25-30 base pairs upstream of the
transcription initiation site, is thought to be involved in
directing RNA polymerase to begin RNA synthesis. The other upstream
promoter elements determine the rate at which transcription is
initiated.
[0465] Preferably, the promoter utilized by the nucleic acid
construct of some embodiments of the invention is active in the
specific cell population transformed.
[0466] Enhancer elements can stimulate transcription up to 1,000
fold from linked homologous or heterologous promoters. Enhancers
are active when placed downstream or upstream from the
transcription initiation site. Many enhancer elements derived from
viruses have a broad host range and are active in a variety of
tissues. For example, the SV40 early gene enhancer is suitable for
many cell types. Other enhancer/promoter combinations that are
suitable for some embodiments of the invention include those
derived from polyoma virus, human or murine cytomegalovirus (CMV),
the long term repeat from various retroviruses such as murine
leukemia virus, murine or Rous sarcoma virus and HIV. See,
Enhancers and Eukaryotic Expression, Cold Spring Harbor Press, Cold
Spring Harbor, N.Y. 1983, which is incorporated herein by
reference.
[0467] In the construction of the expression vector, the promoter
is preferably positioned approximately the same distance from the
heterologous transcription start site as it is from the
transcription start site in its natural setting. As is known in the
art, however, some variation in this distance can be accommodated
without loss of promoter function.
[0468] Polyadenylation sequences can also be added to the
expression vector in order to increase the efficiency of myoD1
and/or myogenin mRNA translation. Two distinct sequence elements
are required for accurate and efficient polyadenylation: GU or U
rich sequences located downstream from the polyadenylation site and
a highly conserved sequence of six nucleotides, AAUAAA, located
11-30 nucleotides upstream. Termination and polyadenylation signals
that are suitable for some embodiments of the invention include
those derived from SV40.
[0469] In addition to the elements already described, the
expression vector of some embodiments of the invention may
typically contain other specialized elements intended to increase
the level of expression of cloned nucleic acids or to facilitate
the identification of cells that carry the recombinant DNA. For
example, a number of animal viruses contain DNA sequences that
promote the extra chromosomal replication of the viral genome in
permissive cell types. Plasmids bearing these viral replicons are
replicated episomally as long as the appropriate factors are
provided by genes either carried on the plasmid or with the genome
of the host cell.
[0470] The vector may or may not include a eukaryotic replicon. If
a eukaryotic replicon is present, then the vector is amplifiable in
eukaryotic cells using the appropriate selectable marker. If the
vector does not comprise a eukaryotic replicon, no episomal
amplification is possible. Instead, the recombinant DNA integrates
into the genome of the engineered cell, where the promoter directs
expression of the desired nucleic acid.
[0471] The expression vector of some embodiments of the invention
can further include additional polynucleotide sequences that allow,
for example, the translation of several proteins from a single mRNA
such as an internal ribosome entry site (IRES) and sequences for
genomic integration of the promoter-chimeric polypeptide.
[0472] It will be appreciated that the individual elements
comprised in the expression vector can be arranged in a variety of
configurations. For example, enhancer elements, promoters and the
like, and even the polynucleotide sequence(s) encoding a myoD1
and/or myogenin can be arranged in a "head-to-tail" configuration,
may be present as an inverted complement, or in a complementary
configuration, as an anti-parallel strand. While such variety of
configuration is more likely to occur with non-coding elements of
the expression vector, alternative configurations of the coding
sequence within the expression vector are also envisioned.
[0473] Expression vectors containing regulatory elements from
eukaryotic viruses such as retroviruses can be also used. SV40
vectors include pSVT7 and pMT2. Vectors derived from bovine
papilloma virus include pBV-1MTHA, and vectors derived from Epstein
Bar virus include pHEBO, and p2O5. Other exemplary vectors include
pMSG, pAV009/A.sup.+, pMTO10/A.sup.+, pMAMneo-5, baculovirus pDSVE,
and any other vector allowing expression of proteins under the
direction of the SV-40 early promoter, SV-40 later promoter,
metallothionein promoter, murine mammary tumor virus promoter, Rous
sarcoma virus promoter, polyhedrin promoter, or other promoters
shown effective for expression in eukaryotic cells.
[0474] As described above, viruses are very specialized infectious
agents that have evolved, in many cases, to elude host defense
mechanisms. Typically, viruses infect and propagate in specific
cell types. The targeting specificity of viral vectors utilizes its
natural specificity to specifically target predetermined cell types
and thereby introduce a recombinant gene into the infected cell.
Thus, the type of vector used by some embodiments of the invention
will depend on the cell type transformed. The ability to select
suitable vectors according to the cell type transformed is well
within the capabilities of the ordinary skilled artisan and as such
no general description of selection consideration is provided
herein. For example, bone marrow cells can be targeted using the
human T cell leukemia virus type I (HTLV-I) and kidney cells may be
targeted using the heterologous promoter present in the baculovirus
Autographa californica nucleopolyhedrovirus (AcMNPV) as described
in Liang C Y et al., 2004 (Arch Virol. 149: 51-60).
[0475] Recombinant viral vectors are useful for in vivo expression
of myoD1 and/or myogenin since they offer advantages such as
lateral infection and targeting specificity. Lateral infection is
inherent in the life cycle of, for example, retrovirus and is the
process by which a single infected cell produces many progeny
virions that bud off and infect neighboring cells. The result is
that a large area becomes rapidly infected, most of which was not
initially infected by the original viral particles. This is in
contrast to vertical-type of infection in which the infectious
agent spreads only through daughter progeny. Viral vectors can also
be produced that are unable to spread laterally. This
characteristic can be useful if the desired purpose is to introduce
a specified gene into only a localized number of targeted
cells.
[0476] Various methods can be used to introduce the expression
vector of some embodiments of the invention into stem cells. Such
methods are generally described in Sambrook et al., Molecular
Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New
York (1989, 1992), in Ausubel et al., Current Protocols in
Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989),
Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich.
(1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor Mich.
(1995), Vectors: A Survey of Molecular Cloning Vectors and Their
Uses, Butterworths, Boston Mass. (1988) and Gilboa et at.
[Biotechniques 4 (6): 504-512, 1986] and include, for example,
stable or transient transfection, lipofection, electroporation and
infection with recombinant viral vectors. In addition, see U.S.
Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection
methods.
[0477] Introduction of nucleic acids by viral infection offers
several advantages over other methods such as lipofection and
electroporation, since higher transfection efficiency can be
obtained due to the infectious nature of viruses.
[0478] Currently preferred in vivo nucleic acid transfer techniques
include transfection with viral or non-viral constructs, such as
adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated
virus (AAV) and lipid-based systems. Useful lipids for
lipid-mediated transfer of the gene are, for example, DOTMA, DOPE,
and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65
(1996)]. The most preferred constructs for use in gene therapy are
viruses, most preferably adenoviruses, AAV, lentiviruses, or
retroviruses. A viral construct such as a retroviral construct
includes at least one transcriptional promoter/enhancer or
locus-defining element(s), or other elements that control gene
expression by other means such as alternate splicing, nuclear RNA
export, or post-translational modification of messenger. Such
vector constructs also include a packaging signal, long terminal
repeats (LTRs) or portions thereof, and positive and negative
strand primer binding sites appropriate to the virus used, unless
it is already present in the viral construct. In addition, such a
construct typically includes a signal sequence for secretion of the
peptide from a host cell in which it is placed. Preferably the
signal sequence for this purpose is a mammalian signal sequence or
the signal sequence of the polypeptide variants of some embodiments
of the invention. Optionally, the construct may also include a
signal that directs polyadenylation, as well as one or more
restriction sites and a translation termination sequence. By way of
example, such constructs will typically include a 5' LTR, a tRNA
binding site, a packaging signal, an origin of second-strand DNA
synthesis, and a 3' LTR or a portion thereof. Other vectors can be
used that are non-viral, such as cationic lipids, polylysine, and
dendrimers.
[0479] Other than containing the necessary elements for the
transcription and translation of the inserted coding sequence, the
expression construct of some embodiments of the invention can also
include sequences engineered to enhance stability, production,
purification, yield or toxicity of the expressed peptide. For
example, the expression of a fusion protein or a cleavable fusion
protein comprising the myoD1 and/or myogenin protein of some
embodiments of the invention and a heterologous protein can be
engineered. Such a fusion protein can be designed so that the
fusion protein can be readily isolated by affinity chromatography;
e.g., by immobilization on a column specific for the heterologous
protein. Where a cleavage site is engineered between the myoD1
and/or myogenin protein and the heterologous protein, the myoD1
and/or myogenin protein can be released from the chromatographic
column by treatment with an appropriate enzyme or agent that
disrupts the cleavage site [e.g., see Booth et al. (1988) Immunol.
Lett. 19:65-70; and Gardella et al., (1990) J. Biol. Chem.
265:15854-15859].
[0480] As mentioned hereinabove, a variety of prokaryotic or
eukaryotic cells can be used as host-expression systems to express
the polypeptides of some embodiments of the invention. These
include, but are not limited to, microorganisms, such as bacteria
transformed with a recombinant bacteriophage DNA, plasmid DNA or
cosmid DNA expression vector containing the coding sequence; yeast
transformed with recombinant yeast expression vectors containing
the coding sequence; plant cell systems infected with recombinant
virus expression vectors (e.g., cauliflower mosaic virus, CaMV;
tobacco mosaic virus, TMV) or transformed with recombinant plasmid
expression vectors, such as Ti plasmid, containing the coding
sequence. Mammalian expression systems can also be used to express
the polypeptides of some embodiments of the invention.
[0481] Recovery of the recombinant polypeptide is effected
following an appropriate time in culture. The phrase "recovering
the recombinant polypeptide" refers to collecting the whole
fermentation medium containing the polypeptide and need not imply
additional steps of separation or purification. Not withstanding
the above, polypeptides of some embodiments of the invention can be
purified using a variety of standard protein purification
techniques, such as, but not limited to, affinity chromatography,
ion exchange chromatography, filtration, electrophoresis,
hydrophobic interaction chromatography, gel filtration
chromatography, reverse phase chromatography, concanavalin A
chromatography, chromatofocusing and differential
solubilization.
[0482] An agent capable of upregulating a myoD1 and/or myogenin in
a cell may also be any compound which is capable of increasing the
transcription and/or translation of an endogenous DNA or mRNA
encoding the myoD1 and/or myogenin and thus increasing endogenous
myoD1 and/or myogenin activity.
[0483] According to some embodiments of the invention,
over-expression of the polypeptide of the invention is achieved by
means of genome editing using methods well known in the art.
[0484] Genome editing is a powerful mean to impact target traits by
modifications of the target plant genome sequence. Such
modifications can result in new or modified alleles or regulatory
elements. Thus, genome editing employs reverse genetics by
artificially engineered nucleases to cut and create specific
double-stranded breaks at a desired location(s) in the genome,
which are then repaired by cellular endogenous processes such as,
homology directed repair (HDR) and non-homologous end-joining
(NHEJ). NHEJ directly joins the DNA ends in a double-stranded
break, while HDR utilizes a homologous sequence as a template for
regenerating the missing DNA sequence at the break point. In order
to introduce specific nucleotide modifications to the genomic DNA,
a DNA repair template containing the desired sequence must be
present during HDR. Genome editing cannot be performed using
traditional restriction endonucleases since most restriction
enzymes recognize a few base pairs on the DNA as their target and
the probability is very high that the recognized base pair
combination will be found in many locations across the genome
resulting in multiple cuts not limited to a desired location. To
overcome this challenge and create site-specific single- or
double-stranded breaks, several distinct classes of nucleases have
been discovered and bioengineered to date. These include the
meganucleases, Zinc finger nucleases (ZFNs),
transcription-activator like effector nucleases (TALENs) and
CRISPR/Cas system.
[0485] Over expression of a polypeptide by genome editing can be
achieved by: (i) replacing an endogenous sequence encoding the
polypeptide of interest or a regulatory sequence under the control
which it is placed, and/or (ii) inserting a new gene encoding the
polypeptide of interest in a targeted region of the genome, and/or
(iii) introducing point mutations which result in up-regulation of
the gene encoding the polypeptide of interest (e.g., by altering
the regulatory sequences such as promoter, enhancers, 5'-UTR and/or
3'-UTR, or mutations in the coding sequence).
[0486] As used herein the term "about" refers to .+-.10%.
[0487] The terms "comprises", "comprising", "includes",
"including", "having" and their conjugates mean "including but not
limited to".
[0488] The term "consisting of" means "including and limited
to".
[0489] The term "consisting essentially of" means that the
composition, method or structure may include additional
ingredients, steps and/or parts, but only if the additional
ingredients, steps and/or parts do not materially alter the basic
and novel characteristics of the claimed composition, method or
structure.
[0490] As used herein, the singular form "a", "an" and "the"
include plural references unless the context clearly dictates
otherwise. For example, the term "a compound" or "at least one
compound" may include a plurality of compounds, including mixtures
thereof.
[0491] Furthermore, "and/or" where used herein is to be taken as
specific disclosure of each of the two specified features or
components with or without the other. Thus, the term "and/or" as
used in a phrase such as "A and/or B" herein is intended to include
"A and B", "A or B", "A" (alone), and "B" (alone). Likewise, the
term "and/or" as used in a phrase such as "A, B, and/or C" is
intended to encompass each of the following aspects: A, B, and C;
A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A
(alone); B (alone); and C (alone).
[0492] Throughout this application, various embodiments of this
invention may be presented in a range format. It should be
understood that the description in range format is merely for
convenience and brevity and should not be construed as an
inflexible limitation on the scope of the invention. Accordingly,
the description of a range should be considered to have
specifically disclosed all the possible subranges as well as
individual numerical values within that range. For example,
description of a range such as from 1 to 6 should be considered to
have specifically disclosed subranges such as from 1 to 3, from 1
to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as
well as individual numbers within that range, for example, 1, 2, 3,
4, 5, and 6. This applies regardless of the breadth of the
range.
[0493] Whenever a numerical range is indicated herein, it is meant
to include any cited numeral (fractional or integral) within the
indicated range. The phrases "ranging/ranges between" a first
indicate number and a second indicate number and "ranging/ranges
from" a first indicate number "to" a second indicate number are
used herein interchangeably and are meant to include the first and
second indicated numbers and all the fractional and integral
numerals therebetween.
[0494] As used herein the term "method" refers to manners, means,
techniques and procedures for accomplishing a given task including,
but not limited to, those manners, means, techniques and procedures
either known to, or readily developed from known manners, means,
techniques and procedures by practitioners of the chemical,
pharmacological, biological, biochemical and medical arts.
[0495] As used herein, the term "treating" includes abrogating,
substantially inhibiting, slowing or reversing the progression of a
condition, substantially ameliorating clinical or aesthetical
symptoms of a condition or substantially preventing the appearance
of clinical or aesthetical symptoms of a condition.
[0496] When reference is made to particular sequence listings, such
reference is to be understood to also encompass sequences that
substantially correspond to its complementary sequence as including
minor sequence variations, resulting from, e.g., sequencing errors,
cloning errors, or other alterations resulting in base
substitution, base deletion or base addition, provided that the
frequency of such variations is less than 1 in 50 nucleotides,
alternatively, less than 1 in 100 nucleotides, alternatively, less
than 1 in 200 nucleotides, alternatively, less than 1 in 500
nucleotides, alternatively, less than 1 in 1000 nucleotides,
alternatively, less than 1 in 5,000 nucleotides, alternatively,
less than 1 in 10,000 nucleotides.
[0497] It is understood that any Sequence Identification Number
(SEQ ID NO) disclosed in the instant application can refer to
either a DNA sequence or a RNA sequence, depending on the context
where that SEQ ID NO is mentioned, even if that SEQ ID NO is
expressed only in a DNA sequence format or a RNA sequence format.
For example, SEQ ID NO: 5 is expressed in a DNA sequence format
(e.g., reciting T for thymine), but it can refer to either a DNA
sequence that corresponds to a MyoD1 nucleic acid sequence, or the
RNA sequence of an RNA molecule nucleic acid sequence. Similarly,
though some sequences are expressed in a RNA sequence format (e.g.,
reciting U for uracil), depending on the actual type of molecule
being described, it can refer to either the sequence of a RNA
molecule comprising a dsRNA, or the sequence of a DNA molecule that
corresponds to the RNA sequence shown. In any event, both DNA and
RNA molecules having the sequences disclosed with any substitutes
are envisioned.
[0498] It is appreciated that certain features of the invention,
which are, for clarity, described in the context of separate
embodiments, may also be provided in combination in a single
embodiment. Conversely, various features of the invention, which
are, for brevity, described in the context of a single embodiment,
may also be provided separately or in any suitable subcombination
or as suitable in any other described embodiment of the invention.
Certain features described in the context of various embodiments
are not to be considered essential features of those embodiments,
unless the embodiment is inoperative without those elements.
[0499] The system of the present embodiments can be used for other
purposes as well. For example, in an embodiment of the present
invention, the system can be used to generate human tissue from
human cell lines with the scope of transplantations. The cells can
be autologous, allologous or heterologous with respect to the
patient. The procedures described above can be used in the
manufacturing of partial or full organs for transplantation.
Numbered Clauses
[0500] Clause 1: Some embodiments of the present invention provide
a system for growing cells comprising: a primary tissue perfusion
circuit comprising: a tissue growth chamber; at least one first
pump; a culture medium perfusate; an oxygenator; and a heating
element; a secondary dialysis circuit comprising: at least one
second pump; a dialyzer; and a dialysate; where the order of each
component in each circuit of the system can be in any order. [0501]
Clause 2: Some embodiments of the present invention provide the
system where the tissue growth chamber is a jacketed tissue growth
chamber. [0502] Clause 3: Some embodiments of the present invention
provide the system where the tissue growth chamber is characterized
by having a volume and internal dimensions that are configured and
arranged to receive the growing tissue and a sufficient amount of
the culture medium perfusate to continuously circulate the culture
medium perfusate through the growing tissue. [0503] Clause 4: Some
embodiments of the present invention provide the system where the
first, second or third pump are selected from a group consisting of
peristaltic pump, positive displacement pump, impulse pump,
velocity pump, gravity pump, steam pump, valveless pumps, and any
combination thereof. [0504] Clause 5: Some embodiments of the
present invention provide the system where the culture medium
perfusate comprises non-animal serum. [0505] Clause 6: Some
embodiments of the present invention provide the system where the
culture medium perfusate comprises components selected from the
group consisting of: amino acids, vitamins, trace elements,
transferrin, insulin, plant-derived recombinant albumin,
bacteria-derived recombinant albumin, tryptose phosphate,
glutamine, glucose, fructose, sucrose, M199, DMEM/F12 medium,
KO-serum, linoleic acid, oleic acid, palmate acid, lecithin, bFGF,
IGF-1, Insulin, SCF, EGF, TGF.beta.1, IL-11, PGE, BMP4, activin A,
hydrocortisone, ascorbic acid, and any combination thereof. [0506]
Clause 7: Some embodiments of the present invention provide the
system where the oxygenator is a membrane oxygenator. [0507] Clause
8: Some embodiments of the present invention provide the system
where the oxygenator is adapted to provide at least one gas
selected from the group consisting of oxygen (O.sub.2), carbon
dioxide (CO.sub.2), nitrogen (N.sub.2) and any combination thereof.
[0508] Clause 9: Some embodiments of the present invention provide
the system where the oxygenator is adapted to maintain a
ratio:percentage of each gas of O.sub.2 from about 21% to about
95%, CO.sub.2 from about 0% to about 10% and N.sub.2 from about 0%
to about 80%, inside the system. [0509] Clause 10: Some embodiments
of the present invention provide the system where the oxygenator is
adapted to maintain a ratio:percentage of each gas of O.sub.2 at
about 80%, CO.sub.2 at about 5% and N.sub.2 at about 15%, inside
the system. [0510] Clause 11: Some embodiments of the present
invention provide the system where the system further comprises a
bubble trap. [0511] Clause 12: Some embodiments of the present
invention provide the system where the bubble trap is equally
interchangeable with a debubbler or a hybrid bubble trap/debubbler.
[0512] Clause 13: Some embodiments of the present invention provide
the system where the heating element is a heat exchanger. [0513]
Clause 14: Some embodiments of the present invention provide the
system where the heating element is selected from the group
consisting of: shell and tube heat exchanger, plate heat exchanger,
plate and shell heat exchanger, adiabatic wheel heat exchanger,
plate fin heat exchanger, pillow plate heat exchanger, fluid heat
exchanger, waste heat recovery units, dynamic scraped surface heat
exchanger, phase-change heat exchanger, direct contact heat
exchanger, microchannel heat exchanger, helical-coil heat
exchanger, spiral heat exchanger, and any combination thereof.
[0514] Clause 15: Some embodiments of the present invention provide
the system where the oxygenator and the heating element are two
distinct components. [0515] Clause 16: Some embodiments of the
present invention provide the system where the oxygenator and the
heating element are one component. [0516] Clause 17: Some
embodiments of the present invention provide the system where the
dialyzer comprises a membrane having a pore size selected from a
range of 1 to 60 kDa. [0517] Clause 18: Some embodiments of the
present invention provide the system where the dialyzer comprises a
membrane having an area selected from the range of 10 to 10000
cm.sup.2. [0518] Clause 19: Some embodiments of the present
invention provide the system where the system further comprises at
least one carbon filter. [0519] Clause 20: Some embodiments of the
present invention provide the system where the at least one carbon
filter is adapted to clean toxins present in the dialysate. [0520]
Clause 21: Some embodiments of the present invention provide the
system where the at least one ammonia filter is adapted to clean
ammonia present in the dialysate. [0521] Clause 22: Some
embodiments of the present invention provide the system where
toxins and ammonia are removed by the same filter. [0522] Clause
23: Some embodiments of the present invention provide the system
where the dialysate comprises glucose, amino acids, insulin,
hormones such as cortisone, and growth factors in serum-free
medium. [0523] Clause 24: Some embodiments of the present invention
provide the system further comprising at least one sensor selected
from the group consisting of temperature sensor, pH sensor, volume
sensor, flow sensor, optical sensor, glucose sensor, oxygen sensor,
weight sensor, protein sensor and any combination thereof. [0524]
Clause 25: Some embodiments of the present invention provide the
system further comprising at least one computer comprising at least
one non-transitory computer readable medium, the non-transitory
computer-readable medium storing a program that causes the computer
to execute a method using a processor that executes the stored
program. [0525] Clause 26: Some embodiments of the present
invention provide the system where the computer is connected to at
least one remote server allowing to an external remote operator to
access the computer. [0526] Clause 27: Some embodiments of the
present invention provide the system where the program allows the
system to operate automatically without the need of an external
operator. [0527] Clause 28: Some embodiments of the present
invention provide the system where the tissue growth chamber is
adapted to grow tissue originated from cells selected from a group
consisting of: primary cells, embryonic/neonatal fibroblasts cells,
embryonic/neonatal endothelium cells, embryonic/neonatal muscle
cells, pluripotent stem cells, embryonic stem cells, induced
pluripotent stem cells (iPSC), mesenchymal stem cells, fibroblasts
cells, endothelial cells, myocyte cells, satellite cells,
hepatocyte cells, blood cells, neuron cells, fat cells, and any
combination thereof. [0528] Clause 29: Some embodiments of the
present invention provide the system where the cells are exposed to
small molecule-based reprogramming. [0529] Clause 30: Some
embodiments of the present invention provide the system where the
small molecules are selected but not limited to a group consisting
of: CHIR9902, SB431542, RepSox, Parnate, Forskolin, TTNPB, DZnep,
VPA, CHIR99021, PD0325901, PD173074, LIF, A83-01, BIX01294, AS8351,
SC1, Y27632, OAC2, SU16F, JNJ10198409, LDN193189, NSC 228155, CN
009543V, AG1478, PD 153035, 2-Me-5HT, D4476, RG108, BIO, SMI1,
SMI2, 5-azacytidine, phenamil, GW7845, RG14620, or Harmine,
thiazolidinediones (i.e. rosiglitazone, pioglitazone,
lobeglitazone), IBMX, and any combination thereof. [0530] Clause
31: Some embodiments of the present invention provide the system
where the cells may stably comprise an inducible controlled
expression transgene system or similar constructs in their genome.
[0531] Clause 32: Some embodiments of the present invention provide
the system where the inducible controlled expression transgene
system is a TET-on or TET-off system. [0532] Clause 33: Some
embodiments of the present invention provide the system where the
induced controlled transgene expressed is MyoD. [0533] Clause 34:
Some embodiments of the present invention provide the system where
the inducible controlled expression transgene system is activated
or deactivated by Doxycycline or similar activators/deactivators.
[0534] Clause 35: Some embodiments of the present invention provide
the system where the cells are grown in a biodegradable scaffold
contained in the closed-loop perfusion circuit. [0535] Clause 36:
Some embodiments of the present invention provide the system where
the cells are from a non-human animal source selected from the
group consisting of: chicken, turkey, duck, quail, goose, dove,
pheasant, ostrich, cow (calf), deer, goat, sheep (lamb), horse,
lama, camel, rabbit, kangaroo, alligator, turtle, lobster, salmon,
tuna, dolphin, whale and any combination or related species
thereof. [0536] Clause 37: Some embodiments of the present
invention provide the system where the system is used to grow
cells, tissue, partial or full organs from human or animal origin
for transplantation purposes. [0537] Clause 38: It is hence a scope
of the present invention to provide a method for growing cells
comprising: acquiring a primary tissue perfusion circuit
comprising: a tissue growth chamber; at least one first pump; a
culture medium perfusate; an oxygenator; and a heating element;
acquiring a secondary dialysis circuit comprising: at least one
second pump; a dialyzer; and a dialysate; connecting the primary
tissue perfusion circuit with the secondary dialysis circuit;
growing the cells in the tissue growth chamber until reaching the
desired quantity. [0538] Clause 39: Some embodiments of the present
invention provide the method where the tissue growth chamber is a
jacketed tissue growth chamber. [0539] Clause 40: Some embodiments
of the present invention provide the method where the tissue growth
chamber is characterized by having a volume and internal dimensions
that are configured and arranged to receive the growing tissue and
a sufficient amount of the culture medium perfusate to continuously
circulate the culture medium perfusate through the growing tissue.
[0540] Clause 41: Some embodiments of the present invention provide
the method where the first, second or third pump are selected from
a group consisting of peristaltic pump, positive displacement pump,
impulse pump, velocity pump, gravity pump, steam pump, valveless
pumps, and any combination thereof. [0541] Clause 42: Some
embodiments of the present invention provide the method where the
culture medium perfusate comprises non-animal serum. [0542] Clause
43: Some embodiments of the present invention provide the method
where the culture medium perfusate comprises components selected
from the group consisting of: amino acids, vitamins, trace
elements, transferrin, insulin, plant-derived recombinant albumin,
bacteria-derived recombinant albumin, tryptose phosphate,
glutamine, glucose, fructose, sucrose, M199, DMEM/F12 medium,
KO-serum, linoleic acid, oleic acid, palmate acid, lecithin, bFGF,
IGF-1, Insulin, SCF, EGF, TGF.beta.1, IL-11, BMP4, PGE, activin A,
hydrocortisone, ascorbic acid, and any combination thereof. [0543]
Clause 44: Some embodiments of the present invention provide the
method where the oxygenator is a membrane oxygenator. [0544] Clause
45: Some embodiments of the present invention provide the method
where the oxygenator is adapted to provide at least one gas
selected from the group consisting of oxygen (O.sub.2), carbon
dioxide (CO.sub.2), nitrogen (N.sub.2) and any combination thereof.
[0545] Clause 46: Some embodiments of the present invention provide
the method where the oxygenator is adapted to maintain a
ratio:percentage of each gas of O.sub.2 from about 21% to about
95%, CO.sub.2 from about 0% to about 10% and N.sub.2 from about 0%
to about 80%, inside the system. [0546] Clause 47: Some embodiments
of the present invention provide the method where the oxygenator is
adapted to maintain a ratio:percentage of each gas of O.sub.2 at
about 80%, CO.sub.2 at about 5% and N.sub.2 at about 15%, inside
the system. [0547] Clause 48: Some embodiments of the present
invention provide the method where the system further comprises a
bubble trap. [0548] Clause 49: Some embodiments of the present
invention provide the method where the bubble trap is equally
interchangeable with a debubbler or a hybrid bubble trap/debubbler.
[0549] Clause 50: Some embodiments of the present invention provide
the method where the heating element is a heat exchanger. [0550]
Clause 51: Some embodiments of the present invention provide the
method where the heating element is selected from the group
consisting of: shell and tube heat exchanger, plate heat exchanger,
plate and shell heat exchanger, adiabatic wheel heat exchanger,
plate fin heat exchanger, pillow plate heat exchanger, fluid heat
exchanger, waste heat recovery units, dynamic scraped surface heat
exchanger, phase-change heat exchanger, direct contact heat
exchanger, microchannel heat exchanger, helical-coil heat
exchanger, spiral heat exchanger, and any combination thereof.
[0551] Clause 52: Some embodiments of the present invention provide
the method where the oxygenator and the heating element are two
distinct components. [0552] Clause 53: Some embodiments of the
present invention provide the method where the oxygenator and the
heating element are one component. [0553] Clause 54: Some
embodiments of the present invention provide the method where the
dialyzer comprises a membrane having a pore size selected from a
range of 1 to 300 kDa. [0554] Clause 55: Some embodiments of the
present invention provide the method where the dialyzer comprises a
membrane having an area selected from the range of 10 to 10000
cm.sup.2. [0555] Clause 56: Some embodiments of the present
invention provide the method where the system further comprises at
least one carbon filter. [0556] Clause 57: Some embodiments of the
present invention provide the method where the at least one carbon
filter is adapted to clean toxins present in the dialysate. [0557]
Clause 58: Some embodiments of the present invention provide the
method where the dialysate comprises glucose, amino acids, insulin,
hormones such as cortisone, and growth factors in serum-free
medium. [0558] Clause 59: Some embodiments of the present invention
provide the method further comprising at least one sensor selected
from the group consisting of temperature sensor, pH sensor, volume
sensor, flow sensor, optical sensor, glucose sensor, oxygen sensor,
weight sensor, protein sensor and any combination thereof. [0559]
Clause 60: Some embodiments of the present invention provide the
method further comprising at least one computer comprising at least
one non-transitory computer readable medium, the non-transitory
computer-readable medium storing a program that causes the computer
to execute a method using a processor that executes the stored
program.
[0560] Clause 61: Some embodiments of the present invention provide
the method where the computer is connected to at least one remote
server allowing to an external remote operator to access the
computer. [0561] Clause 62: Some embodiments of the present
invention provide the method where the program allows the system to
operate automatically without the need of an external operator.
[0562] Clause 63: Some embodiments of the present invention provide
the method where the tissue growth chamber is adapted to grow
tissue originated from cells selected from a group consisting of:
primary cells, embryonic/neonatal fibroblasts cells,
embryonic/neonatal endothelium cells, embryonic/neonatal muscle
cells, pluripotent stem cells, embryonic stem cells, induced
pluripotent stem cells (iPSC), mesenchymal stem cells, fibroblasts
cells, endothelial cells, myocyte cells, satellite cells,
hepatocyte cells, blood cells, neuron cells, fat cells, and any
combination thereof. [0563] Clause 64: Some embodiments of the
present invention provide the method where the cells are exposed to
small molecule-based reprogramming. [0564] Clause 65: Some
embodiments of the present invention provide the method where the
small molecules are selected but not limited to a group consisting
of: CHIR9902, SB431542, RepSox, Parnate, Forskolin, TTNPB, DZnep,
VPA, CHIR99021, PD0325901, PD173074, LIF, A83-01, BIX01294, AS8351,
SC1, Y27632, OAC2, SU16F, JNJ10198409, LDN193189, NSC 228155, CN
009543V, AG1478, PD 153035, 2-Me-5HT, D4476, RG108, BIO, SMI1,
SMI2, 5-azacytidine and any combination thereof. [0565] Clause 66:
Some embodiments of the present invention provide the method where
the cells may stably comprise an inducible controlled expression
transgene system or similar constructs in their genome. [0566]
Clause 67: Some embodiments of the present invention provide the
method where the inducible controlled expression transgene system
is a TET-on or TET-off system. [0567] Clause 68: Some embodiments
of the present invention provide the method where the induced
controlled transgene expressed is MyoD. [0568] Clause 69: Some
embodiments of the present invention provide the method where the
inducible controlled expression transgene system is activated or
deactivated by Doxycycline or similar activators/deactivators.
[0569] Clause 70: Some embodiments of the present invention provide
the method where the cells are grown in a biodegradable scaffold
contained in the closed-loop perfusion circuit. [0570] Clause 71:
Some embodiments of the present invention provide the method where
the cells are from a non-human animal source selected from the
group consisting of: chicken, turkey, duck, quail, goose, dove,
pheasant, ostrich, cow (calf), deer, goat, sheep (lamb), horse,
lama, camel, rabbit, kangaroo, alligator, turtle, lobster, salmon,
tuna, dolphin, whale and any combination or related species
thereof. [0571] Clause 72: It is hence a scope of some embodiments
of the present invention to grow cells wherein the cells are grown
in a system as described herein. [0572] Clause 73: Some embodiments
of the present invention provide the edible in-vitro meat, where
the in-vitro meat is grown in the presence of components selected
from the group consisting of: amino acids, vitamins, trace
elements, transferrin, insulin, plant-derived recombinant albumin,
bacteria-derived recombinant albumin, tryptose phosphate,
glutamine, glucose, fructose, sucrose, M199 medium, KO-serum,
linoleic acid, oleic acid, palmate acid, lecithin, bFGF, IGF-1,
SCF, EGF, TGF.beta.1, IL-11, BMP4, activin A, hydrocortisone,
ascorbic acid, and any combination thereof. [0573] Clause 74: Some
embodiments of the present invention provide the edible in-vitro
meat, where the in-vitro meat is grown in an environment
characterized by a ratio:percentage of each gas of O.sub.2 from
about 21% to about 95%, CO.sub.2 from about 0% to about 10% and
N.sub.2 from about 0% to about 80%, inside the system. [0574]
Clause 75: Some embodiments of the present invention provide the
edible in-vitro meat, where the in-vitro meat is grown in an
environment characterized by a ratio:percentage of each gas of
O.sub.2 at about 80%, CO.sub.2 at about 5% and N.sub.2 at about
15%, inside the system. [0575] Clause 76: Some embodiments of the
present invention provide the edible in-vitro meat, where the
in-vitro meat is originated from cells selected from a group
consisting of: primary cells, embryonic/neonatal fibroblasts cells,
embryonic/neonatal endothelium cells, embryonic/neonatal muscle
cells, pluripotent stem cells, embryonic stem cells, induced
pluripotent stem cells (iPSC), mesenchymal stem cells, fibroblasts
cells, endothelial cells, myocyte cells, satellite cells,
hepatocyte cells, blood cells, neuron cells, fat cells, and any
combination thereof. [0576] Clause 77: Some embodiments of the
present invention provide the edible in-vitro meat, where the cells
are exposed to small molecule-based reprogramming. [0577] Clause
78: Some embodiments of the present invention provide the edible
in-vitro meat, where the small molecules are selected but not
limited to a group consisting of: CHIR9902, SB431542, RepSox,
Parnate, Forskolin, TTNPB, DZnep, VPA, CHIR99021, PD0325901,
PD173074, LIF, A83-01, BIX01294, AS8351, SC1, Y27632, OAC2, SU16F,
JNJ10198409, LDN193189, NSC 228155, CN 009543V, AG1478, PD 153035,
2-Me-5HT, D4476, RG108, BIO, SMI1, SMI2, 5-azacytidine and any
combination thereof. [0578] Clause 79: Some embodiments of the
present invention provide the edible in-vitro meat, where the cells
may stably comprise an inducible controlled expression transgene
system or similar constructs in their genome. [0579] Clause 80:
Some embodiments of the present invention provide the edible
in-vitro meat, where the inducible controlled expression transgene
system is a TET-on or TET-off system. [0580] Clause 81: Some
embodiments of the present invention provide the edible in-vitro
meat, where the induced controlled transgene expressed is MyoD.
[0581] Clause 82: Some embodiments of the present invention provide
the edible in-vitro meat, where the inducible controlled expression
transgene system is activated or deactivated by Doxycycline or
similar activators/deactivators. [0582] Clause 83: Some embodiments
of the present invention provide the edible in-vitro meat, where
the cells are grown in a biodegradable scaffold. [0583] Clause 84:
Some embodiments of the present invention provide the edible
in-vitro meat, where the cells are from a non-human animal source
selected from the group consisting of: chicken, turkey, duck,
quail, goose, dove, pheasant, ostrich, cow (calf), deer, goat,
sheep (lamb), horse, lama, camel, rabbit, kangaroo, alligator,
turtle, lobster, salmon, tuna, dolphin, whale and any combination
or related species thereof. [0584] Clause 85: Some embodiments of
the present invention provide the edible in-vitro meat, where the
cells are grown in a non-animal serum medium. [0585] Clause 86:
Some embodiments of the present invention provide the edible
in-vitro meat, where the cells are grown in a medium which
comprises glucose, amino acids, insulin, hormones such as
cortisone, and growth factors in serum-free medium. [0586] Clause
87: It is hence a scope of the present invention to provide a
transplantable in-vitro tissue wherein the in-vitro tissue is
manufactured in a system as described herein. [0587] Clause 88:
Some embodiments of the present invention provide the
transplantable in-vitro tissue where the in-vitro tissue is grown
in the presence of components selected from the group consisting
of: amino acids, vitamins, trace elements, transferrin, insulin,
plant-derived recombinant albumin, bacteria-derived recombinant
albumin, tryptose phosphate, glutamine, glucose, fructose, sucrose,
M199 medium, KO-serum, linoleic acid, oleic acid, palmate acid,
lecithin, bFGF, IGF-1, SCF, EGF, TGF.beta.1, IL-11, BMP4, activin
A, hydrocortisone, ascorbic acid, and any combination thereof
Clause 89: Some embodiments of the present invention provide the
transplantable in-vitro tissue where the in-vitro meat is grown in
an environment characterized by a ratio:percentage of each gas of
O.sub.2 from about 21% to about 95%, CO.sub.2 from about 0% to
about 10% and N.sub.2 from about 0% to about 80%, inside the
system. [0588] Clause 90: Some embodiments of the present invention
provide the transplantable in-vitro tissue where the in-vitro meat
is grown in an environment characterized by a ratio:percentage of
each gas of O.sub.2 at about 80%, CO.sub.2 at about 5% and N.sub.2
at about 15%, inside the system. [0589] Clause 91: Some embodiments
of the present invention provide the transplantable in-vitro tissue
where the tissue is originated from cells selected from a group
consisting of: primary cells, embryonic/neonatal fibroblasts cells,
embryonic/neonatal endothelium cells, embryonic/neonatal muscle
cells, pluripotent stem cells, embryonic stem cells, induced
pluripotent stem cells (iPSC), mesenchymal stem cells, fibroblasts
cells, endothelial cells, myocyte cells, satellite cells,
hepatocyte cells, blood cells, neuron cells, fat cells, and any
combination thereof. [0590] Clause 92: Some embodiments of the
present invention provide the transplantable in-vitro tissue where
the cells are exposed to small molecule-based reprogramming. [0591]
Clause 93: Some embodiments of the present invention provide the
transplantable in-vitro tissue where the small molecules are
selected but not limited to a group consisting of: CHIR9902,
SB431542, RepSox, Parnate, Forskolin, TTNPB, DZnep, VPA, CHIR99021,
PD0325901, PD173074, LIF, A83-01, BIX01294, AS8351, SC1, Y27632,
OAC2, SU16F, JNJ10198409, LDN193189, NSC 228155, CN 009543V,
AG1478, PD 153035, 2-Me-5HT, D4476, RG108, BIO, SMI1, SMI2,
5-azacytidine and any combination thereof. [0592] Clause 94: Some
embodiments of the present invention provide the transplantable
in-vitro tissue where the cells may stably comprise an inducible
controlled expression transgene system or similar constructs in
their genome. [0593] Clause 95: Some embodiments of the present
invention provide the transplantable in-vitro tissue where the
inducible controlled expression transgene system is a TET-on or
TET-off system. [0594] Clause 96: Some embodiments of the present
invention provide the transplantable in-vitro tissue where the
induced controlled transgene expressed is MyoD. [0595] Clause 97:
Some embodiments of the present invention provide the
transplantable in-vitro tissue where the inducible controlled
expression transgene system is activated or deactivated by
Doxycycline or similar activators/deactivators. [0596] Clause 98:
Some embodiments of the present invention provide the
transplantable in-vitro tissue where the cells are grown in a
biodegradable scaffold. [0597] Clause 99: Some embodiments of the
present invention provide the transplantable in-vitro tissue where
the cells are from a non-human animal source selected from the
group consisting of: chicken, turkey, duck, quail, goose, dove,
pheasant, ostrich, cow (calf), deer, goat, sheep (lamb), horse,
lama, camel, rabbit, kangaroo, alligator, turtle, lobster, salmon,
tuna, dolphin, whale and any combination or related species
thereof. [0598] Clause 100: Some embodiments of the present
invention provide the transplantable in-vitro tissue where the
cells are from a human source. [0599] Clause 101: Some embodiments
of the present invention provide the transplantable in-vitro tissue
where the cells are grown in a non-animal serum medium. [0600]
Clause 102: Some embodiments of the present invention provide the
transplantable in-vitro tissue where the cells are grown in a
medium which comprises glucose, amino acids, insulin, hormones such
as cortisone, and growth factors in serum-free medium.
[0601] Various embodiments and aspects of the present invention as
delineated hereinabove and as claimed in the claims section below
find experimental, and/or calculated support in the following
examples.
EXAMPLES
[0602] Reference is now made to the following examples, which
together with the above descriptions illustrate some embodiments of
the invention in a non limiting fashion.
[0603] Generally, the nomenclature used herein and the laboratory
procedures utilized in the present invention include molecular,
biochemical, microbiological and recombinant DNA techniques. Such
techniques are thoroughly explained in the literature. See, for
example, "Molecular Cloning: A laboratory Manual" Sambrook et al.,
(1989); "Current Protocols in Molecular Biology" Volumes I-III
Ausubel, R. M., ed. (1994); Ausubel et al., "Current Protocols in
Molecular Biology", John Wiley and Sons, Baltimore, Md. (1989);
Perbal, "A Practical Guide to Molecular Cloning", John Wiley &
Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific
American Books, New York; Birren et al. (eds) "Genome Analysis: A
Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory
Press, New York (1998); methodologies as set forth in U.S. Pat.
Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057;
"Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E.,
ed. (1994); "Current Protocols in Immunology" Volumes I-III Coligan
J. E., ed. (1994); Stites et al. (eds), "Basic and Clinical
Immunology" (8th Edition), Appleton & Lange, Norwalk, Conn.
(1994); Mishell and Shiigi (eds), "Selected Methods in Cellular
Immunology", W. H. Freeman and Co., New York (1980); available
immunoassays are extensively described in the patent and scientific
literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153;
3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654;
3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219;
5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J.,
ed. (1984); "Nucleic Acid Hybridization" Hames, B. D., and Higgins
S. J., eds. (1985); "Transcription and Translation" Hames, B. D.,
and Higgins S. J., Eds. (1984); "Animal Cell Culture" Freshney, R.
I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986);
"A Practical Guide to Molecular Cloning" Perbal, B., (1984) and
"Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols:
A Guide To Methods And Applications", Academic Press, San Diego,
Calif. (1990); Marshak et al., "Strategies for Protein Purification
and Characterization--A Laboratory Course Manual" CSHL Press
(1996); all of which are incorporated by reference as if fully set
forth herein. Other general references are provided throughout this
document. The procedures therein are believed to be well known in
the art and are provided for the convenience of the reader. All the
information contained therein is incorporated herein by
reference.
Example 1
Closed-Loop Perfusion Circuit for Growth of Chicken Liver
[0604] Liver is a highly nutritious, high value product, with
relatively soft consistency due to the low abundance of fibrillar
matrix and hive-like structure. A genetic modification is used to
induce the proliferation of chicken hepatocytes and endothelial
cells, allowing to optimize the close-loop perfusion circuit for
high-density tissue growth. Closed-loop perfusion includes, as
mentioned above, a dialysis unit permitting physiological addition
of nutrients and removal of toxins, instead of complete media
replacement.
[0605] 1.1 Closed-Loop Perfusion Circuit The perfusion system is
composed of a primary tissue perfusion circuit and a secondary
dialysis circuit for nutrient and toxin exchange (10). The primary
circuit includes culture medium perfusate that is recirculated
using a peristaltic pump through a jacketed tissue growth chamber,
a membrane oxygenator, a heat exchanger, and a bubble trap. The
oxygenator is gassed with a mixture of 80% O.sub.2/5% CO.sub.2/15%
N.sub.2 maintaining constant pH.
[0606] A fraction of the perfusate is diverted to secondary circuit
through a Spectrum Labs hollow fiber dialyzer (Rancho Dominguez,
Calif.) with a 790 cm.sup.2 membrane area and a 30 kDa molecular
weight cutoff at a rate of 3 mL/min/gram tissue. The secondary
circuit dialyzed the perfusate by counter-current exposure to
protein-free dialysate, recirculated through a carbon filter using
a third peristaltic pump. Temperature within the system is
maintained at 37.degree. C.
[0607] The main advantage of dialysis is that albumin, with a
molecular weight of 66.5 kDa, is retained in the main perfusion
circuit. Albumin has a half-life of 20 days and is a carrier
protein of growth factors, peptides (e.g. insulin), and fatty
acids. Albumin and growth factors are the main cost driver of
culture medium.
[0608] 1.2 Model Cells and Tissue Growth
[0609] Recently, it has been demonstrated that expression of E6/E7
proteins permitted the rapid expiation of functional human
hepatocytes, liver endothelial and stellate cells under
OSM-stimulation (1). Stably infected E6/E7LOW hepatocytes with GFP,
endothelial cells with mCherry, and stellate cells with CFP using
lentivirus reporters were used for optimization of the device.
These fluorescent markers helped assess tissue organization and
proliferation rates before beginning the actual production of the
chicken liver. Seeded on a soft hydrogel matrix, this cell mixture
rapidly forms a proliferating liver organoid (11).
[0610] Cells are mixed in ratio of 1:1:0.1 for hepatocytes,
endothelial cells, and stellate cells, respectively, spun down and
re-suspended in 0.1 ml hydrogel matrix composed of animal-free
synthetic polypeptides with pore size of 50 to 200 nm (Sigma,
A6982). Hydrogel-cell suspension are injected into a biodegradable
polymer scaffold with pore size of 50 to 1000 .mu.m, and placed in
the jacked tissue growth chamber. While the hydrogel polypeptides
will be replaced with native extracellular matrix within 5-7 days,
the polymer scaffold will support the growing tissue for 14-28 days
until it reaches significant mass and the cells cannot be washed
away.
[0611] 1.3 Growth Optimization
[0612] To optimize tissue growth and minimization of nutrient
addition, tissue uptake rates of glucose, glutamine, fatty acids
and albumin were carefully analyzed by present inventor aiming to
keep consternations constant. Perfusate and dialysate were
automatically sampled using microfluidic switchboard every 4 hours
to monitor glucose, lactate, glutamine, fatty acid and albumin
content (12). Oxygen content was measured dynamically using optical
sensors (13).
[0613] Data was used to determine rate and volume of medium
supplementation as a function of tissue growth rate.
[0614] Tissue morphology and growth rates were quantified daily
using confocal microscopy. Human albumin and bile acid production
were measured in the perfusate every 24 hours, marking
liver-specific function. Finally, the absence of necrosis or
apoptosis was assessed using H&E and TUNEL staining following
7, 14 and 28 days of growth.
Example 2
Development of Small Molecule-Based Expansion of Serum-Free
Cultures of Chicken Hepatocytes, Endothelial Cells and
Fibroblasts
[0615] Chemical compounds offer an attractive alternative to growth
factors that are generally used to stimulate serum-free cell
growth. Small molecules are far less expensive than recombinant
growth factors, have lower lot-to-lot variability, are
non-immunogenic and are much more stable.
[0616] 2.1 Developing and Optimizing Minimal Growth Medium
Chicken fibroblasts were purchased from Charles River Laboratories
(Wilmington, Mass.) and expanded in serum-free medium composed of
M199 supplemented with 0.5 mg/mL plant-derived albumin
(Cellastim.TM.), 0.6 .mu.M linoleic and oleic acid, 0.6 .mu.g/mL
soy lecithin, 7.5 mM L-Alanyl-L-Glutamine, 0.1 .mu.M dexamethasone,
50 .mu.g/mL ascorbic acid, and 0.5 U/mL insulin (Eli Lilly). This
minimal medium was generally further supplemented with 5 ng/mL
bFGF, 5 ng/mL EGF, and 30 pg/mL TGF.beta.1 to support 4-fold faster
proliferation of fibroblasts, at considerable expense. Cells were
expanded in complete medium up to PD (population doubling) 15 to
generate frozen stocks, and were used between PD 15 and 25. To
study whether all growth factors were essential for chicken
fibroblast expansion, the present inventor assessed proliferation
rates as a function of growth factor concentration aiming to find a
minimal combination.
[0617] Chicken embryonic endothelial cells were isolated from
fertilized eggs or purchased from Charles River Laboratories
(Wilmington, Mass.). Cells were expanded in serum-free endothelium
medium composed of RPMI1640 supplemented with 3.75 mg/mL
plant-derived albumin (Cellastim.TM.), 0.6 .mu.M linoleic and oleic
acid, 0.6 .mu.g/mL soy lecithin, 7.5 mM L-Alanyl-L-Glutamine, 0.1
.mu.M dexamethasone, 50 .mu.g/mL ascorbic acid, and 0.5 U/mL
insulin (Eli Lilly). This minimal medium was further supplemented
with 5 ng/mL bFGF, 5 ng/mL EGF, and 10 ng/mL VEGF. Cells were
expanded in complete medium up to PD 5 to generate frozen stocks,
and are used between PD 5 and 10. To study whether all growth
factors were essential for chicken endothelial cell expansion, the
present inventor assessed proliferation rates as a function of
growth factor concentration aiming to find a minimal
combination.
[0618] Chicken embryonic muscle cells were isolated from fertilized
eggs or purchased from Charles River Laboratories (Wilmington,
Mass.). Cells were expanded in serum-free medium composed of M199
supplemented with 0.5 mg/mL plant-derived albumin (Cellastim.TM.),
0.6 .mu.M linoleic and oleic acid, 0.6 .mu.g/mL soy lecithin, 7.5
mM L-Alanyl-L-Glutamine, 0.1 .mu.M dexamethasone, 50 .mu.g/mL
ascorbic acid, and 0.5 U/mL insulin (Eli Lilly). This minimal
medium was generally further supplemented with 5 ng/mL bFGF, 5
ng/mL EGF, and 30 pg/mL IGF-1. Cells were expanded in complete
medium up to PD 15 to generate frozen stocks, and were used between
PD 5 and 10. To study whether all growth factors were essential for
chicken myocytes expansion, the present inventor assessed
proliferation rates as a function of growth factor concentration
aiming to find a minimal combination.
[0619] Chicken hepatocytes were purchased from Charles River
Laboratories (Wilmington, Mass.) and seeded in serum-free
formulation composed of Williams E medium supplemented with 3.75
mg/mL plant-derived albumin (Cellastim.TM.), 0.2 .mu.M linoleic and
oleic acids, 2 mM L-Alanyl-L-Glutamine, 0.1 .mu.M dexamethasone, 5
.mu.g/mL transferrin, and 0.5 U/mL insulin (Eli Lilly). It has been
shown that this serum-free medium supports the robust expansion of
genetically modified human hepatocytes (1). Cells were exposed to
FPH1 (BRD-6125), FPH2 (BRD-9424), and FH1 (BRD-K4477) small
molecules identified to enhance proliferation of unmodified human
hepatocytes (7). The present inventor expected that limited
proliferation would be achieved due to evolutionary conservation of
liver regeneration signaling pathways. High throughput screen of
chicken hepatocytes without small-molecule driven expansion is
still possible, but it is simply more expensive.
[0620] 2.2 Identification of Small Molecule Growth Enhancers in a
High Throughput Screen
High content screening of small molecules is carried out at the
Broad Institute of MIT and Harvard or an equivalent robotic
screening facility. A separate screening for chicken fibroblasts,
endothelial cells, myocytes and hepatocytes is carried out. Cells
are seeded in 384-well screening plates (Corning) at a density of
10,000 cells/cm.sup.2 in the appropriate minimal growth medium
without supplements. Plates are incubated at 37.degree. C. and 5%
CO.sub.2 and medium is replaced daily. A library of 12,480
compounds is added at concentration of 15 .mu.M and incubated for
48 hours. The present inventor carries out a standard MTT analysis;
acquired phase images of the treated cells, and Hoechst analysis
for total DNA. To identify functional proliferation hits, the
positive MTT and DNA increase are integrated based on p-value.
[0621] Chemicals producing functional proliferation hits were
combined in a smaller screening profile aiming to identify minimal
functional combinations that produce the greatest fold increase in
proliferation. Based on earlier reports (7), the present inventor
expected 2 to 3 small molecules to be identified in each screen.
For example, NSC-228155 was recently shown to be an EGF-R agonist
(16). Once small molecules cocktails were identified, the present
inventor attempted to add back growth factors at lower
concentrations to see if greater proliferation enhancement can be
achieved in a cost-efficient manner.
Example 3
Development of Small-Molecule Based Differentiation of Chicken
Muscle Cells
[0622] Myocyte expansion is usually limited to 15 population
doublings, producing 16-gram tissue from each isolate. However,
myocytes can be differentiated from pluripotent stem cells in a
multistep process mimicking myogenesis (17). Alternatively,
fibroblasts can be converted to myocytes using MyoD expression (18)
or a cocktail of small molecules (8).
[0623] Pluripotent stem cells double every 44.+-.13 hours and their
serum free medium costs about $540/liter. In contrast, fibroblasts
double every 21.+-.3 hours and their serum free medium costs about
$272/liter. This means that using current techniques, pluripotent
stem cells will produce 1 kg tissue after 39 days, at $100,000/kg,
while fibroblasts will do so after 18 days, at $50,000/kg.
Therefore, the present inventor' approach primarily focused on
genetic and chemical differentiation of fibroblasts to myocytes,
with pluripotent stem cells studied to mitigate risk.
[0624] 3.1 Generation of Tetracycline-Dependent MyoD Expressing
Chicken Fibroblasts
[0625] Doxycycline (Dox) is an analog of tetracycline that can be
used to rapidly activate gene expression by binding a reverse
tetracycline-controlled advanced transactivator (rtTA2.sup.S-M2)
that acts on a tetracycline responsive element (TRE). Dox shows no
apparent toxicity, is inexpensive and can be readily washed out of
the cells following activation. The system has been shown to
reliably work on chicken embryos (19).
[0626] The present inventor has generated a stable line of chicken
fibroblasts expressing Dox-inducible chicken MyoD, by introducing
pCAGGS-rtTA2.sup.S-M2 and pTRE-MyoD plasmids under puromycin
selection. Chicken fibroblasts were exposed to 0.5 ng/.mu.l Dox for
48 hour and MyoD expression was evaluated by qRT-PCR. Conversion to
myocytes was evaluated 7 and 12 days after Dox induction by
staining for myosin heavy chain (MyHC) and titin (18). Dox-induced
muscle cells served as positive control and a genetically
engineered (GE) alternative to small molecule-induced conversion of
fibroblasts to myocytes.
[0627] 3.2 Identification of Small-Molecule Cocktail for Conversion
of Myocytes
Recently mouse fibroblasts were converted to cardiomyocytes by a
two-step combination of small molecules promoting reprogramming;
including CHIR9902, RepSox, Forskolin, and VPA followed by 2i
(CHIR99021 and PD0325901) conditions promoting myocardium
development; including CHIR99021, PD0325901, and LIF (9). Human
fibroblasts were similarly converted using a combination of
reprogramming and differentiation-inducing factors CHIR99021,
A83-01, BIX01294, AS8351, SC1, Y27632, OAC2, SU16F and JNJ10198409
(8). Conversion was slow, taking 20 to 30 days and producing about
6% cardiomyocytes.
[0628] In a screen of zebrafish, mouse, and human cells, Xu (Xu et
al. Cell 155, 909-921, 2013) and colleagues identified 6 small
molecules that expanded muscle progenitors, including the adenylyl
cyclase activator, forskolin. A combination of bFGF, forskolin, and
the GSK3b inhibitor BIO induced skeletal muscle differentiation of
human induced pluripotent stem cells (21). In a different screen, a
group identified SMI1 and SMI2 to robustly induce skeletal muscle
differentiation from pluripotent stem cells, while others showed
5-azacytidine can similarly promote myogenesis (22). These results
suggest that a two-step procedure to trans-differentiate skeletal
muscle using a reprogramming cocktail (6), followed factors that
promote skeletal muscle myogenesis in pluripotent stem cells, can
produce promising results.
[0629] The present inventor' approach was to stably transfect
chicken fibroblasts with EGFP reporter for MyHC for high throughput
screening (8). Cells were exposed to varying cocktails of
reprogramming and myogenic factors discussed above, as well as
those identified in example 2.2. Cells were evaluated based on EGFP
fluorescence and myofiber morphology after 20 days of induction. To
identify functional hits, the present inventor integrated positive
MyHC and morphology hits based on p-value.
[0630] 3.3. Developing Direct Differentiation of Chicken
Pluripotent Stem Cells
The avian embryo spends only 20 hours in utero as it descends down
the oviduct. By the time the egg is laid, the epiblast is a single
layer comprised of 20,000-50,000 cells. Chicken embryonic stem
cells are derived from this blastodisc and can be perpetuated in
culture, producing all somatic lineages but not the germline (3).
Like mouse embryonic stem cells, they require LIF to remain
undifferentiated. Culture medium includes bFGF, IGF-1, SCF, and
IL-11, in addition to LIF (23).
[0631] Recently, serum-free protocols for differentiation of muscle
fibers were published for mouse and human pluripotent stem cells
(17). Mouse stem cells were induced toward a mesoderm phenotype in
N2B27 medium containing 10 ng/ml BMP4 for 2 days, DMEM medium
containing 15% knockout serum, 0.5% DMSO, 0.1 .mu.M LDN193189, and
1 .mu.M CHIR99021 for 4 days. Then mesodermal cells differentiated
to skeletal muscle in DMEM medium containing 15% knockout serum, 10
ng/ml HGF, 2 ng/ml IGF-1, 20 ng/ml bFGF, and 0.1 .mu.M LDN193189
for 8 days. The protocol is robust, generating 30-60% muscle cells
in 14 days.
[0632] As noted above, other groups identified additional small
molecules that drive the differentiation of pluripotent stem cells
toward skeletal muscle cells. These include the combination of
bFGF, forskolin and BIO (21), SMI1 and SMI2 (24), and finally
5-azacytidine (22).
[0633] The present inventor' approach was to translate existing
serum-free mouse protocols to chicken embryonic stem cells taking
into account differences in avian development pathways (25). Small
molecules identified in previous studies were used to augment
differentiation and increase muscle fiber density.
Example 4
Establishing Closed-Loop Perfusion Circuit for Growth and
Differentiation of Chicken Muscle
[0634] Muscle tissue is highly packed myofiber cluster nourished by
endothelial capillaries. Fibrillar collagen, secreted by the
mesenchyme plays a significant role in tissue consistency. The
present inventor's approach was to grow a high density of chicken
fibroblasts and endothelial cells in a biodegradable scaffold
contained in a closed-loop perfusion circuit optimized in example
1. Shear forces helped align collagen fibers deposited by the
growing fibroblasts. Once sufficient mass was reached, small
molecules were introduced in differentiation medium converting
fibroblasts to skeletal muscle cells (example 3) and allowing the
myofiber to align along to shear-aligned fibers.
Closed-loop perfusion included a dialysis unit permitting
physiological addition of nutrients and removal of toxins, instead
of complete media replacement. The main advantage of dialysis was
that albumin, with a molecular weight of 66.5 kDa, was retained in
the main perfusion circuit. Albumin has a half-life of 20 days and
is a carrier protein of growth factors and fatty acids. Albumin and
growth factors are the main cost drivers of culture medium.
[0635] 4.1 Closed-Loop Perfusion Circuit
[0636] The perfusion system that was optimized in example 1.1 was
used here. Briefly, the primary circuit included culture medium
perfusate that was recirculated using a peristaltic pump through a
jacketed tissue growth chamber, a membrane oxygenator (80% 02, 5%
CO.sub.2, and 15% N.sub.2), a heat exchanger (37.degree. C.), and a
bubble trap. A fraction of the perfusate was diverted to a hollow
fiber dialyzer with a 2200 cm.sup.2 membrane area and a 30 kDa
molecular weight cutoff at a rate of 3 mL/min/gram tissue. The
secondary circuit dialyzed the perfusate by counter-current
exposure to protein-free dialysate and recirculated through a
carbon filter using a second peristaltic pump.
[0637] 4.2 Model Cells and Tissue Growth
[0638] Cell seeding that was optimized in example 1.2 was used
here. The experiment used a mixture of Dox-MyoD chicken fibroblasts
developed in example 3.1 and endothelial cells at 10:1 ratio.
Briefly, cells were suspended in 0.1 ml hydrogel matrix composed of
animal-free synthetic polypeptides with pore size of 50 to 200 nm
(Beaver Labs). Hydrogel-cell suspension was injected into a
biodegradable polymer scaffold with pore size of 50 to 1000 .mu.m,
and placed in the jacked tissue growth chamber. While the hydrogel
polypeptides were replaced with native extracellular matrix within
5-7 days, the polymer scaffold supported the growing tissue for 14
days until it reached significant mass and the cells could not be
washed away. Scaffold was removed at 5 and 10 days fixed and
sectioned for analysis. The present inventor stained for collagen
type-I deposition and alignment, and analyzed connective tissue
density and health using H&E staining.
[0639] The present inventor introduced 0.5 ng/.mu.l Dox for 4 days,
inducing conversion of fibroblasts to muscle cells. Then Dox was
washed out for 4 days, replaced with IFG-1 to promote cell fusion
to muscle fibers. Tissue was removed at day 14 and 18 fixed and
sections for analysis. The present inventor stained for MyHC,
desmin and titin, and analyzed the resulting muscle tissue density
and health using H&E staining. Comparing desmin and MyHC
positive cells, as well as qRT-PCR assessed the degree of muscle
formation.
[0640] 4.3 Growth Optimization
[0641] Tissue growth was optimized to adjust the feeding parameters
to the growing cells and the differentiation method used. Tissue
uptake rates of glucose, glutamine, fatty acids and albumin were
analyzed aiming to keep consternations constant. Perfusate and
dialysate were automatically sampled using microfluidic switchboard
every 4 hours to monitor glucose, lactate, glutamine, fatty acid
and albumin content (12). Oxygen content was measured dynamically
using optical sensors (13). Data was used to determine rate and
volume of medium supplementation as a function of tissue growth
rate.
[0642] Tissue growth rates were quantified using AlamarBlue.RTM.
(Thermo Fisher Sci.) a non-toxic, secreted, cell viability
indicator. Finally, the absence of necrosis or apoptosis was
assessed using H&E and TUNEL staining following 6, 12 and 18
days of growth.
[0643] 4.4 Cell-Specific Approach
[0644] Some embodiments of the present intention are to reach 150
grams of chicken muscle tissue in each circuit, equivalent to a
large drumstick or chicken breast. This represents a mass of
3.times.10.sup.10 cells achieved in about 18 population
doublings.
For fibroblasts, it represents 16 to 18 days of growth.
MyoD-induced conversion is rapid (18) allowing to grow fibroblasts
for 10 days and differentiate them for 8 days in culture. In
contrast, small molecule based reprogramming approaches (8) (9) are
reported to take between 24 to 30 days, at least for
cardiomyocytes. While the developmentally simpler skeletal muscle
differentiation will undoubtedly be shorter, insights from example
3.2 played a critical role in deciding the initial seeding
densities and the timing of conversion.
[0645] Importantly, this cell density represents 33 to 35 days of
growth for embryonic stem cells. The current serum-free
differentiation protocol (17) requires only 14 days of
differentiation. Therefore, chicken embryonic stem cells can be
seeded at higher densities and grown in pluripotency medium for 19
days. The main challenge for embryonic stem cells growth is that
the tissue cannot be endothelialized as endothelial cells would
promote differentiation. This means that individual embryonic stem
cell clusters must be smaller than 0.5 mm in diameter, or suffer
necrosis at the core. One solution was to seed embryonic stem cells
on biodegradable alginate microparticles (Quad Technologies)
allowing the suspension to grow separately within the tissue growth
chamber. The present inventor has previously been successful in
growing human embryonic stem cells in a similar high-density
suspension cultures (26).
Example 5
Chicken-Based Laboratory Grown Meat: Generation of Spontaneously
Immortalized Chicken Fibroblast Cell Line
[0646] The following Example illustrates non-limiting cells, which
can be used for culturing meat in-vitro.
[0647] Animal-free, high-density expansion of chicken
cells--Various independent cell sources can be used for growing
meat in-vitro.
[0648] (1) Chicken embryonic fibroblasts were isolated and expanded
until spontaneous immortalization occurred.
[0649] (2) An immortal chicken iPSC line is generated using
non-integrating vectors or small molecules from which fibroblasts
can be obtained by routine differentiation.
[0650] (3) Several established ATCC cell lines can be used. These
include DF1 (chicken), QM7 (quail), and DE (duck).
[0651] (4) Integrating vectors are used to establish chicken iPSC
lines as described in literature (Intarapat & Stern 2013).
[0652] Derivation of a Spontaneously Immortalized Line of Chicken
Embryonic Fibroblasts
[0653] Experimental methods--Fertilized broiler chicken eggs were
grown at 38.5.degree. C. for 10-12 days in a humidified incubator.
Eggs were opened between day 10 to 12 and embryos removed. Heads,
limbs and internal organs were removed, and cells were mechanically
extracted and plated on tissue culture treated plastic in DMEM/F12
medium supplemented with 15% FBS (fetal bovine serum), and 2 mM of
L-Analyl-L-Glutamine.
[0654] Experimental Results--Under these conditions, in the absence
of any other growth factors, fibroblasts outgrow the culture
resulting in homogenous populations of primary chicken embryonic
fibroblasts (CEFs) (FIGS. 2A-B). Roughly 2.times.10.sup.7 cells
were isolated per embryo, with multiple populations cultured in
parallel. Initial CEF morphology was elongated, becoming more
compact with increasing passage number (FIG. 2B and data not
shown). Most CEF cultures became senescent by population doubling
(PD) 30-40 (data not shown); with 2-3 colonies surviving the crisis
becoming spontaneously immortalized chicken fibroblasts (CSIFs;
FIG. 2C). CSIF show fibroblast morphology and exhibit a doubling
time of 18.+-.2 hours by PD 90 (FIG. 2E).
Example 6
Chicken-Based Laboratory Grown Meat: Identification of a Serum-Free
Medium for Propagating Spontaneously Immortalized Chicken
Fibroblast Cell Line
[0655] Development of Serum-Free Medium for CSIF Propagation--The
CSIFs readily grow on tissue culture plastic in DMEM/F12 medium
supplemented with 15% FBS, and 2 mM of L-Analyl-L-Glutamine (FIG.
2D). There are several serum-free medium formulations for the
growth of human and mouse fibroblasts, including PCS-201-040 (ATCC)
and TheraPEAK (Lonza), both failed to support the proliferation of
primary CEF or the novel CSIF line obtained by the present inventor
(FIGS. 2D, 2E and data not shown).
[0656] To develop a serum-free medium that supports the culture of
CEF and CSIF, the present inventor formulated a minimal medium
composed of DMEM/F12 supplemented with 0.1 .mu.M dexamethasone, 10
.mu.g/ml insulin, 5.5 .mu.g/ml transferrin, and 5 ng/ml selenium
(ITS), 12 .mu.M linoleic and 12 .mu.M oleic acids, and 2 mM of
L-Analyl-L-Glutamine. Cells were plated in FBS containing medium,
and transferred to minimal medium after overnight attachment. Basal
medium was supplemented with growth factors and hormones showing
that while heparin and T3 had little effect of CSIF growth (data
not shown), the addition of basic Fibroblast Growth Factor (bFGF,
10 ng/ml) was essential (FIGS. 3C and 3F), showing 20.+-.2 hours
doubling time (data not shown). In addition, Epidermal Growth
Factor (EGF, 5 ng/ml), Prostaglandin E2 (PGE2, 0.01 .mu.M) and
Growth Hormone (GH, 10 ng/ml) supported the proliferation of CEF
and CSIF (FIGS. 3D, 3E, 3F and data not shown).
[0657] The optimal growth medium tested by the present inventor was
composed of DMEM/F12 supplemented with dexamethasone (0.1 .mu.M),
1.times.ITS+3 (Sigma, I2771), bFGF (10 ng/ml), EGF (5 ng/ml), and
PGE2 (0.01 .mu.M) resulting in similar growth rates to a culture
medium containing 15% FBS.
[0658] Under some conditions, insulin could be replaced with IGF-1
(5 ng/ml), or the stabilized Long R3 IGF-1 [Sigma (5 ng/ml)]. EGF
can be replaced with the EGF-R agonist [NSC-228155 (Sakanyan et al.
Sci. Reports. 2014] at a concentration of 5-50 ng/ml. FGF can
similarly be replaced with a small molecule or synthetic agonist
such as C19-jun (Ballinger et al. Nature. Biotech. 1999) at a
concentration of 10-20 ng/ml.
[0659] A screen for small molecules is carried out essentially as
described in Example 2 above. The first small molecule screen
attempts to identify molecules that can replace growth factors and
hormones in the culture medium (e.g. insulin, FGF, EGF, TGF.beta.).
Thus, a sequential removal of one growth factor or hormone at a
time is performed, aiming to reach the same growth rate with a
small molecule replacement.
[0660] The co-culture of endothelial cells with the fibroblasts
allows the present inventor to remove some growth factors that are
naturally produced by the endothelium.
[0661] Additionally or alternatively, cells are engineered to
specifically produce these growth factors, thereby reducing overall
cost.
[0662] It should be noted that the lack of attachment factors (e.g.
vitronectin, fibronectin) in serum-free medium makes it difficult
to serially passage CEF or CSIF. Since animal or human derived
extracellular matrix proteins must be avoided other natural,
recombinant proteins and/or synthetic polymers such as
Poly-D-Lysine can be used to propagate cells in the absence of
serum.
Example 7
Chicken-Based Laboratory Grown Meat: Conversion of a Spontaneously
Immortalized Chicken Fibroblast Cell Line into Adipocute Ina
Serum-Free Medium
[0663] Conversion of CSIF to Adipocytes in Serum-free Medium--In
mammalian species, preadipocytes can be readily differentiated into
adipocytes using 3-isobutyl-1-methylxanthine (IBMX) in the presence
of insulin, and cortisone (e.g. dexamethasone). Preadipocytes are
seeded at 70% confluence in serum-containing medium supplemented
with 0.5 mM IBMX, 0.1 .mu.M dexamethasone, and 10 .mu.g/ml insulin
for 3 days, followed by 3-day treatment with insulin alone, which
is then removed at day 6 to finalize differentiation. The protocol
works on primary preadipocyte and preadipocyte cell lines such as
3T3-L1 and 3T3-F442A, but not on fibroblasts. Recent work
identified multiple small molecules that can enhance the
differentiation of preadipocytes to adipocytes in serum-containing
medium, including PPARg activators: phenamil, GW7845, RG14620, or
Harmine (Park et al. J. Lipid Research. 2010; Waki et al. Cell Met.
2007). Clinically approved drugs of the thiazolidinedione family
(i.e. rosiglitazone, pioglitazone, lobeglitazone) that target PPARg
could potentially have similar effects on preadipocytes.
[0664] Chicken preadipocyte have yet to be identified, leading most
groups to use stromal-vascular cells derived from chicken adipose
tissues (Matsubara et al. Comp. Bio. & Phys 2008). However,
IBMX and dexamethasone have no affect on these chicken
preadipocytes, while exposure to 200-400 .mu.M oleic acid induces
their differentiation to adipocytes in the presence of serum
(Zhouchun et al. Biosci. Rep. 2014; Matsubara et al. Comp. Bio.
& Phys 2008).
[0665] Efforts to differentiate primary CEF to adipocytes showed
that exposure to 400 .mu.M oleic acid and 20% serum induced lipid
accumulation in the elongated primary cells (Liu et al. Comp. Bio.
& Phys 2009). The master's thesis of Aishlin Elizabeth Lee
(Ohio State U. 2013) showed a similar effect in response to 100-300
.mu.g/l of selenium and 2% serum. Both works used primary chicken
cells, cultured in the presence of serum.
[0666] To develop a protocol for conversion of the spontaneously
immortalized chicken fibroblasts (CSIF line) under serum-free
conditions, the present inventor seeded the CSIF at 70% confluence
in the optimized serum-free DMEM/F12 medium supplemented with
dexamethasone (0.1 .mu.M), 1.times.ITS+3 (Sigma, I2771), and bFGF
(10 ng/ml). The CSIF cells were treated for 4 or 7 days with 200 to
400 .mu.M oleic acid alone, or in combination with 0.5 mM IBMX, or
10 .mu.M of the FDA-approved small molecule Rosiglitazone. While
all oleic acid treatments increased lipid accumulation, only the
addition of IBMX or Rosiglitazone supported a rounded adipogenic
phenotype (FIGS. 4A-D).
[0667] Stimulation of mitochondria proliferation in
myocytes--Additionally or alternatively, a dual-PPAR.alpha./.gamma.
agonist such as naringenin (Goldwasser et al. PLoS One 2010) is
used to stimulate mitochondria proliferation in myocytes, expanding
their protein content, and adipogenic differentiation of the
remaining fibroblasts to fat.
Example 8
Chicken-Based Laboratory Grown Meat: Conversion of a Spontaneously
Immortalized Chicken Fibroblast Cell Line into Myocytes
[0668] Generation of Dox-inducible MyoD1 and PPAR.gamma.
vectors--Dox-inducible MyoD1 and PPAR.gamma. vectors were
generated. These vectors are capable of transforming chicken
fibroblasts (primary or immortalized) toward myocytes and
adipocytes with high efficiency, respectively (data not shown).
[0669] Previous work showed that expression of the MyoD1 gene is
sufficient to induce myogenesis of human and mouse fibroblasts. A
parallel but connected myogenesis pathway goes through Myogenin
(MYOG) in mammals.
Experimental Results
[0670] Genetic Conversion of CSIF to Myocytes--To examine if
similar conversion of chicken cells to myocytes is possible, the
present inventor generated several nucleic acid constructs
(vectors) as is schematically illustrated in FIGS. 6-8 and 12. The
first construct [FIG. 6, "pinducer-VP64-cMyoD1", SEQ ID NO:3]
included the chicken MyoD1 gene (SEQ ID NO:5) cloned into a
Dox-inducible lentiviral vector (pInducer20) being fused to the
VP64 transcriptional activator (SEQ ID NO: 6) that has been shown
to improve MyoD1 induced differentiation in mouse cells (Kabadi et
al. ACS Synthetic Biology. 2015). A second lentiviral vector (SEQ
ID NO:2, FIG. 7) was created for Dox-inducible chicken MYOG
expression included the cMyogenin coding sequence (SEQ ID NO: 7)
under the control of the minimal CMV promoter (SEQ ID NO: 8). A
third lentiviral vector (SEQ ID NO:1, FIG. 12) was created for
Dox-inducible chicken MYOD1 expression included the cMyoD1 coding
sequence (SEQ ID NO: 5) under the control of the minimal CMV
promoter (SEQ ID NO: 8). All three vectors were sequenced and were
found to be mutation free (data not shown).
[0671] To rapidly detect myogenesis in culture the present inventor
created a GFP reporter construct (lentiviral reporter construct;
SEQ ID NO: 4, FIG. 8) for the rat myosin light chain-3
promoter-enhancer (rMLC3-GFP), including the rat MLC3 enhancer (SEQ
ID NO: 10; 1.5 kb enhancer sequence from the rat MLC3 gene), the
rat MLC3 promoter (SEQ ID NO: 11; 628 bp promoter sequence) and the
COP-GFP coding sequence (SEQ ID NO: 12). In this lentiviral
reporter construct the rat MCL3 enhancer and promoter driving
expression of the COP-GFP. This reporter has been shown to be
specific and effective in chicken embryos and cells (McGrew et al.
BMC Developmental Biology 2010). The various constructs were
introduced into 293T cells in order to generate lentivirus.
[0672] Primary CEF and CSIF lines were infected 3 times with the
lentivirus vectors and split a day later. Cells were cultured in
standard DMEM/F12 medium containing 15% serum. CEF and CSIF
cultures were induced by doxycycline and were followed for 30 days.
While non-induced cultures were negative for GFP (Data not shown),
both CEF and CSIF show strong expression of MLC3 by day 11 of
culture with cells forming distinct fibers maintained to day 30 of
culture (FIGS. 5B and 5C). Immunofluorescence analysis showed
F-actin organization and multinucleated (syncytia) fiber formation
(FIG. 5D). Staining showed clear induction of .alpha.1-skeletal
muscle actin (ACTA1) and Troponin T shows a clear muscle phenotype
as early as day 7 of induction (FIG. 5E).
[0673] As described above in Example 3 hereinabove, a small
molecule screen aiming to identify small molecules that can
transdifferentiate fibroblasts to muscle cells in the absence of
Dox-inducible MyoD1 is carried out using the a GFP reporter
construct (lentiviral reporter construct) for the rat myosin light
chain-3 promoter-enhancer (FIG. 8). Thus, the present inventor uses
variants of small molecule cocktails recently shown to
transdifferentiate mouse and human fibroblasts to cardiomyocytes
(Cao et al 2016; Fu et al. 2015). A GFP-linked MLC reporter ensures
a rapid detection of successful conversion as shown in FIGS.
5B-C.
[0674] It should be noted that there are regulatory concerns
regarding the use of some small molecules that can affect DNA
structure in the reprogramming step. Regulatory agencies are
already looking at this issue for human regenerative medicine,
while other groups are rapidly producing alternative small
molecules for conversion. In contrast to regenerative medicine
approaches, the perfusion system of some embodiments of the
invention can rapidly flush the system and remove any residual
small molecules before the process terminates. Additionally or
alternatively, a Dox-inducible differentiation method can be used
as shown in FIGS. 5A-E.
[0675] Metabolomic analysis of the perfusate and tissue is carried
out over time to identify which nutrients are rate limiting (i.e.
missing). A metabolic flux balance model of the tissue is
established (as described in Levy et al. 2016) which allows to see
changing fluxes and determine the metabolic requirements of the
cells. Growth factors are introduced in access and their removal is
determined by protein array analysis, as small molecules are to
replace them. Metabolic analysis using Jobst Technologies
(Freiburg, German) metabolic sensors and an oxygen sensor, showed
proliferating CSIF consume oxygen at a rate of 2.4
nmol/min/10.sup.6 cells, consume glucose at a rate of 1.8
nmol/min/10.sup.6 cells and produce lactate at a rate of 198
pmol/min/10.sup.6 cells during the growth phase.
Example 9
Generation of a Hybrid of Plant-Based Meat Substitute Product with
Laboratory Grown Fat
[0676] A meat analogue, also called a meat substitute, approximates
certain aesthetic qualities (primarily texture, flavor and
appearance) or chemical characteristics of specific types of meat.
Many analogues are based on cereal, gluten, or legumes such as soy
or pea. Global meat substitute market was $3.3 billion in 2014, and
grows at a CAGR of 7.5% including products such as veggie burgers,
soy hotdogs, and chicken nuggets. However, these products fail to
emulate the flavor and aroma of animal meat. Recent work on
plant-based meat substitutes identified fermented leghemoglobin
(also called "(also leghaemoglobin or legoglobin") as a source for
a metallic flavor resembling blood. Using molecular gastronomy
tools companies such as Impossible Foods and Beyond Meat produced
ground meat-like patty with the texture and aroma of beef. However,
the cooking of protein-bound saturated fat produces the distinct
flavor of meat. Current products use coconut or palm oil as a
source of palmitate (16:0) that is solid at room temperature, but
rapidly melts at 62.9.degree. C. This results in an oily, dripping
product that is distinct from real beef. Similarly, several
companies such as Beyond Meat extrude layered legume protein to
create the texture and mouth feel of chicken strips. Similar lack
of animal fat results in a dry mouth feel distinct from real
chicken.
[0677] To produce animal fat, CSIF are cultured in serum free
medium composed of DMEM/F12 supplemented with dexamethasone (0.1
.mu.M), bFGF (10 ng/ml), long IGF-1 (Sigma I1271) (5 ng/ml), 12
.mu.M linoleic acid, and 2 mM of L-Analyl-L-Glutamine. Cells are
cultured in fed-batch bioreactors, perfusion bioreactors, or
closed-loop perfusion described above to a density of
10.times.10.sup.6 cells/ml. Medium further supplemented with 400
.mu.M oleic acid and 10 .mu.M rosiglitazone. Cells acquire lipid
droplets and reach a density of 100.times.10.sup.6 cells/ml. The
adipocyte slurry is concentrated and added as raw material to the
plant-based matrix composed of cereal or legume-based protein
isolate such as the Pea Protein Organic Powder (Now Sports). Raw
material density is changed as a function of the desired end
product. Chicken strips require 5 to 10% laboratory grown
adipocytes, resulting in about 1.5.times.10.sup.8 cells in final
product. Hamburgers require 10 to 20% laboratory grown adipocytes,
resulting in about 3.times.10.sup.8 cells in final product.
Example 10
Generation of a Chicken Patty or Nugget in a Stirred Bioreactor
[0678] Culturing of chicken fibroblasts in a stirred
bioreactor--Chicken fibroblasts can be cultured in a stirred
bioreactor (BioFlo.RTM. 320) in small single use vessels of 250-400
mL volume.
[0679] The cells are aggregated into small micro-clusters and are
cultured in suspension without micro-carrier beads. This permits
the high-density growth of cells reaching 4-6.times.10.sup.6
cells/mL. Once this density is reached a chicken patty or nugget
with a density of 200.times.10.sup.6 cells/gram is prepared for a
public tasting.
[0680] Alternatively, fibroblasts can be grown on collagen-coated
micro-carrier beads (e.g. SoloHill Engineering) as previously
described (Mg & Ma Sha 2015).
Example 11
Establishment and Isolation of Chicken Embryonic Endothelial
Cells
[0681] Differentiation of chicken induced pluripotent stem cells
(iPSCs) into endothelial cells--Using chicken fibroblasts
(non-immortalized) the present inventor generated chicken induced
pluripotent stem cells (iPSCs) essentially as described by Vodyanik
et al. 2010. Then the chicken iPSCs are used for the
differentiation of chicken endothelial cells in a similar manner to
human and mouse derived cells (Giacomelli et al. Development 2017).
The iPS-derived chicken endothelial cells can be used as is with
limited population doubling (up to 20) or can be used to generate
spontaneously immortalized endothelial cells as described
below.
[0682] Spontaneous immortalization of chicken endothelial
cells--Chicken microvascular endothelial cells which are either
obtained from a commercial source (Charles River Labs) or which are
isolated from young chickens according to established protocols
(Twal & Leach In Vitro Cell. Dev. Biol. Animal 1996) are then
being cultured on 50 .mu.g/ml collagen type I or 0.2% gelatin in
standard culture medium, such as EGM2mv (Lonza, Switzerland) or
serum free formulation (e.g. ThermoFisher #11111044) containing
bFGF (20 ng/ml), EGF (10 ng/ml), and human plasma fibronectin (10
.mu.g/ml) until a spontaneous immortalization occurs, so as to
obtain a chicken endothelial cell line which is not genetically
modified.
[0683] It is noted that the present inventor was able to obtain a
spontaneously immortalized endothelial cell from rat cardiac
microvascular endothelial cells purchased from Vec Technologies
(Rensselaer, N.Y.), reaching at least population doubling 120 (data
not shown), thus proving that a spontaneous immortalization of
endothelial cells is feasible.
Example 12
Generation of Chicken Muscle Using Sponges
[0684] Generation of chicken muscle tissue by co-culturing of
spontaneously immortalized fibroblasts and spontaneously
immortalized endothelial cells on sponges (scaffolds)--The present
inventor has designed generation of chicken muscle by seeding
spontaneously immortalized chicken fibroblasts and spontaneously
immortalized rat endothelial cells mixtures into a biodegradable
large pore sponges, such as collagen hydrogel, that permits rapid
vascularization and uniform distribution of nutrients. The
micro-tissue is characterized by confocal and electron
microscopy.
[0685] Other suitable sponges (scaffolds) include, but are not
limited to, polylactic acid, polyglycolic acid, or
poly(lactic-co-glycolic acid), sponges, polyglicolic acid sponges,
Variotis.TM. (Biometic, AU) or Cellusponge.TM. (hydroxypropyl
cellulose. Bio-Byblos Catalogue No. Z741057).
[0686] It is noted that one possible way of avoiding loss of cells
by the perfusion system, is to first embed the cells in an
injectable hydrogel polypeptide matrix which is then being injected
into the biodegradable sponge.
[0687] The micro-tissue scaffold is cultured under perfusion and
the cell proliferation and metabolic uptake of nutrients and growth
factors was tracked as shown in Table 2 below. Non-specific
absorption by the system is monitored, even in the absence of
cells, since this could lead to loss of peptides and lipids.
TABLE-US-00002 TABLE 2 Metabolic Flux Measurement Oxygen
Consumption Rate 2.4 nmol/min/10.sup.6 cells Glucose Uptake Rate
1.8 nmol/min/10.sup.6 cells Lactate Production Rate 198
pmol/min/10.sup.6 cells
[0688] Growth rates and metabolic parameters are reintroduced into
the model and systems parameters are adjusted.
[0689] Cell growth and the maximal cell density are determined in
the absence of dialysis.
[0690] Following the successful demonstration of cell growth under
perfusion the tissue organization and the proper vascular
connectivity and distribution are characterized as shown in FIGS.
11A-C. Spontaneously immortalized chicken fibroblasts (CSIF) and
spontaneously immortalized rat microvascular endothelial cells
(RCEC) were suspended at a density of 150.times.10.sup.6 CSIF/ml
and 15.times.10.sup.6 RCEC/ml in collagen type 1 scaffold and
seeding for microscope evaluate and perfusion. High-density tissue
formed overnight and compacted the collagen scaffold. As shown by
sulforhodamine B stain, the cultured cells revealed high protein
content (FIG. 11A). The tissue seeded in the bioreactor were sealed
and perfused in serum free medium, without antibiotics for 11 days.
No loss of cell mass was observed. Confocal analysis showed clear
organization of vascular structures and associated tissue.
[0691] Growth factors and cytokines are used to define vascular
maturation. Tissue assembly and growth are characterized by live
imaging and end point microscopic evaluation. Once cell density
outstrips nutrient uptake, perfusion rate through the nested
dialysis circuit is increased to rapidly remove toxins while adding
stable supply of nutrients to the growing tissue. The
above-described model shows that the minimal perfusion rate
required to support cell growth increases exponentially with time
or linearly with tissue mass to supply the oxygen consumption rates
of the cells. A minimal perfusion rate of 36.9 ml/s is necessary to
sustain 1 kg of tissue in ambient 21% oxygen, but only 8.2 ml/s is
be required if oxygen partial pressure is raised to 95% in the
oxygenator. The minimal perfusion rate can decrease by increasing
the oxygen carrying capacity of the medium using an oxygen carrier
such as perfluorocarbon emulsion (e.g. Fluosol) or modified
hemoglobin (e.g. Hemopure). Hemopure.RTM. is a hemoglobin-based
oxygen carrier manufactured by HbO2 Therapeutics LLC that has an
oxygen carrying capacity of 1.39 ml O2/g Hb, meaning that if we add
3.55 .mu.g of Hemopure per ml of media we double the oxygen
content, decreasing by 2 the perfusion rate needed to perfuse a
large bulk of tissue.
[0692] The model also suggests that glucose is not a limiting
factor for perfusion, as flow rates under 0.4 ml/sec can deliver
sufficient glucose to over 1 kg of cells. However, as glucose if is
not replenished, 1 kg of tissue will consume all glucose in the
system within 48 minutes. A total of 140 grams of glucose are
required for tissue growth. Glucose only becomes limiting when
tissue passes 24 grams in mass, and will need to be added at hourly
intervals on the final two days of growth.
[0693] Alternatively, tissue growth is explored in edible hollow
fiber cartridge, where nutrient supply is homogenously distributed
in the absence of an integrated vascular network.
[0694] Here, the fibers of the cartridge are made from edible
natural or synthetic polymers, such as cellulose (FiberCell,
#C3008), and the cells form a mass surrounding the fibers.
Cellulose is FDA approved as GRAS, and used to control moisture and
stabilizer shredded cheese, bread, and various sauces.
Example 13
[0695] A prototype system as been designed, according to some
embodiments of the present invention. The prototype system is
illustrated schematically in FIG. 9, and is based on a closed loop
dialysis bioreactor. The core circuit is a recirculating perfusion
bioreactor, 1 to 5 liters in volume, that grows muscle tissue
growing from 20 mg to 1000 grams, and that retains cells using a
hollow fiber cartridge, packed bed design, or vascularized embedded
tissue configuration. An increasing percentage of the bioreactor
outflow is circulated through a counter flow dialysis, whose pores
are designed to exclude albumin, about 30 kDa molecular weight
cutoff. As the cells are not present during this filtration step it
can occur at high pressures. This design retains the albumin and
with it the growth factors and lipids is carries in the medium.
Another perfusion circulates the dialysate through a filter that
removes ammonia and toxins (e.g. Zeolite molecular sieve). This
design can reach the volume/mass ratio of animals, nominally 100 ml
per kg mass. It is estimated that about 2 liters medium can be used
with per 5 liters bioreactor volume. This design can produce 2.5 kg
mass every 10 days, consuming only 2 liters of medium, as it does
not require a seed train. This translates to $4 per kg mass for the
medium costs alone.
[0696] Capital costs are also considered. Current estimate of the
bill of parts using off the shelf components is about $7,000,
suggesting manufacturing costs of about $300 for a system having a
5 liter bioreactor chamber. A production facility with 5,000 such
systems can cost about $1.5 million, so that an estimate of about
$5 million for the entire facility. Assuming the same 10% annual
depreciation and maintenance costs, a production capacity of about
450,000 kg/year is obtained with about $500,000 annual costs to
maintain. This results in a capital cost of only about $1.1 per kg
mass produced.
[0697] The prototype system is composed of a primary tissue
perfusion circuit and a secondary dialysis circuit for nutrient and
toxin exchange. The primary circuit includes culture medium
perfusate that is recirculated using a peristaltic pump through a
jacketed tissue growth chamber, an oxygenator, a heat exchanger,
and a bubble trap. The oxygenator is gassed with a mixture of 95%
O.sub.2, 5% CO.sub.2 and 15% N.sub.2 maintaining constant pH.
[0698] A fraction of the perfusate is diverted to a secondary
circuit through a hollow fiber dialyzer, such as Spectrum Labs
(Rancho Dominguez, Calif.) with up to 790 cm.sup.2 membrane area
and a 30 kDa molecular weight cutoff (the total filtration surface
area in a human kidney is only 516.1 cm.sup.2). A particular
advantage of the dialysis of the present embodiments is that
albumin, with a molecular weight of 66.5 kDa, is retained in the
main perfusion circuit, as further detailed hereinabove.
[0699] The secondary circuit dialyzes the perfusate using
counter-flow to maximize diffusion, against a protein-free
dialysate, recirculated through an ammonia filter using another
peristaltic pump. Ammonia filters such as Zeolites trap clearing
the ammonia from the solution. Temperature within the bioreactor
are optimized between 38.degree. C. to 40.5.degree. C. mimicking
the normal body temperature of chickens.
[0700] Perfusion and nutrient consumption rates are also
considered. Under ambient conditions, partial pressure of 21% (160
mmHg) of oxygen results in a concentration of 220 nmol O.sub.2/ml
medium. Using a SeaHorse Bioanalyzer the Inventor showed that
chicken embryonic fibroblasts consume 2.4 nmol O.sub.2/min/10.sup.6
cells. Considering that 1 g of tissue contains approximately
200.times.10.sup.6 cells, a perfusion rate of about 36.9 ml/s is
sufficient to sustain 1 kg of tissue in standard incubators gas
pressures. If oxygen partial pressure is raised to 95%, a perfusion
rate of about 8.2 ml/s is sufficient.
[0701] Glucose consumption is additionally considered. Using online
sensors, a glucose uptake rate of 1.8 nmol/min/10.sup.6 cells, and
lactate production rate of 198 pmol/min/10.sup.6 cells were
measured for chicken embryonic fibroblasts. Considering that
DMEM/F12 medium contains 3.15 g/L of glucose, the perfusion rate
required to sustain 1 kg of tissue would be 0.36 ml/sec. Therefore,
glucose is not a limiting factor for medium perfusion. Yet,
continuous addition of glucose is preferred, optionally at
narrowing intervals, during late stage culture, since at this rate
1 kg tissue consumes the glucose in 1 liter medium within about 48
min.
[0702] FIGS. 10A and 10B are graph showing the produce mass and
applied perfusion rates (FIG. 10A), and accumulated glucose
consumption (FIG. 10B). In this example, an exponential growth rate
characterized by a doubling time constant of 20 h has been
employed. At this growth rate, it is preferred to add glucose
starting from the day 13, so as to provide the glucose demand.
[0703] The peristaltic pumps are selected to provide perfusion rate
of at least 36 ml/s, particularly towards the last days of the
cycle (e.g., beginning of the 13th day). Yet, this rate can be
decreased using different strategies such as oxygen transporters to
increase basal level of O.sub.2 in the media. For example,
Hemopure.RTM. is a hemoglobin-based oxygen carrier manufactured by
HbO.sub.2 Therapeutics LLC that has an oxygen carrying capacity of
1.39 ml O.sub.2/g Hb, meaning that adding 3.55 .mu.g of Hemopure
per ml of media the oxygen content can be doubled, and the
perfusion rate can be decreasing by a factor of 2.
[0704] Table 3 below provides a comparison between the fed-batch
process, the concentrated perfusion process, and the technique
according to exemplary embodiments of the invention.
TABLE-US-00003 TABLE 3 Circulating The inventive Parameter
Fed-Batch Perfusion technique Seed Train 20 L, 80 L, 20 L run for
10 None 400 L, 2000 L days; 6 reactor volumes Production Reactor
10,000 L 1,000 L 5 L Cell Density 25 .times. 10.sup.6 100 .times.
10.sup.6 100 .times. 10.sup.6 Growth Phase 19 days 30 days 10 days
Media Consumption 12,500 L 2,120 L 2 L Media Cost $20/L $5/L $5/L
Consumable Costs +$200/kg +$21/kg +$4/kg Facility Cost $50M $30M
$5M * Capital Burden $5M $3M $0.5M Production Capacity 24,000 kg/yr
6,000 kg/yr 450,000 kg/yr Capital Costs +$200/kg +$500/kg +$1/kg *
5,000 small 5 L bioreactors in a factory
[0705] Although the invention has been described in conjunction
with specific embodiments thereof, it is evident that many
alternatives, modifications and variations will be apparent to
those skilled in the art. Accordingly, it is intended to embrace
all such alternatives, modifications and variations that fall
within the spirit and broad scope of the appended claims.
[0706] All publications, patents and patent applications mentioned
in this specification are herein incorporated in their entirety by
reference into the specification, to the same extent as if each
individual publication, patent or patent application was
specifically and individually indicated to be incorporated herein
by reference. In addition, citation or identification of any
reference in this application shall not be construed as an
admission that such reference is available as prior art to the
present invention. To the extent that section headings are used,
they should not be construed as necessarily limiting.
[0707] It will be evident to those skilled in the art that the
invention is not limited to the details of the foregoing
illustrated embodiments and that the present invention may be
embodied in other specific forms without departing from the spirit
or essential attributes thereof The present embodiments are
therefore to be considered in all respects as illustrative and not
restrictive, the scope of the invention being indicated by the
appended claims rather than by the foregoing description, and all
changes which come within the meaning and range of equivalency of
the claims are therefore intended to be embraced therein.
REFERENCES
Additional References are Cited in Text
[0708] 1. Long-term culture and expansion of primary human
hepatocytes. G. Levy, D. Bomze, S. Heinz, S. D. Ramachandran, A.
Noerenberg, M. Cohen, O. Shibolet, E. Sklan, J. Braspenning, Y.
Nahmias. 2015, Nature biotechnology, pp. 1264-1271. [0709] 2. An
active bubble trap and debubbler for microfluidic systems. A. M.
Skelley, J. Voldmana. 2008, The Royal Society of Chemistry, pp.
1733-1737. [0710] 3. Real-time monitoring of metabolic function in
liver-on-chip microdevices tracks the dynamics of mitochondrial
dysfunction. D. Bavli, S. Prill, E. Ezra, G. Levy, M. Cohen, M.
Vinken, J. Vanfleteren, M. Jaeger, Y. Nahmias. E2231-E2240, s.l.:
PNAS, 2016. [0711] 4. Chick stem cells: current progress and future
prospects. S. Intarapat, C. D. Stern. 2013, Stem cell research, pp.
1378-1392. [0712] 5. Avian-induced pluripotent stem cells derived
using human reprogramming factors. Y. Lu, F. D. West, B. J. Jordan,
J. L. Mumaw, E. T. Jordan, A. Gallegos-Cardenas, R. B. Beckstead,
S. L. Stice. s.l.: Stem Cells Dev., 2012, Vols. 394-403. [0713] 6.
Mammalian genes induce partially reprogrammed pluripotent stem
cells in non-mammalian vertebrate and invertebrate species. R. A.
Rossello, C. C. Chen, R. Dai, J. T. Howard, U. Hochgeschwender, E.
D. Jarvis. 2013, eLife 2. [0714] 7. Pluripotent stem cells induced
from mouse somatic cells by small-molecule compounds. P. Hou, Y.
Li, X. Zhang, C. Liu, J. Guan, H. Li, T. Zhao, J. Ye, W. Yang, K.
Liu, J. Ge, J. Xu, Q. Zhang, Y. Zhao, H. Deng. 2013, Science, pp.
651-654. [0715] 8. Identification of small molecules for human
hepatocyte expansion and iPS differentiation. J. Shan, R. E.
Schwartz, N. T. Ross, D. J. Logan, D. Thomas, S. A. Duncan, T. E.
North, W. Goessling, A. E. Carpenter, S. N. Bhatia. 2013, Nature
chemical biology, pp. 514-520. [0716] 9. Conversion of human
fibroblasts into functional cardiomyocytes by small molecules. N.
Cao, Y. Huang, J. Zheng, C. I. Spencer, Y. Zhang, J. D. Fu, B. Nie,
M. Xie, M. Zhang, H. Wang, T. Ma, T. Xu, G. Shi, D. Srivastava, S.
Ding. 2016, Science. [0717] 10. Direct reprogramming of mouse
fibroblasts into cardiomyocytes with chemical cocktails. Y. Fu, C.
Huang, X. Xu, H. Gu, Y. Ye, C. Jiang, Z. Qiu, X. Xie. 2015, Cell
research, pp. 1013-1024. [0718] 11. Endothelium-mediated hepatocyte
recruitment in the establishment of liver-like tissue in vitro. Y.
Nahmias, R. E. Schwartz, W. S. Hu, C. M. Verfaillie, D. J. Odde.
2006, Tissue engineering, pp. 1627-1638. [0719] 12. Recovery of
warm ischemic rat liver grafts by normothermic extracorporeal
perfusion. H. Tolboom, R. E. Pouw, M. L. Izamis, J. M. Milwid, N.
Sharma, A. Soto-Gutierrez, Y. Nahmias, K. Uygun, F. Berthiaume, M.
L. Yarmush. 2009, Transplantation, pp. 170-177. [0720] 13.
Real-time monitoring of metabolic function in liver-on-chip
microdevices tracks the dynamics of mitochondrial dysfunction. D.
Bavli, S. Prill, E. Ezra, G. Levy, M. Cohen, M. Vinken, J.
Vanfleteren, M. Jaeger, Y. Nahmias. 2016, Proceedings of the
National Academy of Sciences of the United States of America, pp.
E2231-2240. [0721] 14. Real-time monitoring of oxygen uptake in
hepatic bioreactor shows CYP450-independent mitochondrial toxicity
of acetaminophen and amiodarone. S. Prill, D. Bavli, G. Levy, E.
Ezra, E. Schmalzlin, M. S. Jaeger, M. Schwarz, C. Duschl, M. Cohen,
Y. Nahmias. 2016, Archives of toxicology, pp. 1181-1191. [0722] 15.
Serum free primary human fibroblast and keratinocyte coculture. S.
Mujaj, K. Manton, Z. Upton, S. Richards. 2010, Tissue engineering,
pp. 1407-1420. [0723] 16. Insulin-like growth factor I stimulates
myoblast expansion and myofiber development in the limb. P. J.
Mitchell, S. E. Johnson, K. Hannon. 2002, Developmental dynamics:
an official publication of the American Association of Anatomists,
pp. 12-23. [0724] 17. Screening and discovery of
nitro-benzoxadiazole compounds activating epidermal growth factor
receptor (EGFR) in cancer cells. V. Sakanyan, M. Angelini, M. Le
Bechec, M. F. Lecocq, F. Benaiteau, B. Rousseau, A. Gyulkhandanyan,
L. Gyulkhandanyan, C. Loge, E. Reiter, C. Roussakis, F. Fleury.
2014, Scientific reports, p. 3977. [0725] 18. Differentiation of
pluripotent stem cells to muscle fiber to model Duchenne muscular
dystrophy. J. Chal, M. Oginuma, Z. Al Tanoury, B. Gobert, O.
Sumara, A. Hick, F. Bousson, Y. Zidouni, C. Mursch, P. Moncuquet,
O. Tassy, S. Vincent, A. Miyanari, A. Bera, J. M. Gamier, G.
Guevara, M. Hestin, L. Kennedy, S. Hayashi, B. Drayton, T.
Cherrier, B. Gayra. 2015, Nature biotechnology, pp. 962-969. [0726]
19. MyoD converts primary dermal fibroblasts, chondroblasts, smooth
muscle, and retinal pigmented epithelial cells into striated
mononucleated myoblasts and multinucleated myotubes. J. Choi, M. L.
Costa, C. S. Mermelstein, C. Chagas, S. Holtzer, H. Holtzer. 1990,
Proceedings of the National Academy of Sciences of the United
States of America, pp. 7988-7992. [0727] 20. Tet-on inducible
system combined with in ovo electroporation dissects multiple roles
of genes in somitogenesis of chicken embryos. T. Watanabe, D.
Saito, K. Tanabe, R. Suetsugu, Y. Nakaya, S. Nakagawa, Y.
Takahashi. 2007, Developmental biology, pp. 625-636. [0728] 21.
Efficient selection for high-expression transfectants with a novel
eukaryotic vector. H. Niwa, K. Yamamura, J. Miyazaki. 1991, Gene,
pp. 193-199. [0729] 22. A zebrafish embryo culture system defines
factors that promote vertebrate myogenesis across species. C. Xu,
M. Tabebordbar, S. Iovino, C. Ciarlo, J. Liu, A. Castiglioni, E.
Price, M. Liu, E. R. Barton, C. R. Kahn, A. J. Wagers, L. I. Zon.
2013, Cell, pp. 909-921. [0730] 23. Skeletal myogenesis by human
embryonic stem cells. J. K. Zheng, Y. Wang, A. Karandikar, Q. Wang,
H. Gai, A. L. Liu, C. Peng, H. Z. Sheng. 2006, Cell research, pp.
713-722. [0731] 24. Long-term in vitro culture and characterisation
of avian embryonic stem cells with multiple morphogenetic
potentialities. B. Pain, M. E. Clark, M. Shen, H. Nakazawa, M.
Sakurai, J. Samarut, R. J. Etches. 1996, Development, pp.
2339-2348. [0732] 25. Identification of Small Molecules Which
Induce Skeletal Muscle Differentiation in Embryonic Stem Cells via
Activation of the Wnt and Inhibition of Smad2/3 and Sonic Hedgehog
Pathways. H. Lee, C. Haller, C. Manneville, T. Doll, I. Fruh, C. G.
Keller, S. M. Richards, Y. Ibig-Rehm, M. Patoor, M. Goette, L. C.
Bouchez, M. Mueller. 2016, Stem cells, pp. 299-310. [0733] 26.
Building muscle: molecular regulation of myogenesis. C. F.
Bentzinger, Y. X. Wang, M. A. Rudnicki. 2012, Cold Spring Harbor
perspectives in biology. [0734] 27. Glycolysis-mediated changes in
acetyl-CoA and histone acetylation control the early
differentiation of embryonic stem cells. A. Moussaieff, M. Rouleau,
D. Kitsberg, M. Cohen, G. Levy, D. Barasch, A. Nemirovski, S.
Shen-Orr, I. Laevsky, M. Amit, D. Bomze, B. Elena-Herrmann, T.
Scherf, M. Nissim-Rafinia, S. Kempa, J. Itskovitz-Eldor, E.
Meshorer, D. Aberdam, Y. Nahmias. 2015, Cell metabolism, pp.
392-402. [0735] 28. Roxarsone, inorganic arsenic, and other arsenic
species in chicken: a U.S.-based market basket sample. K. E.
Nachman, P. A. Baron, G. Raber, K. A. Francesconi, A. Navas-Acien,
D. C. Love. 2013, Environmental health perspectives, pp. 818-824.
[0736] 29. Multidrug-Resistant Staphylococcus aureus in US Meat and
Poultry. A. E. Waters, T. Contente-Cuomo, J. Buchhagen, C. M. Liu,
L. Watson, K. Pearce, J. T. Foster, J. Bowers, E. M. Driebe, D. M.
Engelthaler, P. S. Keim, L. B. Price. 2011, Clinical infectious
diseases: an official publication of the Infectious Diseases
Society of America, pp. 1227-1230. [0737] 30. Micropatterning of
living cells by laser-guided direct writing: application to
fabrication of hepatic-endothelial sinusoid-like structures. Y.
Nahmias, D. J. Odde. 2006, Nature protocols, pp. 2288-2296. [0738]
31. Integration of technologies for hepatic tissue engineering. Y.
Nahmias, F. Berthiaume, M. L. Yarmush. 2007, Advances in
biochemical engineering/biotechnology, pp. 309-329. [0739] 32.
Vascularized and functional human liver from an iPSC-derived organ
bud transplant. T. Takebe, K. Sekine, M. Enomura, H. Koike, M.
Kimura, T. Ogaeri, R. R. Zhang, Y. Ueno, Y. W. Zheng, N. Koike, S.
Aoyama, Y. Adachi, H. Taniguchi. 2013, Nature, pp. 481-484. [0740]
33. A novel formulation of oxygen-carrying matrix enhances
liver-specific function of cultured hepatocytes. Y. Nahmias, Y.
Kramvis, L. Barbe, M. Casali, F. Berthiaume, M. L. Yarmush.
2531-2533, s.l.: FASEB, 2006.
Sequence CWU 1
1
22110975DNAArtificial sequencepInducer20-cMyoD1 1tggaagggct
aattcactcc caaagaagac aagatatcct tgatctgtgg atctaccaca 60cacaaggcta
cttccctgat tagcagaact acacaccagg gccaggggtc agatatccac
120tgacctttgg atggtgctac aagctagtac cagttgagcc agataaggta
gaagaggcca 180ataaaggaga gaacaccagc ttgttacacc ctgtgagcct
gcatgggatg gatgacccgg 240agagagaagt gttagagtgg aggtttgaca
gccgcctagc atttcatcac gtggcccgag 300agctgcatcc ggagtacttc
aagaactgct gatatcgagc ttgctacaag ggactttccg 360ctggggactt
tccagggagg cgtggcctgg gcgggactgg ggagtggcga gccctcagat
420cctgcatata agcagctgct ttttgcctgt actgggtctc tctggttaga
ccagatctga 480gcctgggagc tctctggcta actagggaac ccactgctta
agcctcaata aagcttgcct 540tgagtgcttc aagtagtgtg tgcccgtctg
ttgtgtgact ctggtaacta gagatccctc 600agaccctttt agtcagtgtg
gaaaatctct agcagtggcg cccgaacagg gacttgaaag 660cgaaagggaa
accagaggag ctctctcgac gcaggactcg gcttgctgaa gcgcgcacgg
720caagaggcga ggggcggcga ctggtgagta cgccaaaaat tttgactagc
ggaggctaga 780aggagagaga tgggtgcgag agcgtcagta ttaagcgggg
gagaattaga tcgcgatggg 840aaaaaattcg gttaaggcca gggggaaaga
aaaaatataa attaaaacat atagtatggg 900caagcaggga gctagaacga
ttcgcagtta atcctggcct gttagaaaca tcagaaggct 960gtagacaaat
actgggacag ctacaaccat cccttcagac aggatcagaa gaacttagat
1020cattatataa tacagtagca accctctatt gtgtgcatca aaggatagag
ataaaagaca 1080ccaaggaagc tttagacaag atagaggaag agcaaaacaa
aagtaagacc accgcacagc 1140aagcggccgg ccgctgatct tcagacctgg
aggaggagat atgagggaca attggagaag 1200tgaattatat aaatataaag
tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc 1260aaagagaaga
gtggtgcaga gagaaaaaag agcagtggga ataggagctt tgttccttgg
1320gttcttggga gcagcaggaa gcactatggg cgcagcgtca atgacgctga
cggtacaggc 1380cagacaatta ttgtctggta tagtgcagca gcagaacaat
ttgctgaggg ctattgaggc 1440gcaacagcat ctgttgcaac tcacagtctg
gggcatcaag cagctccagg caagaatcct 1500ggctgtggaa agatacctaa
aggatcaaca gctcctgggg atttggggtt gctctggaaa 1560actcatttgc
accactgctg tgccttggaa tgctagttgg agtaataaat ctctggaaca
1620gatttggaat cacacgacct ggatggagtg ggacagagaa attaacaatt
acacaagctt 1680aatacactcc ttaattgaag aatcgcaaaa ccagcaagaa
aagaatgaac aagaattatt 1740ggaattagat aaatgggcaa gtttgtggaa
ttggtttaac ataacaaatt ggctgtggta 1800tataaaatta ttcataatga
tagtaggagg cttggtaggt ttaagaatag tttttgctgt 1860actttctata
gtgaatagag ttaggcaggg atattcacca ttatcgtttc agacccacct
1920cccaaccccg aggggacccg acaggcccga aggaatagaa gaagaaggtg
gagagagaga 1980cagagacaga tccattcgat tagtgaacgg atctcgacgg
tatcgccgaa ttcacaaatg 2040gcagtattca tccacaattt taaaagaaaa
ggggggattg gggggtacag tgcaggggaa 2100agaatagtag acataatagc
aacagacata caaactaaag aattacaaaa acaaattaca 2160aaaattcaaa
attttcgggt ttattacagg gacagcagag atccagtttg gactaggatc
2220ctttaccact ccctatcagt gatagagaaa agtgaaagtc gagtttacca
ctccctatca 2280gtgatagaga aaagtgaaag tcgagtttac cactccctat
cagtgataga gaaaagtgaa 2340agtcgagttt accactccct atcagtgata
gagaaaagtg aaagtcgagt ttaccactcc 2400ctatcagtga tagagaaaag
tgaaagtcga gtttaccact ccctatcagt gatagagaaa 2460agtgaaagtc
gagtttacca ctccctatca gtgatagaga aaagtgaaag tcgagctcgg
2520tacccgggtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc
tcgtttagtg 2580aaccgtcaga tcgcctggag acgccatcca cgctgttttg
acctccatag aagacaccgg 2640gaccgatcca gcctccgcgg ccccgaacta
gtccagtgtg gtgggtcgag actagcgcta 2700gcatggacct tttgggaccg
atggaaatga ctgagggttc tctctgttct tttaccgctg 2760cggatgattt
ctatgatgac ccctgtttca acacgagcga tatgcacttt ttcgaagatc
2820tggaccccag gctcgtccac gttggcggtc ttctgaaagc cgaagaacat
cctcatcatc 2880atgggcacca tcatggtaat cctcatgagg aggagcatgt
aagggccccc agcggtcatc 2940atcaggccgg taggtgcctg ctttgggcgt
gcaaggcttg caaaaggaaa acaactaatg 3000ctgaccggcg gaaagcagcc
acgatgcgcg aacgccgcag gttgtctaaa gtcaacgaag 3060cattcgagac
gcttaagcgg tgtacaagta ctaatccaaa ccagaggctc cccaaagttg
3120aaatccttcg gaatgcaatt cggtatatcg aaagcctgca agcgctgctc
cgggaacaag 3180aagacgcata ttaccccgtc ctcgaacact actctggaga
aagtgacgcc tccagcccac 3240gcagtaactg ctccgacggg atgatggaat
attctggacc accgtgctct agccggcgca 3300gaaattcata cgactcctct
tactacacag agagcccgaa tgatccgaag cacgggaagt 3360ctagcgtggt
ctcttcactg gattgtctca gtagcattgt cgagcgcatc agtactgaca
3420actccacctg cccgatattg ccgcccgccg aagctgttgc tgagggcagt
ccatgtagcc 3480cccaggaggg gggaaatctt tctgactccg gggctcaaat
tccatccccg accaactgta 3540ccccactgcc gcaggaatct agctccagta
gttcaagcaa cccgatatat caagttcttt 3600agtcgacgtc gagtctagag
ggcccgcggt tcgaataccc atacgacgtc ccagactacg 3660cttagtaatg
attaattaaa ctagaaattc taccgggtag gggaggcgct tttcccaagg
3720cagtctggag taacccaccc aagatctggc ctccgcgccg ggttttggcg
cctcccgcgg 3780gcgcccccct cctcacggcg agcgctgcca cgtcagacga
agggcgcagc gagcgtcctg 3840atccttccgc ccggacgctc aggacagcgg
cccgctgctc ataagactcg gccttagaac 3900cccagtatca gcagaaggac
attttaggac gggacttggg tgactctagg gcactggttt 3960tctttccaga
gagcggaaca ggcgaggaaa agtagtccct tctcggcgat tctgcggagg
4020gatctccgtg gggcggtgaa cgccgatgat tatataagga cgcgccgggt
gtggcacagc 4080tagttccgtc gcagccggga tttgggtcgc ggttcttgtt
tgtggatcgc tgtgatcgtc 4140acttggtgag tagcgggctg ctgggctggc
cggggctttc gtggccgccg ggccgctcgg 4200tgggacggaa gcgtgtggag
agaccgccaa gggctgtagt ctgggtccgc gagcaaggtt 4260gccctgaact
gggggttggg gggagcgcag caaaatggcg gctgttcccg agtcttgaat
4320ggaagacgct tgtgaggcgg gctgtgaggt cgttgaaaca aggtgggggg
catggtgggc 4380ggcaagaacc caaggtcttg aggccttcgc taatgcggga
aagctcttat tcgggtgaga 4440tgggctgggg caccatctgg ggaccctgac
gtgaagtttg tcactgactg gagaactcgg 4500tttgtcgtct gttgcggggg
cggcagttat ggcggtgccg ttgggcagtg cacccgtacc 4560tttgggagcg
cgcgccctcg tcgtgtcgtg acgtcacccg ttctgttggc ttataatgca
4620gggtggggcc acctgccggt aggtgtgcgg taggcttttc tccgtcgcag
gacgcagggt 4680tcgggcctag ggtaggctct cctgaatcga caggcgccgg
acctctggtg aggggaggga 4740taagtgaggc gtcagtttct ttggtcggtt
ttatgtacct atcttcttaa gtagctgaag 4800ctccggtttt gaactatgcg
ctcggggttg gcgagtgtgt tttgtgaagt tttttaggca 4860ccttttgaaa
tgtaatcatt tgggtcaata tgtaattttc agtgttagac tagtaaattg
4920tccgctaaat tctggccgtt tttggctttt ttgttagacg aagcttggta
ccgagctcgg 4980atctccaccc cgtaccggtc ctgcagtcga attcaccatg
tctagactgg acaagagcaa 5040agtcataaac ggagctctgg aattactcaa
tggtgtcggt atcgaaggcc tgacgacaag 5100gaaactcgct caaaagctgg
gagttgagca gcctaccctg tactggcacg tgaagaacaa 5160gcgggccctg
ctcgatgccc tgccaatcga gatgctggac aggcatcata cccacttctg
5220ccccctggaa ggcgagtcat ggcaagactt tctgcggaac aacgccaagt
cataccgctg 5280tgctctcctc tcacatcgcg acggggctaa agtgcatctc
ggcacccgcc caacagagaa 5340acagtacgaa accctggaaa atcagctcgc
gttcctgtgt cagcaaggct tctccctgga 5400gaacgcactg tacgctctgt
ccgccgtggg ccactttaca ctgggctgcg tattggagga 5460acaggagcat
caagtagcaa aagaggaaag agagacacct accaccgatt ctatgccccc
5520acttctgaga caagcaattg agctgttcga ccggcaggga gccgaacctg
ccttcctttt 5580cggcctggaa ctaatcatat gtggcctgga gaaacagcta
aagtgcgaaa gcggcgggcc 5640gaccgacgcc cttgacgatt ttgacttaga
catgctccca gccgatgccc ttgacgactt 5700tgaccttgat atgctgcctg
ctgacgctct tgacgatttt gaccttgaca tgctccccgg 5760gtaactaagt
aaggatccgc ggccgcacta gaggaattcc gcccctctcc ctcccccccc
5820cctaacgtta ctggccgaag ccgcttggaa taaggccggt gtgtgtttgt
ctatatgtta 5880ttttccacca tattgccgtc ttttggcaat gtgagggccc
ggaaacctgg ccctgtcttc 5940ttgacgagca ttcctagggg tctttcccct
ctcgccaaag gaatgcaagg tctgttgaat 6000gtcgtgaagg aagcagttcc
tctggaagct tcttgaagac aaacaacgtc tgtagcgacc 6060ctttgcaggc
agcggaaccc cccacctggc gacaggtgcc tctgcggcca aaagccacgt
6120gtataagata cacctgcaaa ggcggcacaa ccccagtgcc acgttgtgag
ttggatagtt 6180gtggaaagag tcaaatggct ctcctcaagc gtagtcaaca
aggggctgaa ggatgcccag 6240aaggtacccc attgtatggg aatctgatct
ggggcctcgg tgcacatgct ttacatgtgt 6300ttagtcgagg ttaaaaaaac
gtctaggccc cccgaaccac ggggacgtgg ttttcctttg 6360aaaaacacga
tgataagctt accggtccac catgattgaa caagatggat tgcacgcagg
6420ttctccggcc gcttgggtgg agaggctatt cggctatgac tgggcacaac
agacaatcgg 6480ctgctctgat gccgccgtgt tccggctgtc agcgcagggg
cgcccggttc tttttgtcaa 6540gaccgacctg tccggtgccc tgaatgaact
gcaagacgag gcagcgcggc tatcgtggct 6600ggccacgacg ggcgttcctt
gcgcagctgt gctcgacgtt gtcactgaag cgggaaggga 6660ctggctgcta
ttgggcgaag tgccggggca ggatctcctg tcatctcacc ttgctcctgc
6720cgagaaagta tccatcatgg ctgatgcaat gcggcggctg catacgcttg
atccggctac 6780ctgcccattc gaccaccaag cgaaacatcg catcgagcga
gcacgtactc ggatggaagc 6840cggtcttgtc gatcaggatg atctggacga
agagcatcag gggctcgcgc cagccgaact 6900gttcgccagg ctcaaggcga
gcatgcccga cggcgaggat ctcgtcgtga cccatggcga 6960tgcctgcttg
ccgaatatca tggtggaaaa tggccgcttt tctggattca tcgactgtgg
7020ccggctgggt gtggcggacc gctatcagga catagcgttg gctacccgtg
atattgctga 7080agagcttggc ggcgaatggg ctgaccgctt cctcgtgctt
tacggtatcg ccgctcccga 7140ttcgcagcgc atcgccttct atcgccttct
tgacgagttc ttctgatgta caagtaaagc 7200ggccgcgact ctagatcata
atcagccata ccacatttgt agaggtttta cttgctttaa 7260aaaacctccc
acacctcccc ctgaacctga aacataaaat gaatgcaatt gttgttgttt
7320agtccctccc aattcgatat caagcttatc gatcgataga tcctaatcaa
cctctggatt 7380acaaaatttg tgaaagattg actggtattc ttaactatgt
tgctcctttt acgctatgtg 7440gatacgctgc tttaatgcct ttgtatcatg
ctattgcttc ccgtatggct ttcattttct 7500cctccttgta taaatcctgg
ttgctgtctc tttatgagga gttgtggccc gttgtcaggc 7560aacgtggcgt
ggtgtgcact gtgtttgctg acgcaacccc cactggttgg ggcattgcca
7620ccacctgtca gctcctttcc gggactttcg ctttccccct ccctattgcc
acggcggaac 7680tcatcgccgc ctgccttgcc cgctgctgga caggggctcg
gctgttgggc actgacaatt 7740ccgtggtgtt gtcggggaaa tcatcgtcct
ttccttggct gctcgcctgt gttgccacct 7800ggattctgcg cgggacgtcc
ttctgctacg tcccttcggc cctcaatcca gcggaccttc 7860cttcccgcgg
cctgctgccg gctctgcggc ctcttccgcg tcttcgcctt cgccctcaga
7920cgagtcggat ctccctttgg gccgcctccc cgcctgagat cctttaagac
caatgactta 7980caaggcagct gtagatctta gccacttttt aaaagaaaag
gggggactgg aagggctaat 8040tcactcccaa cgaagacaag atctgctttt
tgcttgtact gggtctctct ggttagacca 8100gatctgagcc tgggagctct
ctggctaact agggaaccca ctgcttaagc ctcaataaag 8160cttgccttga
gtgcttcaag tagtgtgtgc ccgtctgttg tgtgactctg gtaactagag
8220atccctcaga cccttttagt cagtgtggaa aatctctagc agtagtagtt
catgtcatct 8280tattattcag tatttataac ttgcaaagaa atgaatatca
gagagtgaga ggcccgggtt 8340aattaaggaa agggctagat cattcttgaa
gacgaaaggg cctcgtgata cgcctatttt 8400tataggttaa tgtcatgata
ataatggttt cttagacgtc aggtggcact tttcggggaa 8460atgtgcgcgg
aacccctatt tgtttatttt tctaaataca ttcaaatatg tatccgctca
8520tgagacaata accctgataa atgcttcaat aatattgaaa aaggaagagt
atgagtattc 8580aacatttccg tgtcgccctt attccctttt ttgcggcatt
ttgccttcct gtttttgctc 8640acccagaaac gctggtgaaa gtaaaagatg
ctgaagatca gttgggtgca cgagtgggtt 8700acatcgaact ggatctcaac
agcggtaaga tccttgagag ttttcgcccc gaagaacgtt 8760ttccaatgat
gagcactttt aaagttctgc tatgtggcgc ggtattatcc cgtgttgacg
8820ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg
gttgagtact 8880caccagtcac agaaaagcat cttacggatg gcatgacagt
aagagaatta tgcagtgctg 8940ccataaccat gagtgataac actgcggcca
acttacttct gacaacgatc ggaggaccga 9000aggagctaac cgcttttttg
cacaacatgg gggatcatgt aactcgcctt gatcgttggg 9060aaccggagct
gaatgaagcc ataccaaacg acgagcgtga caccacgatg cctgtagcaa
9120tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct
tcccggcaac 9180aattaataga ctggatggag gcggataaag ttgcaggacc
acttctgcgc tcggcccttc 9240cggctggctg gtttattgct gataaatctg
gagccggtga gcgtgggtct cgcggtatca 9300ttgcagcact ggggccagat
ggtaagccct cccgtatcgt agttatctac acgacgggga 9360gtcaggcaac
tatggatgaa cgaaatagac agatcgctga gataggtgcc tcactgatta
9420agcattggta actgtcagac caagtttact catatatact ttagattgat
ttaaaacttc 9480atttttaatt taaaaggatc taggtgaaga tcctttttga
taatctcatg accaaaatcc 9540cttaacgtga gttttcgttc cactgagcgt
cagaccccgt agaaaagatc aaaggatctt 9600cttgagatcc tttttttctg
cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac 9660cagcggtggt
ttgtttgccg gatcaagagc taccaactct ttttccgaag gtaactggct
9720tcagcagagc gcagatacca aatactgttc ttctagtgta gccgtagtta
ggccaccact 9780tcaagaactc tgtagcaccg cctacatacc tcgctctgct
aatcctgtta ccagtggctg 9840ctgccagtgg cgataagtcg tgtcttaccg
ggttggactc aagacgatag ttaccggata 9900aggcgcagcg gtcgggctga
acggggggtt cgtgcacaca gcccagcttg gagcgaacga 9960cctacaccga
actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag
10020ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag
cgcacgaggg 10080agcttccagg gggaaacgcc tggtatcttt atagtcctgt
cgggtttcgc cacctctgac 10140ttgagcgtcg atttttgtga tgctcgtcag
gggggcggag cctatggaaa aacgccagca 10200acgcggcctt tttacggttc
ctggcctttt gctggccttt tgctcacatg ttctttcctg 10260cgttatcccc
tgattctgtg gataaccgta ttaccgcctt tgagtgagct gataccgctc
10320gccgcagccg aacgaccgag cgcagcgagt cagtgagcga ggaagcggaa
gagcgcccaa 10380tacgcaaacc gcctctcccc gcgcgttggc cgattcatta
atgcagcaag ctcatggctg 10440actaattttt tttatttatg cagaggccga
ggccgcctcg gcctctgagc tattccagaa 10500gtagtgagga ggcttttttg
gaggcctagg cttttgcaaa aagctccccg tggcacgaca 10560ggtttcccga
ctggaaagcg ggcagtgagc gcaacgcaat taatgtgagt tagctcactc
10620attaggcacc ccaggcttta cactttatgc ttccggctcg tatgttgtgt
ggaattgtga 10680gcggataaca atttcacaca ggaaacagct atgacatgat
tacgaatttc acaaataaag 10740catttttttc actgcattct agttgtggtt
tgtccaaact catcaatgta tcttatcatg 10800tctggatcaa ctggataact
caagctaacc aaaatcatcc caaacttccc accccatacc 10860ctattaccac
tgccaattac ctgtggtttc atttactcta aacctgtgat tcctctgaat
10920tattttcatt ttaaagaaat tgtatttgtt aaatatgtac tacaaactta gtagt
10975210748DNAArtificial sequencepInducer-cMyogenin 2tggaagggct
aattcactcc caaagaagac aagatatcct tgatctgtgg atctaccaca 60cacaaggcta
cttccctgat tagcagaact acacaccagg gccaggggtc agatatccac
120tgacctttgg atggtgctac aagctagtac cagttgagcc agataaggta
gaagaggcca 180ataaaggaga gaacaccagc ttgttacacc ctgtgagcct
gcatgggatg gatgacccgg 240agagagaagt gttagagtgg aggtttgaca
gccgcctagc atttcatcac gtggcccgag 300agctgcatcc ggagtacttc
aagaactgct gatatcgagc ttgctacaag ggactttccg 360ctggggactt
tccagggagg cgtggcctgg gcgggactgg ggagtggcga gccctcagat
420cctgcatata agcagctgct ttttgcctgt actgggtctc tctggttaga
ccagatctga 480gcctgggagc tctctggcta actagggaac ccactgctta
agcctcaata aagcttgcct 540tgagtgcttc aagtagtgtg tgcccgtctg
ttgtgtgact ctggtaacta gagatccctc 600agaccctttt agtcagtgtg
gaaaatctct agcagtggcg cccgaacagg gacttgaaag 660cgaaagggaa
accagaggag ctctctcgac gcaggactcg gcttgctgaa gcgcgcacgg
720caagaggcga ggggcggcga ctggtgagta cgccaaaaat tttgactagc
ggaggctaga 780aggagagaga tgggtgcgag agcgtcagta ttaagcgggg
gagaattaga tcgcgatggg 840aaaaaattcg gttaaggcca gggggaaaga
aaaaatataa attaaaacat atagtatggg 900caagcaggga gctagaacga
ttcgcagtta atcctggcct gttagaaaca tcagaaggct 960gtagacaaat
actgggacag ctacaaccat cccttcagac aggatcagaa gaacttagat
1020cattatataa tacagtagca accctctatt gtgtgcatca aaggatagag
ataaaagaca 1080ccaaggaagc tttagacaag atagaggaag agcaaaacaa
aagtaagacc accgcacagc 1140aagcggccgg ccgctgatct tcagacctgg
aggaggagat atgagggaca attggagaag 1200tgaattatat aaatataaag
tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc 1260aaagagaaga
gtggtgcaga gagaaaaaag agcagtggga ataggagctt tgttccttgg
1320gttcttggga gcagcaggaa gcactatggg cgcagcgtca atgacgctga
cggtacaggc 1380cagacaatta ttgtctggta tagtgcagca gcagaacaat
ttgctgaggg ctattgaggc 1440gcaacagcat ctgttgcaac tcacagtctg
gggcatcaag cagctccagg caagaatcct 1500ggctgtggaa agatacctaa
aggatcaaca gctcctgggg atttggggtt gctctggaaa 1560actcatttgc
accactgctg tgccttggaa tgctagttgg agtaataaat ctctggaaca
1620gatttggaat cacacgacct ggatggagtg ggacagagaa attaacaatt
acacaagctt 1680aatacactcc ttaattgaag aatcgcaaaa ccagcaagaa
aagaatgaac aagaattatt 1740ggaattagat aaatgggcaa gtttgtggaa
ttggtttaac ataacaaatt ggctgtggta 1800tataaaatta ttcataatga
tagtaggagg cttggtaggt ttaagaatag tttttgctgt 1860actttctata
gtgaatagag ttaggcaggg atattcacca ttatcgtttc agacccacct
1920cccaaccccg aggggacccg acaggcccga aggaatagaa gaagaaggtg
gagagagaga 1980cagagacaga tccattcgat tagtgaacgg atctcgacgg
tatcgccgaa ttcacaaatg 2040gcagtattca tccacaattt taaaagaaaa
ggggggattg gggggtacag tgcaggggaa 2100agaatagtag acataatagc
aacagacata caaactaaag aattacaaaa acaaattaca 2160aaaattcaaa
attttcgggt ttattacagg gacagcagag atccagtttg gactaggatc
2220ctttaccact ccctatcagt gatagagaaa agtgaaagtc gagtttacca
ctccctatca 2280gtgatagaga aaagtgaaag tcgagtttac cactccctat
cagtgataga gaaaagtgaa 2340agtcgagttt accactccct atcagtgata
gagaaaagtg aaagtcgagt ttaccactcc 2400ctatcagtga tagagaaaag
tgaaagtcga gtttaccact ccctatcagt gatagagaaa 2460agtgaaagtc
gagtttacca ctccctatca gtgatagaga aaagtgaaag tcgagctcgg
2520tacccgggtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc
tcgtttagtg 2580aaccgtcaga tcgcctggag acgccatcca cgctgttttg
acctccatag aagacaccgg 2640gaccgatcca gcctccgcgg ccccgaacta
gtccagtgtg gtgggtcgag gctagcatgg 2700agctctttga gaccaaccct
tactttttcc cggagcagag gttttacgat ggggaaaact 2760tcctgggctc
ccgcttgcag ggctacgagg cggccgcgtt tcctgagcgt cccgaggtga
2820ccctgtgccc tgaaagcaga ggggctttgg aggagaagga ctcgacgctg
cccgagcact 2880gccccgggca atgcttgcca tgggcttgca aaatctgcaa
gcgcaaaacc gtgtccatcg 2940accggcgtcg ggcggccacg ctgcgggaga
agcggaggct gaagaaggtg aacgaagcct 3000tcgaggctct gaaacgcagc
actctgctca accccaacca gcggctgccc aaggtggaga 3060tcctgcgcag
cgccatccag tacatcgagc gcctgcagag cctgctcagc agcctcaacc
3120agcaggagcg tgagcagagg gagctgcgct accgccccgc tgcaccacaa
cctgctgcac 3180ccagcgagtg cggctctggc agctcatcct gcagccctga
gtggagcacc cagctggagt 3240ttggcaccaa ccccgcagat cacctcctga
gcgatgacca ggcagaggac cgcaacctcc 3300actcgctctc ctccatcgtg
gagagcatcg ccgtggagga cgtggccgtg acgttcccag 3360aggagcgggt
ccaaaactga gtcgagtcta gagggcccgc ggttcgaata cccatacgac
3420gtcccagact acgcttagta atgattaatt aaactagaaa ttctaccggg
taggggaggc 3480gcttttccca aggcagtctg gagtaaccca cccaagatct
ggcctccgcg ccgggttttg 3540gcgcctcccg cgggcgcccc cctcctcacg
gcgagcgctg ccacgtcaga cgaagggcgc 3600agcgagcgtc ctgatccttc
cgcccggacg ctcaggacag cggcccgctg ctcataagac 3660tcggccttag
aaccccagta tcagcagaag gacattttag gacgggactt gggtgactct
3720agggcactgg ttttctttcc agagagcgga acaggcgagg aaaagtagtc
ccttctcggc 3780gattctgcgg agggatctcc gtggggcggt gaacgccgat
gattatataa ggacgcgccg 3840ggtgtggcac agctagttcc gtcgcagccg
ggatttgggt cgcggttctt gtttgtggat 3900cgctgtgatc gtcacttggt
gagtagcggg ctgctgggct ggccggggct ttcgtggccg 3960ccgggccgct
cggtgggacg gaagcgtgtg gagagaccgc
caagggctgt agtctgggtc 4020cgcgagcaag gttgccctga actgggggtt
ggggggagcg cagcaaaatg gcggctgttc 4080ccgagtcttg aatggaagac
gcttgtgagg cgggctgtga ggtcgttgaa acaaggtggg 4140gggcatggtg
ggcggcaaga acccaaggtc ttgaggcctt cgctaatgcg ggaaagctct
4200tattcgggtg agatgggctg gggcaccatc tggggaccct gacgtgaagt
ttgtcactga 4260ctggagaact cggtttgtcg tctgttgcgg gggcggcagt
tatggcggtg ccgttgggca 4320gtgcacccgt acctttggga gcgcgcgccc
tcgtcgtgtc gtgacgtcac ccgttctgtt 4380ggcttataat gcagggtggg
gccacctgcc ggtaggtgtg cggtaggctt ttctccgtcg 4440caggacgcag
ggttcgggcc tagggtaggc tctcctgaat cgacaggcgc cggacctctg
4500gtgaggggag ggataagtga ggcgtcagtt tctttggtcg gttttatgta
cctatcttct 4560taagtagctg aagctccggt tttgaactat gcgctcgggg
ttggcgagtg tgttttgtga 4620agttttttag gcaccttttg aaatgtaatc
atttgggtca atatgtaatt ttcagtgtta 4680gactagtaaa ttgtccgcta
aattctggcc gtttttggct tttttgttag acgaagcttg 4740gtaccgagct
cggatctcca ccccgtaccg gtcctgcagt cgaattcacc atgtctagac
4800tggacaagag caaagtcata aacggagctc tggaattact caatggtgtc
ggtatcgaag 4860gcctgacgac aaggaaactc gctcaaaagc tgggagttga
gcagcctacc ctgtactggc 4920acgtgaagaa caagcgggcc ctgctcgatg
ccctgccaat cgagatgctg gacaggcatc 4980atacccactt ctgccccctg
gaaggcgagt catggcaaga ctttctgcgg aacaacgcca 5040agtcataccg
ctgtgctctc ctctcacatc gcgacggggc taaagtgcat ctcggcaccc
5100gcccaacaga gaaacagtac gaaaccctgg aaaatcagct cgcgttcctg
tgtcagcaag 5160gcttctccct ggagaacgca ctgtacgctc tgtccgccgt
gggccacttt acactgggct 5220gcgtattgga ggaacaggag catcaagtag
caaaagagga aagagagaca cctaccaccg 5280attctatgcc cccacttctg
agacaagcaa ttgagctgtt cgaccggcag ggagccgaac 5340ctgccttcct
tttcggcctg gaactaatca tatgtggcct ggagaaacag ctaaagtgcg
5400aaagcggcgg gccgaccgac gcccttgacg attttgactt agacatgctc
ccagccgatg 5460cccttgacga ctttgacctt gatatgctgc ctgctgacgc
tcttgacgat tttgaccttg 5520acatgctccc cgggtaacta agtaaggatc
cgcggccgca ctagaggaat tccgcccctc 5580tccctccccc ccccctaacg
ttactggccg aagccgcttg gaataaggcc ggtgtgtgtt 5640tgtctatatg
ttattttcca ccatattgcc gtcttttggc aatgtgaggg cccggaaacc
5700tggccctgtc ttcttgacga gcattcctag gggtctttcc cctctcgcca
aaggaatgca 5760aggtctgttg aatgtcgtga aggaagcagt tcctctggaa
gcttcttgaa gacaaacaac 5820gtctgtagcg accctttgca ggcagcggaa
ccccccacct ggcgacaggt gcctctgcgg 5880ccaaaagcca cgtgtataag
atacacctgc aaaggcggca caaccccagt gccacgttgt 5940gagttggata
gttgtggaaa gagtcaaatg gctctcctca agcgtagtca acaaggggct
6000gaaggatgcc cagaaggtac cccattgtat gggaatctga tctggggcct
cggtgcacat 6060gctttacatg tgtttagtcg aggttaaaaa aacgtctagg
ccccccgaac cacggggacg 6120tggttttcct ttgaaaaaca cgatgataag
cttaccggtc caccatgatt gaacaagatg 6180gattgcacgc aggttctccg
gccgcttggg tggagaggct attcggctat gactgggcac 6240aacagacaat
cggctgctct gatgccgccg tgttccggct gtcagcgcag gggcgcccgg
6300ttctttttgt caagaccgac ctgtccggtg ccctgaatga actgcaagac
gaggcagcgc 6360ggctatcgtg gctggccacg acgggcgttc cttgcgcagc
tgtgctcgac gttgtcactg 6420aagcgggaag ggactggctg ctattgggcg
aagtgccggg gcaggatctc ctgtcatctc 6480accttgctcc tgccgagaaa
gtatccatca tggctgatgc aatgcggcgg ctgcatacgc 6540ttgatccggc
tacctgccca ttcgaccacc aagcgaaaca tcgcatcgag cgagcacgta
6600ctcggatgga agccggtctt gtcgatcagg atgatctgga cgaagagcat
caggggctcg 6660cgccagccga actgttcgcc aggctcaagg cgagcatgcc
cgacggcgag gatctcgtcg 6720tgacccatgg cgatgcctgc ttgccgaata
tcatggtgga aaatggccgc ttttctggat 6780tcatcgactg tggccggctg
ggtgtggcgg accgctatca ggacatagcg ttggctaccc 6840gtgatattgc
tgaagagctt ggcggcgaat gggctgaccg cttcctcgtg ctttacggta
6900tcgccgctcc cgattcgcag cgcatcgcct tctatcgcct tcttgacgag
ttcttctgat 6960gtacaagtaa agcggccgcg actctagatc ataatcagcc
ataccacatt tgtagaggtt 7020ttacttgctt taaaaaacct cccacacctc
cccctgaacc tgaaacataa aatgaatgca 7080attgttgttg tttagtccct
cccaattcga tatcaagctt atcgatcgat agatcctaat 7140caacctctgg
attacaaaat ttgtgaaaga ttgactggta ttcttaacta tgttgctcct
7200tttacgctat gtggatacgc tgctttaatg cctttgtatc atgctattgc
ttcccgtatg 7260gctttcattt tctcctcctt gtataaatcc tggttgctgt
ctctttatga ggagttgtgg 7320cccgttgtca ggcaacgtgg cgtggtgtgc
actgtgtttg ctgacgcaac ccccactggt 7380tggggcattg ccaccacctg
tcagctcctt tccgggactt tcgctttccc cctccctatt 7440gccacggcgg
aactcatcgc cgcctgcctt gcccgctgct ggacaggggc tcggctgttg
7500ggcactgaca attccgtggt gttgtcgggg aaatcatcgt cctttccttg
gctgctcgcc 7560tgtgttgcca cctggattct gcgcgggacg tccttctgct
acgtcccttc ggccctcaat 7620ccagcggacc ttccttcccg cggcctgctg
ccggctctgc ggcctcttcc gcgtcttcgc 7680cttcgccctc agacgagtcg
gatctccctt tgggccgcct ccccgcctga gatcctttaa 7740gaccaatgac
ttacaaggca gctgtagatc ttagccactt tttaaaagaa aaggggggac
7800tggaagggct aattcactcc caacgaagac aagatctgct ttttgcttgt
actgggtctc 7860tctggttaga ccagatctga gcctgggagc tctctggcta
actagggaac ccactgctta 7920agcctcaata aagcttgcct tgagtgcttc
aagtagtgtg tgcccgtctg ttgtgtgact 7980ctggtaacta gagatccctc
agaccctttt agtcagtgtg gaaaatctct agcagtagta 8040gttcatgtca
tcttattatt cagtatttat aacttgcaaa gaaatgaata tcagagagtg
8100agaggcccgg gttaattaag gaaagggcta gatcattctt gaagacgaaa
gggcctcgtg 8160atacgcctat ttttataggt taatgtcatg ataataatgg
tttcttagac gtcaggtggc 8220acttttcggg gaaatgtgcg cggaacccct
atttgtttat ttttctaaat acattcaaat 8280atgtatccgc tcatgagaca
ataaccctga taaatgcttc aataatattg aaaaaggaag 8340agtatgagta
ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt
8400cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga
tcagttgggt 8460gcacgagtgg gttacatcga actggatctc aacagcggta
agatccttga gagttttcgc 8520cccgaagaac gttttccaat gatgagcact
tttaaagttc tgctatgtgg cgcggtatta 8580tcccgtgttg acgccgggca
agagcaactc ggtcgccgca tacactattc tcagaatgac 8640ttggttgagt
actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa
8700ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact
tctgacaacg 8760atcggaggac cgaaggagct aaccgctttt ttgcacaaca
tgggggatca tgtaactcgc 8820cttgatcgtt gggaaccgga gctgaatgaa
gccataccaa acgacgagcg tgacaccacg 8880atgcctgtag caatggcaac
aacgttgcgc aaactattaa ctggcgaact acttactcta 8940gcttcccggc
aacaattaat agactggatg gaggcggata aagttgcagg accacttctg
9000cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg
tgagcgtggg 9060tctcgcggta tcattgcagc actggggcca gatggtaagc
cctcccgtat cgtagttatc 9120tacacgacgg ggagtcaggc aactatggat
gaacgaaata gacagatcgc tgagataggt 9180gcctcactga ttaagcattg
gtaactgtca gaccaagttt actcatatat actttagatt 9240gatttaaaac
ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc
9300atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc
cgtagaaaag 9360atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa
tctgctgctt gcaaacaaaa 9420aaaccaccgc taccagcggt ggtttgtttg
ccggatcaag agctaccaac tctttttccg 9480aaggtaactg gcttcagcag
agcgcagata ccaaatactg ttcttctagt gtagccgtag 9540ttaggccacc
acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg
9600ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga
ctcaagacga 9660tagttaccgg ataaggcgca gcggtcgggc tgaacggggg
gttcgtgcac acagcccagc 9720ttggagcgaa cgacctacac cgaactgaga
tacctacagc gtgagctatg agaaagcgcc 9780acgcttcccg aagggagaaa
ggcggacagg tatccggtaa gcggcagggt cggaacagga 9840gagcgcacga
gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt
9900cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg
gagcctatgg 9960aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct
tttgctggcc ttttgctcac 10020atgttctttc ctgcgttatc ccctgattct
gtggataacc gtattaccgc ctttgagtga 10080gctgataccg ctcgccgcag
ccgaacgacc gagcgcagcg agtcagtgag cgaggaagcg 10140gaagagcgcc
caatacgcaa accgcctctc cccgcgcgtt ggccgattca ttaatgcagc
10200aagctcatgg ctgactaatt ttttttattt atgcagaggc cgaggccgcc
tcggcctctg 10260agctattcca gaagtagtga ggaggctttt ttggaggcct
aggcttttgc aaaaagctcc 10320ccgtggcacg acaggtttcc cgactggaaa
gcgggcagtg agcgcaacgc aattaatgtg 10380agttagctca ctcattaggc
accccaggct ttacacttta tgcttccggc tcgtatgttg 10440tgtggaattg
tgagcggata acaatttcac acaggaaaca gctatgacat gattacgaat
10500ttcacaaata aagcattttt ttcactgcat tctagttgtg gtttgtccaa
actcatcaat 10560gtatcttatc atgtctggat caactggata actcaagcta
accaaaatca tcccaaactt 10620cccaccccat accctattac cactgccaat
tacctgtggt ttcatttact ctaaacctgt 10680gattcctctg aattattttc
attttaaaga aattgtattt gttaaatatg tactacaaac 10740ttagtagt
10748311244DNAArtificial sequencepInducer-VP64-cMyoD1 3tggaagggct
aattcactcc caaagaagac aagatatcct tgatctgtgg atctaccaca 60cacaaggcta
cttccctgat tagcagaact acacaccagg gccaggggtc agatatccac
120tgacctttgg atggtgctac aagctagtac cagttgagcc agataaggta
gaagaggcca 180ataaaggaga gaacaccagc ttgttacacc ctgtgagcct
gcatgggatg gatgacccgg 240agagagaagt gttagagtgg aggtttgaca
gccgcctagc atttcatcac gtggcccgag 300agctgcatcc ggagtacttc
aagaactgct gatatcgagc ttgctacaag ggactttccg 360ctggggactt
tccagggagg cgtggcctgg gcgggactgg ggagtggcga gccctcagat
420cctgcatata agcagctgct ttttgcctgt actgggtctc tctggttaga
ccagatctga 480gcctgggagc tctctggcta actagggaac ccactgctta
agcctcaata aagcttgcct 540tgagtgcttc aagtagtgtg tgcccgtctg
ttgtgtgact ctggtaacta gagatccctc 600agaccctttt agtcagtgtg
gaaaatctct agcagtggcg cccgaacagg gacttgaaag 660cgaaagggaa
accagaggag ctctctcgac gcaggactcg gcttgctgaa gcgcgcacgg
720caagaggcga ggggcggcga ctggtgagta cgccaaaaat tttgactagc
ggaggctaga 780aggagagaga tgggtgcgag agcgtcagta ttaagcgggg
gagaattaga tcgcgatggg 840aaaaaattcg gttaaggcca gggggaaaga
aaaaatataa attaaaacat atagtatggg 900caagcaggga gctagaacga
ttcgcagtta atcctggcct gttagaaaca tcagaaggct 960gtagacaaat
actgggacag ctacaaccat cccttcagac aggatcagaa gaacttagat
1020cattatataa tacagtagca accctctatt gtgtgcatca aaggatagag
ataaaagaca 1080ccaaggaagc tttagacaag atagaggaag agcaaaacaa
aagtaagacc accgcacagc 1140aagcggccgg ccgctgatct tcagacctgg
aggaggagat atgagggaca attggagaag 1200tgaattatat aaatataaag
tagtaaaaat tgaaccatta ggagtagcac ccaccaaggc 1260aaagagaaga
gtggtgcaga gagaaaaaag agcagtggga ataggagctt tgttccttgg
1320gttcttggga gcagcaggaa gcactatggg cgcagcgtca atgacgctga
cggtacaggc 1380cagacaatta ttgtctggta tagtgcagca gcagaacaat
ttgctgaggg ctattgaggc 1440gcaacagcat ctgttgcaac tcacagtctg
gggcatcaag cagctccagg caagaatcct 1500ggctgtggaa agatacctaa
aggatcaaca gctcctgggg atttggggtt gctctggaaa 1560actcatttgc
accactgctg tgccttggaa tgctagttgg agtaataaat ctctggaaca
1620gatttggaat cacacgacct ggatggagtg ggacagagaa attaacaatt
acacaagctt 1680aatacactcc ttaattgaag aatcgcaaaa ccagcaagaa
aagaatgaac aagaattatt 1740ggaattagat aaatgggcaa gtttgtggaa
ttggtttaac ataacaaatt ggctgtggta 1800tataaaatta ttcataatga
tagtaggagg cttggtaggt ttaagaatag tttttgctgt 1860actttctata
gtgaatagag ttaggcaggg atattcacca ttatcgtttc agacccacct
1920cccaaccccg aggggacccg acaggcccga aggaatagaa gaagaaggtg
gagagagaga 1980cagagacaga tccattcgat tagtgaacgg atctcgacgg
tatcgccgaa ttcacaaatg 2040gcagtattca tccacaattt taaaagaaaa
ggggggattg gggggtacag tgcaggggaa 2100agaatagtag acataatagc
aacagacata caaactaaag aattacaaaa acaaattaca 2160aaaattcaaa
attttcgggt ttattacagg gacagcagag atccagtttg gactaggatc
2220ctttaccact ccctatcagt gatagagaaa agtgaaagtc gagtttacca
ctccctatca 2280gtgatagaga aaagtgaaag tcgagtttac cactccctat
cagtgataga gaaaagtgaa 2340agtcgagttt accactccct atcagtgata
gagaaaagtg aaagtcgagt ttaccactcc 2400ctatcagtga tagagaaaag
tgaaagtcga gtttaccact ccctatcagt gatagagaaa 2460agtgaaagtc
gagtttacca ctccctatca gtgatagaga aaagtgaaag tcgagctcgg
2520tacccgggtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc
tcgtttagtg 2580aaccgtcaga tcgcctggag acgccatcca cgctgttttg
acctccatag aagacaccgg 2640gaccgatcca gcctccgcgg ccccgaacta
gtccagtgtg gtgggtcgag actagcgcta 2700gctgaaaacg tctgggcaag
cgggtcaggc atccccgaag aagaaaagga aggtcgggag 2760agcggacgcg
ctcgatgact tcgatttgga catgctcggc tccgatgctc tggatgactt
2820tgatctggac atgctcggtt cagatgcgct ggatgatttt gatttggata
tgctcggaag 2880cgacgcactc gacgattttg accttgacat gctcatcaat
tatccgtatg atgttcccga 2940ttatgcgtct gggggaagtg gtggggggtc
catggacctt ttgggaccga tggaaatgac 3000tgagggttct ctctgttctt
ttaccgctgc ggatgatttc tatgatgacc cctgtttcaa 3060cacgagcgat
atgcactttt tcgaagatct ggaccccagg ctcgtccacg ttggcggtct
3120tctgaaagcc gaagaacatc ctcatcatca tgggcaccat catggtaatc
ctcatgagga 3180ggagcatgta agggccccca gcggtcatca tcaggccggt
aggtgcctgc tttgggcgtg 3240caaggcttgc aaaaggaaaa caactaatgc
tgaccggcgg aaagcagcca cgatgcgcga 3300acgccgcagg ttgtctaaag
tcaacgaagc attcgagacg cttaagcggt gtacaagtac 3360taatccaaac
cagaggctcc ccaaagttga aatccttcgg aatgcaattc ggtatatcga
3420aagcctgcaa gcgctgctcc gggaacaaga agacgcatat taccccgtcc
tcgaacacta 3480ctctggagaa agtgacgcct ccagcccacg cagtaactgc
tccgacggga tgatggaata 3540ttctggacca ccgtgctcta gccggcgcag
aaattcatac gactcctctt actacacaga 3600gagcccgaat gatccgaagc
acgggaagtc tagcgtggtc tcttcactgg attgtctcag 3660tagcattgtc
gagcgcatca gtactgacaa ctccacctgc ccgatattgc cgcccgccga
3720agctgttgct gagggcagtc catgtagccc ccaggagggg ggaaatcttt
ctgactccgg 3780ggctcaaatt ccatccccga ccaactgtac cccactgccg
caggaatcta gctccagtag 3840ttcaagcaac ccgatatatc aagttcttta
gtcgacgtcg agtctagagg gcccgcggtt 3900cgaataccca tacgacgtcc
cagactacgc ttagtaatga ttaattaaac tagaaattct 3960accgggtagg
ggaggcgctt ttcccaaggc agtctggagt aacccaccca agatctggcc
4020tccgcgccgg gttttggcgc ctcccgcggg cgcccccctc ctcacggcga
gcgctgccac 4080gtcagacgaa gggcgcagcg agcgtcctga tccttccgcc
cggacgctca ggacagcggc 4140ccgctgctca taagactcgg ccttagaacc
ccagtatcag cagaaggaca ttttaggacg 4200ggacttgggt gactctaggg
cactggtttt ctttccagag agcggaacag gcgaggaaaa 4260gtagtccctt
ctcggcgatt ctgcggaggg atctccgtgg ggcggtgaac gccgatgatt
4320atataaggac gcgccgggtg tggcacagct agttccgtcg cagccgggat
ttgggtcgcg 4380gttcttgttt gtggatcgct gtgatcgtca cttggtgagt
agcgggctgc tgggctggcc 4440ggggctttcg tggccgccgg gccgctcggt
gggacggaag cgtgtggaga gaccgccaag 4500ggctgtagtc tgggtccgcg
agcaaggttg ccctgaactg ggggttgggg ggagcgcagc 4560aaaatggcgg
ctgttcccga gtcttgaatg gaagacgctt gtgaggcggg ctgtgaggtc
4620gttgaaacaa ggtggggggc atggtgggcg gcaagaaccc aaggtcttga
ggccttcgct 4680aatgcgggaa agctcttatt cgggtgagat gggctggggc
accatctggg gaccctgacg 4740tgaagtttgt cactgactgg agaactcggt
ttgtcgtctg ttgcgggggc ggcagttatg 4800gcggtgccgt tgggcagtgc
acccgtacct ttgggagcgc gcgccctcgt cgtgtcgtga 4860cgtcacccgt
tctgttggct tataatgcag ggtggggcca cctgccggta ggtgtgcggt
4920aggcttttct ccgtcgcagg acgcagggtt cgggcctagg gtaggctctc
ctgaatcgac 4980aggcgccgga cctctggtga ggggagggat aagtgaggcg
tcagtttctt tggtcggttt 5040tatgtaccta tcttcttaag tagctgaagc
tccggttttg aactatgcgc tcggggttgg 5100cgagtgtgtt ttgtgaagtt
ttttaggcac cttttgaaat gtaatcattt gggtcaatat 5160gtaattttca
gtgttagact agtaaattgt ccgctaaatt ctggccgttt ttggcttttt
5220tgttagacga agcttggtac cgagctcgga tctccacccc gtaccggtcc
tgcagtcgaa 5280ttcaccatgt ctagactgga caagagcaaa gtcataaacg
gagctctgga attactcaat 5340ggtgtcggta tcgaaggcct gacgacaagg
aaactcgctc aaaagctggg agttgagcag 5400cctaccctgt actggcacgt
gaagaacaag cgggccctgc tcgatgccct gccaatcgag 5460atgctggaca
ggcatcatac ccacttctgc cccctggaag gcgagtcatg gcaagacttt
5520ctgcggaaca acgccaagtc ataccgctgt gctctcctct cacatcgcga
cggggctaaa 5580gtgcatctcg gcacccgccc aacagagaaa cagtacgaaa
ccctggaaaa tcagctcgcg 5640ttcctgtgtc agcaaggctt ctccctggag
aacgcactgt acgctctgtc cgccgtgggc 5700cactttacac tgggctgcgt
attggaggaa caggagcatc aagtagcaaa agaggaaaga 5760gagacaccta
ccaccgattc tatgccccca cttctgagac aagcaattga gctgttcgac
5820cggcagggag ccgaacctgc cttccttttc ggcctggaac taatcatatg
tggcctggag 5880aaacagctaa agtgcgaaag cggcgggccg accgacgccc
ttgacgattt tgacttagac 5940atgctcccag ccgatgccct tgacgacttt
gaccttgata tgctgcctgc tgacgctctt 6000gacgattttg accttgacat
gctccccggg taactaagta aggatccgcg gccgcactag 6060aggaattccg
cccctctccc tccccccccc ctaacgttac tggccgaagc cgcttggaat
6120aaggccggtg tgtgtttgtc tatatgttat tttccaccat attgccgtct
tttggcaatg 6180tgagggcccg gaaacctggc cctgtcttct tgacgagcat
tcctaggggt ctttcccctc 6240tcgccaaagg aatgcaaggt ctgttgaatg
tcgtgaagga agcagttcct ctggaagctt 6300cttgaagaca aacaacgtct
gtagcgaccc tttgcaggca gcggaacccc ccacctggcg 6360acaggtgcct
ctgcggccaa aagccacgtg tataagatac acctgcaaag gcggcacaac
6420cccagtgcca cgttgtgagt tggatagttg tggaaagagt caaatggctc
tcctcaagcg 6480tagtcaacaa ggggctgaag gatgcccaga aggtacccca
ttgtatggga atctgatctg 6540gggcctcggt gcacatgctt tacatgtgtt
tagtcgaggt taaaaaaacg tctaggcccc 6600ccgaaccacg gggacgtggt
tttcctttga aaaacacgat gataagctta ccggtccacc 6660atgattgaac
aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc
6720ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt
ccggctgtca 6780gcgcaggggc gcccggttct ttttgtcaag accgacctgt
ccggtgccct gaatgaactg 6840caagacgagg cagcgcggct atcgtggctg
gccacgacgg gcgttccttg cgcagctgtg 6900ctcgacgttg tcactgaagc
gggaagggac tggctgctat tgggcgaagt gccggggcag 6960gatctcctgt
catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg
7020cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc
gaaacatcgc 7080atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg
atcaggatga tctggacgaa 7140gagcatcagg ggctcgcgcc agccgaactg
ttcgccaggc tcaaggcgag catgcccgac 7200ggcgaggatc tcgtcgtgac
ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 7260ggccgctttt
ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac
7320atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc
tgaccgcttc 7380ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca
tcgccttcta tcgccttctt 7440gacgagttct tctgatgtac aagtaaagcg
gccgcgactc tagatcataa tcagccatac 7500cacatttgta gaggttttac
ttgctttaaa aaacctccca cacctccccc tgaacctgaa 7560acataaaatg
aatgcaattg ttgttgttta gtccctccca attcgatatc aagcttatcg
7620atcgatagat cctaatcaac ctctggatta caaaatttgt gaaagattga
ctggtattct 7680taactatgtt gctcctttta cgctatgtgg atacgctgct
ttaatgcctt tgtatcatgc 7740tattgcttcc cgtatggctt tcattttctc
ctccttgtat aaatcctggt tgctgtctct 7800ttatgaggag ttgtggcccg
ttgtcaggca acgtggcgtg gtgtgcactg tgtttgctga 7860cgcaaccccc
actggttggg gcattgccac cacctgtcag ctcctttccg ggactttcgc
7920tttccccctc cctattgcca cggcggaact catcgccgcc tgccttgccc
gctgctggac 7980aggggctcgg ctgttgggca ctgacaattc cgtggtgttg
tcggggaaat catcgtcctt 8040tccttggctg ctcgcctgtg ttgccacctg
gattctgcgc gggacgtcct tctgctacgt 8100cccttcggcc ctcaatccag
cggaccttcc ttcccgcggc ctgctgccgg ctctgcggcc 8160tcttccgcgt
cttcgccttc gccctcagac gagtcggatc
tccctttggg ccgcctcccc 8220gcctgagatc ctttaagacc aatgacttac
aaggcagctg tagatcttag ccacttttta 8280aaagaaaagg ggggactgga
agggctaatt cactcccaac gaagacaaga tctgcttttt 8340gcttgtactg
ggtctctctg gttagaccag atctgagcct gggagctctc tggctaacta
8400gggaacccac tgcttaagcc tcaataaagc ttgccttgag tgcttcaagt
agtgtgtgcc 8460cgtctgttgt gtgactctgg taactagaga tccctcagac
ccttttagtc agtgtggaaa 8520atctctagca gtagtagttc atgtcatctt
attattcagt atttataact tgcaaagaaa 8580tgaatatcag agagtgagag
gcccgggtta attaaggaaa gggctagatc attcttgaag 8640acgaaagggc
ctcgtgatac gcctattttt ataggttaat gtcatgataa taatggtttc
8700ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga acccctattt
gtttattttt 8760ctaaatacat tcaaatatgt atccgctcat gagacaataa
ccctgataaa tgcttcaata 8820atattgaaaa aggaagagta tgagtattca
acatttccgt gtcgccctta ttcccttttt 8880tgcggcattt tgccttcctg
tttttgctca cccagaaacg ctggtgaaag taaaagatgc 8940tgaagatcag
ttgggtgcac gagtgggtta catcgaactg gatctcaaca gcggtaagat
9000ccttgagagt tttcgccccg aagaacgttt tccaatgatg agcactttta
aagttctgct 9060atgtggcgcg gtattatccc gtgttgacgc cgggcaagag
caactcggtc gccgcataca 9120ctattctcag aatgacttgg ttgagtactc
accagtcaca gaaaagcatc ttacggatgg 9180catgacagta agagaattat
gcagtgctgc cataaccatg agtgataaca ctgcggccaa 9240cttacttctg
acaacgatcg gaggaccgaa ggagctaacc gcttttttgc acaacatggg
9300ggatcatgta actcgccttg atcgttggga accggagctg aatgaagcca
taccaaacga 9360cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg
ttgcgcaaac tattaactgg 9420cgaactactt actctagctt cccggcaaca
attaatagac tggatggagg cggataaagt 9480tgcaggacca cttctgcgct
cggcccttcc ggctggctgg tttattgctg ataaatctgg 9540agccggtgag
cgtgggtctc gcggtatcat tgcagcactg gggccagatg gtaagccctc
9600ccgtatcgta gttatctaca cgacggggag tcaggcaact atggatgaac
gaaatagaca 9660gatcgctgag ataggtgcct cactgattaa gcattggtaa
ctgtcagacc aagtttactc 9720atatatactt tagattgatt taaaacttca
tttttaattt aaaaggatct aggtgaagat 9780cctttttgat aatctcatga
ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc 9840agaccccgta
gaaaagatca aaggatcttc ttgagatcct ttttttctgc gcgtaatctg
9900ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt tgtttgccgg
atcaagagct 9960accaactctt tttccgaagg taactggctt cagcagagcg
cagataccaa atactgttct 10020tctagtgtag ccgtagttag gccaccactt
caagaactct gtagcaccgc ctacatacct 10080cgctctgcta atcctgttac
cagtggctgc tgccagtggc gataagtcgt gtcttaccgg 10140gttggactca
agacgatagt taccggataa ggcgcagcgg tcgggctgaa cggggggttc
10200gtgcacacag cccagcttgg agcgaacgac ctacaccgaa ctgagatacc
tacagcgtga 10260gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg
gacaggtatc cggtaagcgg 10320cagggtcgga acaggagagc gcacgaggga
gcttccaggg ggaaacgcct ggtatcttta 10380tagtcctgtc gggtttcgcc
acctctgact tgagcgtcga tttttgtgat gctcgtcagg 10440ggggcggagc
ctatggaaaa acgccagcaa cgcggccttt ttacggttcc tggccttttg
10500ctggcctttt gctcacatgt tctttcctgc gttatcccct gattctgtgg
ataaccgtat 10560taccgccttt gagtgagctg ataccgctcg ccgcagccga
acgaccgagc gcagcgagtc 10620agtgagcgag gaagcggaag agcgcccaat
acgcaaaccg cctctccccg cgcgttggcc 10680gattcattaa tgcagcaagc
tcatggctga ctaatttttt ttatttatgc agaggccgag 10740gccgcctcgg
cctctgagct attccagaag tagtgaggag gcttttttgg aggcctaggc
10800ttttgcaaaa agctccccgt ggcacgacag gtttcccgac tggaaagcgg
gcagtgagcg 10860caacgcaatt aatgtgagtt agctcactca ttaggcaccc
caggctttac actttatgct 10920tccggctcgt atgttgtgtg gaattgtgag
cggataacaa tttcacacag gaaacagcta 10980tgacatgatt acgaatttca
caaataaagc atttttttca ctgcattcta gttgtggttt 11040gtccaaactc
atcaatgtat cttatcatgt ctggatcaac tggataactc aagctaacca
11100aaatcatccc aaacttccca ccccataccc tattaccact gccaattacc
tgtggtttca 11160tttactctaa acctgtgatt cctctgaatt attttcattt
taaagaaatt gtatttgtta 11220aatatgtact acaaacttag tagt
11244411109DNAArtificial sequencerat MLC3 enhancer-promoter in
pGreenfire lentiviral vector 4acgcgtgtag tcttatgcaa tactcttgta
gtcttgcaac atggtaacga tgagttagca 60acatgcctta caaggagaga aaaagcaccg
tgcatgccga ttggtggaag taaggtggta 120cgatcgtgcc ttattaggaa
ggcaacagac gggtctgaca tggattggac gaaccactga 180attgccgcat
tgcagagata ttgtatttaa gtgcctagct cgatacaata aacgggtctc
240tctggttaga ccagatctga gcctgggagc tctctggcta actagggaac
ccactgctta 300agcctcaata aagcttgcct tgagtgcttc aagtagtgtg
tgcccgtctg ttgtgtgact 360ctggtaacta gagatccctc agaccctttt
agtcagtgtg gaaaatctct agcagtggcg 420cccgaacagg gacctgaaag
cgaaagggaa accagagctc tctcgacgca ggactcggct 480tgctgaagcg
cgcacggcaa gaggcgaggg gcggcgactg gtgagtacgc caaaaatttt
540gactagcgga ggctagaagg agagagatgg gtgcgagagc gtcagtatta
agcgggggag 600aattagatcg cgatgggaaa aaattcggtt aaggccaggg
ggaaagaaaa aatataaatt 660aaaacatata gtatgggcaa gcagggagct
agaacgattc gcagttaatc ctggcctgtt 720agaaacatca gaaggctgta
gacaaatact gggacagcta caaccatccc ttcagacagg 780atcagaagaa
cttagatcat tatataatac agtagcaacc ctctattgtg tgcatcaaag
840gatagagata aaagacacca aggaagcttt agacaagata gaggaagagc
aaaacaaaag 900taagaccacc gcacagcaag cggccgctga tcttcagacc
tggaggagga gatatgaggg 960acaattggag aagtgaatta tataaatata
aagtagtaaa aattgaacca ttaggagtag 1020cacccaccaa ggcaaagaga
agagtggtgc agagagaaaa aagagcagtg ggaataggag 1080ctttgttcct
tgggttcttg ggagcagcag gaagcactat gggcgcagcc tcaatgacgc
1140tgacggtaca ggccagacaa ttattgtctg gtatagtgca gcagcagaac
aatttgctga 1200gggctattga ggcgcaacag catctgttgc aactcacagt
ctggggcatc aagcagctcc 1260aggcaagaat cctggctgtg gaaagatacc
taaaggatca acagctcctg gggatttggg 1320gttgctctgg aaaactcatt
tgcaccactg ctgtgccttg gaatgctagt tggagtaata 1380aatctctgga
acagattgga atcacacgac ctggatggag tgggacagag aaattaacaa
1440ttacacaagc ttaatacact ccttaattga agaatcgcaa aaccagcaag
aaaagaatga 1500acaagaatta ttggaattag ataaatgggc aagtttgtgg
aattggttta acataacaaa 1560ttggctgtgg tatataaaat tattcataat
gatagtagga ggcttggtag gtttaagaat 1620agtttttgct gtactttcta
tagtgaatag agttaggcag ggatattcac cattatcgtt 1680tcagacccac
ctcccaaccc cgaggggacc cgacaggccc gaaggaatag aagaagaagg
1740tggagagaga gacagagaca gatccattcg attagtgaac ggatctcgac
ggtatcggtt 1800aacttttaaa agaaaagggg ggattggggg gtacagtgca
ggggaaagaa tagtagacat 1860aatagcaaca gacatacaaa ctaaagaatt
acaaaaacaa attacaaaat tcaaaatttt 1920atcgatgaat tcgctattaa
tcccagagcc cttggaagcc agaggaagat gtatctctga 1980gtttgaggct
accctactct acagaaagag ttccaggaca gacattacac gagaagccct
2040gccccctctc taaaataaaa gtattttcag aagcataaag gtcacagtgt
agagaaaatg 2100actgctacac gtagtcttaa ttatagaggg ctcttttttt
tttttttttg atctgtggtg 2160tacatgtctt tacatttttt tcaagataga
aaagcatgat gtctgtgcgg tataaattgt 2220tcgttttgag ccttgtgtat
aacgctttcc tctcaagatt ttataatagt gctttaactg 2280tccccacggg
ctaacttcag cacactgtca tgggacctaa ccttattaaa ttaccatgtg
2340tgaaccgctc ataactcaag tcgcagcagg tgcaaaaatg gagctgcgca
ggcagaagag 2400tgatcgtcat ttttaaaatc cccaccagct ggcgaagcaa
caggtgccta attcctcatc 2460ttttaaaaat aacttttcaa aagcctgtgc
tgtataagca aatattttca agtttgtttt 2520taaaccatct tcaagttacc
ttcctcacaa aatacattat gtgctgattt ttttgtctca 2580aaatgacatt
tgaagtctaa gcatataaaa atttatttct ttttagaaat gaaattatta
2640tttaactgga gacttaaatt gtgtcttaac tcttgctcct ccccttttcc
ccttttgtcc 2700cttctctccc cactcccctc cccttctctt cacatgctca
tggcgggctc ttctctttcc 2760tactcttctt ctttctctca tccctctccc
ttgtcttgtc ctttcactaa acctttccac 2820atggaaaaaa taaattgtat
cttaaagcta ctagtcataa tgtcaggatg aagggaagcg 2880atagaaaggg
ggaccccaag ccatttttaa acttagatta tactcctgct aatactgctt
2940gcaaaagcct aatctttaat ggcggtttgg gaacctgatc aggttgccac
gtgggtgtat 3000cctaaccagt ccccagagca cgcattgccc tttcaagacc
tcagaacttt accataaggg 3060gcccagcttt ggagactgtt ctttctacac
cagttactat ttcaaacctc aacccagttc 3120catccacgaa gctccattaa
tacccaggct tgctgactag acacttgcaa ggtctgtaat 3180tacgcatcag
aagccagtcg tagatgaatc ccacgttttc cacgagcaaa gcaatgtctt
3240aagcacagtt gcagggaaca tctcagagat gaagaccata aaagtaccga
caggcttcag 3300tctcaccagg gctgttcacg tctggacgct ggattcctaa
aaatagccct agggtacatg 3360tctctctttc tctttgccct aagaaagcta
aagaactcct ccaggaggag tggcaactgc 3420cctgtgaaat ccgatactag
atatgaggtc agtttgccca gaaataaaag gaagccaccg 3480agaggtagga
tccgccacca tgcccgccat gaagatcgag tgccgcatca ccggcaccct
3540gaacggcgtg gagttcgagc tggtgggcgg cggagagggc acccccgagc
agggccgcat 3600gaccaacaag atgaagagca ccaaaggcgc cctgaccttc
agcccctacc tgctgagcca 3660cgtgatgggc tacggcttct accacttcgg
cacctacccc agcggctacg agaacccctt 3720cctgcacgcc atcaacaacg
gcggctacac caacacccgc atcgagaagt acgaggacgg 3780cggcgtgctg
cacgtgagct tcagctaccg ctacgaggcc ggccgcgtga tcggcgactt
3840caaggtggtg ggcaccggct tccccgagga cagcgtgatc ttcaccgaca
agatcatccg 3900cagcaacgcc accgtggagc acctgcaccc catgggcgat
aacgtgctgg tgggcagctt 3960cgcccgcacc ttcagcctgc gcgacggcgg
ctactacagc ttcgtggtgg acagccacat 4020gcacttcaag agcgccatcc
accccagcat cctgcagaac gggggcccca tgttcgcctt 4080ccgccgcgtg
gaggagctgc acagcaacac cgagctgggc atcgtggagt accagcacgc
4140cttcaagacc cccatcgcct tcgccagatc tcgagatatc agccatggct
tcccgccggc 4200ggtggcggcg caggatgatg gcacgctgcc catgtcttgt
gcccaggaga gcgggatgga 4260ccgtcaccct gcagcctgtg cttctgctag
gatcaatgtg accggtgagg gcagaggaag 4320tcttctaaca tgcggtgacg
tggaggagaa tcccggccct tccggtatgg aagacgccaa 4380aaacataaag
aaaggcccgg cgccattcta tccgctagag gatggaaccg ctggagagca
4440actgcataag gctatgaaga gatacgccct ggttcctgga acaattgctt
ttacagatgc 4500acatatcgag gtgaacatca cgtacgcgga atacttcgaa
atgtccgttc ggttggcaga 4560agctatgaaa cgatatgggc tgaatacaaa
tcacagaatc gtcgtatgca gtgaaaactc 4620tcttcaattc tttatgccgg
tgttgggcgc gttatttatc ggagttgcag ttgcgcccgc 4680gaacgacatt
tataatgaac gtgaattgct caacagtatg aacatttcgc agcctaccgt
4740agtgtttgtt tccaaaaagg ggttgcaaaa aattttgaac gtgcaaaaaa
aattaccaat 4800aatccagaaa attattatca tggattctaa aacggattac
cagggatttc agtcgatgta 4860cacgttcgtc acatctcatc tacctcccgg
ttttaatgaa tacgattttg taccagagtc 4920ctttgatcgt gacaaaacaa
ttgcactgat aatgaactcc tctggatcta ctgggttacc 4980taagggtgtg
gcccttccgc atagaactgc ctgcgtcaga ttctcgcatg ccagagatcc
5040tatttttggc aatcaaatca ttccggatac tgcgatttta agtgttgttc
cattccatca 5100cggttttgga atgtttacta cactcggata tttgatatgt
ggatttcgag tcgtcttaat 5160gtatagattt gaagaagagc tgtttttacg
atcccttcag gattacaaaa ttcaaagtgc 5220gttgctagta ccaaccctat
tttcattctt cgccaaaagc actctgattg acaaatacga 5280tttatctaat
ttacacgaaa ttgcttctgg gggcgcacct ctttcgaaag aagtcgggga
5340agcggttgca aaacgcttcc atcttccagg gatacgacaa ggatatgggc
tcactgagac 5400tacatcagct attctgatta cacccgaggg ggatgataaa
ccgggcgcgg tcggtaaagt 5460tgttccattt tttgaagcga aggttgtgga
tctggatacc gggaaaacgc tgggcgttaa 5520tcagagaggc gaattatgtg
tcagaggacc tatgattatg tccggttatg taaacaatcc 5580ggaagcgacc
aacgccttga ttgacaagga tggatggcta cattctggag acatagctta
5640ctgggacgaa gacgaacact tcttcatagt tgaccgcttg aagtctttaa
ttaaatacaa 5700aggataccag gtggcccccg ctgaattgga gtcgatattg
ttacaacacc ccaacatctt 5760cgacgcgggc gtggcaggtc ttcccgacga
tgacgccggt gaacttcccg ccgccgttgt 5820tgttttggag cacggaaaga
cgatgacgga aaaagagatc gtggattacg tcgccagtca 5880agtaacaacc
gcgaaaaagt tgcgcggagg agttgtgttt gtggacgaag taccgaaagg
5940tcttaccgga aaactcgacg caagaaaaat cagagagatc ctcataaagg
ccaagaaggg 6000cggaaagtcc aaattgtaat cgactcgaca atcaacctct
ggattacaaa atttgtgaaa 6060gattgactgg tattcttaac tatgttgctc
cttttacgct atgtggatac gctgctttaa 6120tgcctttgta tcatgctatt
gcttcccgta tggctttcat tttctcctcc ttgtataaat 6180cctggttgct
gtctctttat gaggagttgt ggcccgttgt caggcaacgt ggcgtggtgt
6240gcactgtgtt tgctgacgca acccccactg gttggggcat tgccaccacc
tgtcagctcc 6300tttccgggac tttcgctttc cccctcccta ttgccacggc
ggaactcatc gccgcctgcc 6360ttgcccgctg ctggacaggg gctcggctgt
tgggcactga caattccgtg gtgttgtcgg 6420ggaagctgac gtcctttcca
tggctgctcg cctgtgttgc cacctggatt ctgcgcggga 6480cgtccttctg
ctacgtccct tcggccctca atccagcgga ccttccttcc cgcggcctgc
6540tgccggctct gcggcctctt ccgcatcttc gccttcgccc tcagacgagt
cggatctccc 6600tttgggccgc ctccccgcct ggaattaatt cgagctcggt
accaaggatc tgcgatcgct 6660ccggtgcccg tcagtgggca gagcgcacat
cgcccacagt ccccgagaag ttggggggag 6720gggtcggcaa ttgaacgggt
gcctagagaa ggtggcgcgg ggtaaactgg gaaagtgatg 6780tcgtgtactg
gctccgcctt tttcccgagg gtgggggaga accgtatata agtgcagtag
6840tcgccgtgaa cgttcttttt cgcaacgggt ttgccgccag aacacagctg
aagcttcgag 6900gggctcgcat ctctccttca cgcgcccgcc gccctacctg
aggccgccat ccacgccggt 6960tgagtcgcgt tctgccgcct cccgcctgtg
gtgcctcctg aactgcgtcc gccgtctagg 7020taagtttaaa gctcaggtcg
agaccgggcc tttgtccggc gctcccttgg agcctaccta 7080gactcagccg
gctctccacg ctttgcctga ccctgcttgc tcaactctac gtctttgttt
7140cgttttctgt tctgcgccgt tacagatcca agctgtgacc ggcgcctacg
ctagatgacc 7200gagtacaagc ccacggtgcg cctcgccacc cgcgacgacg
tccccagggc cgtacgcacc 7260ctcgccgccg cgttcgccga ctaccccgcc
acgcgccaca ccgtcgatcc ggaccgccac 7320atcgagcggg tcaccgagct
gcaagaactc ttcctcacgc gcgtcgggct cgacatcggc 7380aaggtgtggg
tcgcggacga cggcgccgcg gtggcggtct ggaccacgcc ggagagcgtc
7440gaagcggggg cggtgttcgc cgagatcggc ccgcgcatgg ccgagttgag
cggttcccgg 7500ctggccgcgc agcaacagat ggaaggcctc ctggcgccgc
accggcccaa ggagcccgcg 7560tggttcctgg ccaccgtcgg cgtctcgccc
gaccaccagg gcaagggtct gggcagcgcc 7620gtcgtgctcc ccggagtgga
ggcggccgag cgcgccgggg tgcccgcctt cctggagacc 7680tccgcgcccc
gcaacctccc cttctacgag cggctcggct tcaccgtcac cgccgacgtc
7740gaggtgcccg aaggaccgcg cacctggtgc atgacccgca agcccggtgc
ctgaggtacc 7800tttaagacca atgacttaca aggcagctgt agatcttagc
cactttttaa aagaaaaggg 7860gggactggaa gggctaattc actcccaacg
aaaataagat ctgctttttg cttgtactgg 7920gtctctctgg ttagaccaga
tctgagcctg ggagctctct ggctaactag ggaacccact 7980gcttaagcct
caataaagct tgccttgagt gcttcaagta gtgtgtgccc gtctgttgtg
8040tgactctggt aactagagat ccctcagacc cttttagtca gtgtggaaaa
tctctagcag 8100tagtagttca tgtcatctta ttattcagta tttataactt
gcaaagaaat gaatatcaga 8160gagtgagagg aacttgttta ttgcagctta
taatggttac aaataaagca atagcatcac 8220aaatttcaca aataaagcat
ttttttcact gcattctagt tgtggtttgt ccaaactcat 8280caatgtatct
tatcatgtct ggctctagct atcccgcccc taactccgcc cagttccgcc
8340cattctccgc cccatggctg actaattttt tttatttatg cagaggccga
ggccgcctcg 8400gcctctgagc tattccagaa gtagtgagga ggcttttttg
gaggcctaga cttttgcaga 8460gacggcccaa attcgtaatc atggtcatag
ctgtttcctg tgtgaaattg ttatccgctc 8520acaattccac acaacatacg
agccggaagc ataaagtgta aagcctgggg tgcctaatga 8580gtgagctaac
tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg
8640tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt
gcgtattggg 8700cgctcttccg cttcctcgct cactgactcg ctgcgctcgg
tcgttcggct gcggcgagcg 8760gtatcagctc actcaaaggc ggtaatacgg
ttatccacag aatcagggga taacgcagga 8820aagaacatgt gagcaaaagg
ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg 8880gcgtttttcc
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag
8940aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg
aagctccctc 9000gtgcgctctc ctgttccgac cctgccgctt accggatacc
tgtccgcctt tctcccttcg 9060ggaagcgtgg cgctttctca tagctcacgc
tgtaggtatc tcagttcggt gtaggtcgtt 9120cgctccaagc tgggctgtgt
gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc 9180ggtaactatc
gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc
9240actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt
cttgaagtgg 9300tggcctaact acggctacac tagaaggaca gtatttggta
tctgcgctct gctgaagcca 9360gttaccttcg gaaaaagagt tggtagctct
tgatccggca aacaaaccac cgctggtagc 9420ggtggttttt ttgtttgcaa
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 9480cctttgatct
tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt
9540ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta
aaaatgaagt 9600tttaaatcaa tctaaagtat atatgagtaa acttggtctg
acagttacca atgcttaatc 9660agtgaggcac ctatctcagc gatctgtcta
tttcgttcat ccatagttgc ctgactcccc 9720gtcgtgtaga taactacgat
acgggagggc ttaccatctg gccccagtgc tgcaatgata 9780ccgcgagacc
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg
9840gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat
taattgttgc 9900cgggaagcta gagtaagtag ttcgccagtt aatagtttgc
gcaacgttgt tgccattgct 9960acaggcatcg tggtgtcacg ctcgtcgttt
ggtatggctt cattcagctc cggttcccaa 10020cgatcaaggc gagttacatg
atcccccatg ttgtgcaaaa aagcggttag ctccttcggt 10080cctccgatcg
ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca
10140ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac
tggtgagtac 10200tcaaccaagt cattctgaga atagtgtatg cggcgaccga
gttgctcttg cccggcgtca 10260atacgggata ataccgcgcc acatagcaga
actttaaaag tgctcatcat tggaaaacgt 10320tcttcggggc gaaaactctc
aaggatctta ccgctgttga gatccagttc gatgtaaccc 10380actcgtgcac
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca
10440aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa
atgttgaata 10500ctcatactct tcctttttca atattattga agcatttatc
agggttattg tctcatgagc 10560ggatacatat ttgaatgtat ttagaaaaat
aaacaaatag gggttccgcg cacatttccc 10620cgaaaagtgc cacctgacgt
ctaagaaacc attattatca tgacattaac ctataaaaat 10680aggcgtatca
cgaggccctt tcgtctcgcg cgtttcggtg atgacggtga aaacctctga
10740cacatgcagc tcccggagac ggtcacagct tgtctgtaag cggatgccgg
gagcagacaa 10800gcccgtcagg gcgcgtcagc gggtgttggc gggtgtcggg
gctggcttaa ctatgcggca 10860tcagagcaga ttgtactgag agtgcaccat
atgcggtgtg aaataccgca cagatgcgta 10920aggagaaaat accgcatcag
gcgccattcg ccattcaggc tgcgcaactg ttgggaaggg 10980cgatcggtgc
gggcctcttc gctattacgc cagctggcga aagggggatg tgctgcaagg
11040cgattaagtt gggtaacgcc agggttttcc cagtcacgac gttgtaaaac
gacggccagt 11100gccaagctg 111095900DNAArtificial sequencechicken
MyoD1 gene 5atggaccttt tgggaccgat ggaaatgact gagggttctc tctgttcttt
taccgctgcg 60gatgatttct atgatgaccc ctgtttcaac acgagcgata tgcacttttt
cgaagatctg 120gaccccaggc tcgtccacgt tggcggtctt ctgaaagccg
aagaacatcc tcatcatcat 180gggcaccatc atggtaatcc tcatgaggag
gagcatgtaa gggcccccag cggtcatcat 240caggccggta ggtgcctgct
ttgggcgtgc aaggcttgca aaaggaaaac aactaatgct 300gaccggcgga
aagcagccac gatgcgcgaa cgccgcaggt tgtctaaagt caacgaagca
360ttcgagacgc ttaagcggtg tacaagtact aatccaaacc agaggctccc
caaagttgaa 420atccttcgga atgcaattcg gtatatcgaa agcctgcaag
cgctgctccg ggaacaagaa 480gacgcatatt accccgtcct cgaacactac
tctggagaaa gtgacgcctc cagcccacgc 540agtaactgct ccgacgggat
gatggaatat tctggaccac cgtgctctag ccggcgcaga 600aattcatacg
actcctctta ctacacagag agcccgaatg atccgaagca cgggaagtct
660agcgtggtct cttcactgga
ttgtctcagt agcattgtcg agcgcatcag tactgacaac 720tccacctgcc
cgatattgcc gcccgccgaa gctgttgctg agggcagtcc atgtagcccc
780caggaggggg gaaatctttc tgactccggg gctcaaattc catccccgac
caactgtacc 840ccactgccgc aggaatctag ctccagtagt tcaagcaacc
cgatatatca agttctttag 9006173DNAArtificial sequenceVP64
transcriptional activator 6tgaaaacgtc tgggcaagcg ggtcaggcat
ccccgaagaa gaaaaggaag gtcgggagag 60cggacgcgct cgatgacttc gatttggaca
tgctcggctc cgatgctctg gatgactttg 120atctggacat gctcggttca
gatgcgctgg atgattttga tttggatatg ctc 1737684DNAArtificial
sequencecMyogenin coding sequence 7atggagctct ttgagaccaa cccttacttt
ttcccggagc agaggtttta cgatggggaa 60aacttcctgg gctcccgctt gcagggctac
gaggcggccg cgtttcctga gcgtcccgag 120gtgaccctgt gccctgaaag
cagaggggct ttggaggaga aggactcgac gctgcccgag 180cactgccccg
ggcaatgctt gccatgggct tgcaaaatct gcaagcgcaa aaccgtgtcc
240atcgaccggc gtcgggcggc cacgctgcgg gagaagcgga ggctgaagaa
ggtgaacgaa 300gccttcgagg ctctgaaacg cagcactctg ctcaacccca
accagcggct gcccaaggtg 360gagatcctgc gcagcgccat ccagtacatc
gagcgcctgc agagcctgct cagcagcctc 420aaccagcagg agcgtgagca
gagggagctg cgctaccgcc ccgctgcacc acaacctgct 480gcacccagcg
agtgcggctc tggcagctca tcctgcagcc ctgagtggag cacccagctg
540gagtttggca ccaaccccgc agatcacctc ctgagcgatg accaggcaga
ggaccgcaac 600ctccactcgc tctcctccat cgtggagagc atcgccgtgg
aggacgtggc cgtgacgttc 660ccagaggagc gggtccaaaa ctga
684839DNAArtificial sequenceminimal CMV promoter sequence
8ggtaggcgtg tacggtggga ggcctatata agcagagct 3992341DNAArtificial
sequencerat myosin light chain-3 promoter-enhancer (rMLC3-GFP)
9gctattaatc ccagagccct tggaagccag aggaagatgt atctctgagt ttgaggctac
60cctactctac agaaagagtt ccaggacaga cattacacga gaagccctgc cccctctcta
120aaataaaagt attttcagaa gcataaaggt cacagtgtag agaaaatgac
tgctacacgt 180agtcttaatt atagagggct cttttttttt tttttttgat
ctgtggtgta catgtcttta 240catttttttc aagatagaaa agcatgatgt
ctgtgcggta taaattgttc gttttgagcc 300ttgtgtataa cgctttcctc
tcaagatttt ataatagtgc tttaactgtc cccacgggct 360aacttcagca
cactgtcatg ggacctaacc ttattaaatt accatgtgtg aaccgctcat
420aactcaagtc gcagcaggtg caaaaatgga gctgcgcagg cagaagagtg
atcgtcattt 480ttaaaatccc caccagctgg cgaagcaaca ggtgcctaat
tcctcatctt ttaaaaataa 540cttttcaaaa gcctgtgctg tataagcaaa
tattttcaag tttgttttta aaccatcttc 600aagttacctt cctcacaaaa
tacattatgt gctgattttt ttgtctcaaa atgacatttg 660aagtctaagc
atataaaaat ttatttcttt ttagaaatga aattattatt taactggaga
720cttaaattgt gtcttaactc ttgctcctcc ccttttcccc ttttgtccct
tctctcccca 780ctcccctccc cttctcttca catgctcatg gcgggctctt
ctctttccta ctcttcttct 840ttctctcatc cctctccctt gtcttgtcct
ttcactaaac ctttccacat ggaaaaaata 900aattgtatct taaagctcat
aatgtcagga tgaagggaag cgatagaaag ggggacccca 960agccattttt
aaacttagat tatactcctg ctaatactgc ttgcaaaagc ctaatcttta
1020atggcggttt gggaacctga tcaggttgcc acgtgggtgt atcctaacca
gtccccagag 1080cacgcattgc cctttcaaga cctcagaact ttaccataag
gggcccagct ttggagactg 1140ttctttctac accagttact atttcaaacc
tcaacccagt tccatccacg aagctccatt 1200aatacccagg cttgctgact
agacacttgc aaggtctgta attacgcatc agaagccagt 1260cgtagatgaa
tcccacgttt tccacgagca aagcaatgtc ttaagcacag ttgcagggaa
1320catctcagag atgaagacca taaaagtacc gacaggcttc agtctcacca
gggctgttca 1380cgtctggacg ctggattcct aaaaatagcc ctagggtaca
tgtctctctt tctctttgcc 1440ctaagaaagc taaagaactc ctccaggagg
agtggcaact gccctgtgaa atccgatact 1500agatatgagg tcagtttgcc
cagaaataaa aggaagccac cgagaggtaa tgaagatcga 1560gtgccgcatc
accggcaccc tgaacggcgt ggagttcgag ctggtgggcg gcggagaggg
1620cacccccgag cagggccgca tgaccaacaa gatgaagagc accaaaggcg
ccctgacctt 1680cagcccctac ctgctgagcc acgtgatggg ctacggcttc
taccacttcg gcacctaccc 1740cagcggctac gagaacccct tcctgcacgc
catcaacaac ggcggctaca ccaacacccg 1800catcgagaag tacgaggacg
gcggcgtgct gcacgtgagc ttcagctacc gctacgaggc 1860cggccgcgtg
atcggcgact tcaaggtggt gggcaccggc ttccccgagg acagcgtgat
1920cttcaccgac aagatcatcc gcagcaacgc caccgtggag cacctgcacc
ccatgggcga 1980taacgtgctg gtgggcagct tcgcccgcac cttcagcctg
cgcgacggcg gctactacag 2040cttcgtggtg gacagccaca tgcacttcaa
gagcgccatc caccccagca tcctgcagaa 2100cgggggcccc atgttcgcct
tccgccgcgt ggaggagctg cacagcaaca ccgagctggg 2160catcgtggag
taccagcacg ccttcaagac ccccatcgcc ttcgccagat ctcgagatat
2220cagccatggc ttcccgccgg cggtggcggc gcaggatgat ggcacgctgc
ccatgtcttg 2280tgcccaggag agcgggatgg accgtcaccc tgcagcctgt
gcttctgcta ggatcaatgt 2340g 234110917DNAArtificial sequencerat MLC3
enhancer 10gctattaatc ccagagccct tggaagccag aggaagatgt atctctgagt
ttgaggctac 60cctactctac agaaagagtt ccaggacaga cattacacga gaagccctgc
cccctctcta 120aaataaaagt attttcagaa gcataaaggt cacagtgtag
agaaaatgac tgctacacgt 180agtcttaatt atagagggct cttttttttt
tttttttgat ctgtggtgta catgtcttta 240catttttttc aagatagaaa
agcatgatgt ctgtgcggta taaattgttc gttttgagcc 300ttgtgtataa
cgctttcctc tcaagatttt ataatagtgc tttaactgtc cccacgggct
360aacttcagca cactgtcatg ggacctaacc ttattaaatt accatgtgtg
aaccgctcat 420aactcaagtc gcagcaggtg caaaaatgga gctgcgcagg
cagaagagtg atcgtcattt 480ttaaaatccc caccagctgg cgaagcaaca
ggtgcctaat tcctcatctt ttaaaaataa 540cttttcaaaa gcctgtgctg
tataagcaaa tattttcaag tttgttttta aaccatcttc 600aagttacctt
cctcacaaaa tacattatgt gctgattttt ttgtctcaaa atgacatttg
660aagtctaagc atataaaaat ttatttcttt ttagaaatga aattattatt
taactggaga 720cttaaattgt gtcttaactc ttgctcctcc ccttttcccc
ttttgtccct tctctcccca 780ctcccctccc cttctcttca catgctcatg
gcgggctctt ctctttccta ctcttcttct 840ttctctcatc cctctccctt
gtcttgtcct ttcactaaac ctttccacat ggaaaaaata 900aattgtatct taaagct
91711632DNAArtificial sequencerat MLC3 promoter sequence
11cataatgtca ggatgaaggg aagcgataga aagggggacc ccaagccatt tttaaactta
60gattatactc ctgctaatac tgcttgcaaa agcctaatct ttaatggcgg tttgggaacc
120tgatcaggtt gccacgtggg tgtatcctaa ccagtcccca gagcacgcat
tgccctttca 180agacctcaga actttaccat aaggggccca gctttggaga
ctgttctttc tacaccagtt 240actatttcaa acctcaaccc agttccatcc
acgaagctcc attaataccc aggcttgctg 300actagacact tgcaaggtct
gtaattacgc atcagaagcc agtcgtagat gaatcccacg 360ttttccacga
gcaaagcaat gtcttaagca cagttgcagg gaacatctca gagatgaaga
420ccataaaagt accgacaggc ttcagtctca ccagggctgt tcacgtctgg
acgctggatt 480cctaaaaata gccctagggt acatgtctct ctttctcttt
gccctaagaa agctaaagaa 540ctcctccagg aggagtggca actgccctgt
gaaatccgat actagatatg aggtcagttt 600gcccagaaat aaaaggaagc
caccgagagg ta 63212792DNAArtificial sequenceCOP-GFP sequence
12atgaagatcg agtgccgcat caccggcacc ctgaacggcg tggagttcga gctggtgggc
60ggcggagagg gcacccccga gcagggccgc atgaccaaca agatgaagag caccaaaggc
120gccctgacct tcagccccta cctgctgagc cacgtgatgg gctacggctt
ctaccacttc 180ggcacctacc ccagcggcta cgagaacccc ttcctgcacg
ccatcaacaa cggcggctac 240accaacaccc gcatcgagaa gtacgaggac
ggcggcgtgc tgcacgtgag cttcagctac 300cgctacgagg ccggccgcgt
gatcggcgac ttcaaggtgg tgggcaccgg cttccccgag 360gacagcgtga
tcttcaccga caagatcatc cgcagcaacg ccaccgtgga gcacctgcac
420cccatgggcg ataacgtgct ggtgggcagc ttcgcccgca ccttcagcct
gcgcgacggc 480ggctactaca gcttcgtggt ggacagccac atgcacttca
agagcgccat ccaccccagc 540atcctgcaga acgggggccc catgttcgcc
ttccgccgcg tggaggagct gcacagcaac 600accgagctgg gcatcgtgga
gtaccagcac gccttcaaga cccccatcgc cttcgccaga 660tctcgagata
tcagccatgg cttcccgccg gcggtggcgg cgcaggatga tggcacgctg
720cccatgtctt gtgcccagga gagcgggatg gaccgtcacc ctgcagcctg
tgcttctgct 780aggatcaatg tg 79213469DNAhomo sapiens 13agccctccag
gacaggctgc atcagaagag gccatcaagc agatcactgt ccttctgcca 60tggccctgtg
gatgcgcctc ctgcccctgc tggcgctgct ggccctctgg ggacctgacc
120cagccgcagc ctttgtgaac caacacctgt gcggctcaca cctggtggaa
gctctctacc 180tagtgtgcgg ggaacgaggc ttcttctaca cacccaagac
ccgccgggag gcagaggacc 240tgcaggtggg gcaggtggag ctgggcgggg
gccctggtgc aggcagcctg cagcccttgg 300ccctggaggg gtccctgcag
aagcgtggca ttgtggaaca atgctgtacc agcatctgct 360ccctctacca
gctggagaac tactgcaact agacgcagcc cgcaggcagc cccacacccg
420ccgcctcctg caccgagaga gatggaataa agcccttgaa ccagcaaaa
46914110PRThomo sapiens 14Met Ala Leu Trp Met Arg Leu Leu Pro Leu
Leu Ala Leu Leu Ala Leu1 5 10 15Trp Gly Pro Asp Pro Ala Ala Ala Phe
Val Asn Gln His Leu Cys Gly 20 25 30Ser His Leu Val Glu Ala Leu Tyr
Leu Val Cys Gly Glu Arg Gly Phe 35 40 45Phe Tyr Thr Pro Lys Thr Arg
Arg Glu Ala Glu Asp Leu Gln Val Gly 50 55 60Gln Val Glu Leu Gly Gly
Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu65 70 75 80Ala Leu Glu Gly
Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys 85 90 95Thr Ser Ile
Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn 100 105 11015495DNAhomo
sapiens 15agccctccag gacaggctgc atcagaagag gccatcaagc aggtctgttc
caagggcctt 60tgcgtcagat cactgtcctt ctgccatggc cctgtggatg cgcctcctgc
ccctgctggc 120gctgctggcc ctctggggac ctgacccagc cgcagccttt
gtgaaccaac acctgtgcgg 180ctcacacctg gtggaagctc tctacctagt
gtgcggggaa cgaggcttct tctacacacc 240caagacccgc cgggaggcag
aggacctgca ggtggggcag gtggagctgg gcgggggccc 300tggtgcaggc
agcctgcagc ccttggccct ggaggggtcc ctgcagaagc gtggcattgt
360ggaacaatgc tgtaccagca tctgctccct ctaccagctg gagaactact
gcaactagac 420gcagcccgca ggcagcccca cacccgccgc ctcctgcacc
gagagagatg gaataaagcc 480cttgaaccag caaaa 49516110PRThomo sapiens
16Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu1
5 10 15Trp Gly Pro Asp Pro Ala Ala Ala Phe Val Asn Gln His Leu Cys
Gly 20 25 30Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg
Gly Phe 35 40 45Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu
Gln Val Gly 50 55 60Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser
Leu Gln Pro Leu65 70 75 80Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly
Ile Val Glu Gln Cys Cys 85 90 95Thr Ser Ile Cys Ser Leu Tyr Gln Leu
Glu Asn Tyr Cys Asn 100 105 11017648DNAhomo sapiens 17agccctccag
gacaggctgc atcagaagag gccatcaagc aggtctgttc caagggcctt 60tgcgtcaggt
gggctcagga ttccagggtg gctggacccc aggccccagc tctgcagcag
120ggaggacgtg gctgggctcg tgaagcatgt gggggtgagc ccaggggccc
caaggcaggg 180cacctggcct tcagcctgcc tcagccctgc ctgtctccca
gatcactgtc cttctgccat 240ggccctgtgg atgcgcctcc tgcccctgct
ggcgctgctg gccctctggg gacctgaccc 300agccgcagcc tttgtgaacc
aacacctgtg cggctcacac ctggtggaag ctctctacct 360agtgtgcggg
gaacgaggct tcttctacac acccaagacc cgccgggagg cagaggacct
420gcaggtgggg caggtggagc tgggcggggg ccctggtgca ggcagcctgc
agcccttggc 480cctggagggg tccctgcaga agcgtggcat tgtggaacaa
tgctgtacca gcatctgctc 540cctctaccag ctggagaact actgcaacta
gacgcagccc gcaggcagcc ccacacccgc 600cgcctcctgc accgagagag
atggaataaa gcccttgaac cagcaaaa 64818110PRThomo sapiens 18Met Ala
Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu1 5 10 15Trp
Gly Pro Asp Pro Ala Ala Ala Phe Val Asn Gln His Leu Cys Gly 20 25
30Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe
35 40 45Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu Gln Val
Gly 50 55 60Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln
Pro Leu65 70 75 80Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val
Glu Gln Cys Cys 85 90 95Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn
Tyr Cys Asn 100 105 11019529DNAhomo sapiens 19agccctccag gacaggctgc
atcagaagag gccatcaagc aggtctgttc caagggcctt 60tgcgtcaggt gggctcagga
ttccagggtg gctggacccc agatcactgt ccttctgcca 120tggccctgtg
gatgcgcctc ctgcccctgc tggcgctgct ggccctctgg ggacctgacc
180cagccgcagc ctttgtgaac caacacctgt gcggctcaca cctggtggaa
gctctctacc 240tagtgtgcgg ggaacgaggc ttcttctaca cacccaagac
ccgccgggag gcagaggacc 300tgcaggtggg gcaggtggag ctgggcgggg
gccctggtgc aggcagcctg cagcccttgg 360ccctggaggg gtccctgcag
aagcgtggca ttgtggaaca atgctgtacc agcatctgct 420ccctctacca
gctggagaac tactgcaact agacgcagcc cgcaggcagc cccacacccg
480ccgcctcctg caccgagaga gatggaataa agcccttgaa ccagcaaaa
52920110PRThomo sapiens 20Met Ala Leu Trp Met Arg Leu Leu Pro Leu
Leu Ala Leu Leu Ala Leu1 5 10 15Trp Gly Pro Asp Pro Ala Ala Ala Phe
Val Asn Gln His Leu Cys Gly 20 25 30Ser His Leu Val Glu Ala Leu Tyr
Leu Val Cys Gly Glu Arg Gly Phe 35 40 45Phe Tyr Thr Pro Lys Thr Arg
Arg Glu Ala Glu Asp Leu Gln Val Gly 50 55 60Gln Val Glu Leu Gly Gly
Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu65 70 75 80Ala Leu Glu Gly
Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys 85 90 95Thr Ser Ile
Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn 100 105 11021288PRThomo
sapiens 21Met Val Gly Val Gly Gly Gly Asp Val Glu Asp Val Thr Pro
Arg Pro1 5 10 15Gly Gly Cys Gln Ile Ser Gly Arg Gly Ala Arg Gly Cys
Asn Gly Ile 20 25 30Pro Gly Ala Ala Ala Trp Glu Ala Ala Leu Pro Arg
Arg Arg Pro Arg 35 40 45Arg His Pro Ser Val Asn Pro Arg Ser Arg Ala
Ala Gly Ser Pro Arg 50 55 60Thr Arg Gly Arg Arg Thr Glu Glu Arg Pro
Ser Gly Ser Arg Leu Gly65 70 75 80Asp Arg Gly Arg Gly Arg Ala Leu
Pro Gly Gly Arg Leu Gly Gly Arg 85 90 95Gly Arg Gly Arg Ala Pro Glu
Arg Val Gly Gly Arg Gly Arg Gly Arg 100 105 110Gly Thr Ala Ala Pro
Arg Ala Ala Pro Ala Ala Arg Gly Ser Arg Pro 115 120 125Gly Pro Ala
Gly Thr Met Ala Ala Gly Ser Ile Thr Thr Leu Pro Ala 130 135 140Leu
Pro Glu Asp Gly Gly Ser Gly Ala Phe Pro Pro Gly His Phe Lys145 150
155 160Asp Pro Lys Arg Leu Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg
Ile 165 170 175His Pro Asp Gly Arg Val Asp Gly Val Arg Glu Lys Ser
Asp Pro His 180 185 190Ile Lys Leu Gln Leu Gln Ala Glu Glu Arg Gly
Val Val Ser Ile Lys 195 200 205Gly Val Cys Ala Asn Arg Tyr Leu Ala
Met Lys Glu Asp Gly Arg Leu 210 215 220Leu Ala Ser Lys Cys Val Thr
Asp Glu Cys Phe Phe Phe Glu Arg Leu225 230 235 240Glu Ser Asn Asn
Tyr Asn Thr Tyr Arg Ser Arg Lys Tyr Thr Ser Trp 245 250 255Tyr Val
Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly Ser Lys Thr 260 265
270Gly Pro Gly Gln Lys Ala Ile Leu Phe Leu Pro Met Ser Ala Lys Ser
275 280 285226774DNAhomo sapiens 22cggccccaga aaacccgagc gagtaggggg
cggcgcgcag gagggaggag aactgggggc 60gcgggaggct ggtgggtgtg gggggtggag
atgtagaaga tgtgacgccg cggcccggcg 120ggtgccagat tagcggacgc
ggtgcccgcg gttgcaacgg gatcccgggc gctgcagctt 180gggaggcggc
tctccccagg cggcgtccgc ggagacaccc atccgtgaac cccaggtccc
240gggccgccgg ctcgccgcgc accaggggcc ggcggacaga agagcggccg
agcggctcga 300ggctggggga ccgcgggcgc ggccgcgcgc tgccgggcgg
gaggctgggg ggccggggcc 360ggggccgtgc cccggagcgg gtcggaggcc
ggggccgggg ccgggggacg gcggctcccc 420gcgcggctcc agcggctcgg
ggatcccggc cgggccccgc agggaccatg gcagccggga 480gcatcaccac
gctgcccgcc ttgcccgagg atggcggcag cggcgccttc ccgcccggcc
540acttcaagga ccccaagcgg ctgtactgca aaaacggggg cttcttcctg
cgcatccacc 600ccgacggccg agttgacggg gtccgggaga agagcgaccc
tcacatcaag ctacaacttc 660aagcagaaga gagaggagtt gtgtctatca
aaggagtgtg tgctaaccgt tacctggcta 720tgaaggaaga tggaagatta
ctggcttcta aatgtgttac ggatgagtgt ttcttttttg 780aacgattgga
atctaataac tacaatactt accggtcaag gaaatacacc agttggtatg
840tggcactgaa acgaactggg cagtataaac ttggatccaa aacaggacct
gggcagaaag 900ctatactttt tcttccaatg tctgctaaga gctgatttta
atggccacat ctaatctcat 960ttcacatgaa agaagaagta tattttagaa
atttgttaat gagagtaaaa gaaaataaat 1020gtgtatagct cagtttggat
aattggtcaa acaatttttt atccagtagt aaaatatgta 1080accattgtcc
cagtaaagaa aaataacaaa agttgtaaaa tgtatattct cccttttata
1140ttgcatctgc tgttacccag tgaagcttac ctagagcaat gatctttttc
acgcatttgc 1200tttattcgaa aagaggcttt taaaatgtgc atgtttagaa
acaaaatttc ttcatggaaa 1260tcatatacat tagaaaatca cagtcagatg
tttaatcaat ccaaaatgtc cactatttct 1320tatgtcattc gttagtctac
atgtttctaa acatataaat gtgaatttaa tcaattcctt 1380tcatagtttt
ataattctct ggcagttcct tatgatagag tttataaaac agtcctgtgt
1440aaactgctgg aagttcttcc acagtcaggt caattttgtc aaacccttct
ctgtacccat 1500acagcagcag cctagcaact ctgctggtga tgggagttgt
attttcagtc ttcgccaggt 1560cattgagatc catccactca catcttaagc
attcttcctg gcaaaaattt atggtgaatg 1620aatatggctt taggcggcag
atgatataca tatctgactt cccaaaagct ccaggatttg 1680tgtgctgttg
ccgaatactc aggacggacc tgaattctga ttttatacca gtctcttcaa
1740aaacttctcg aaccgctgtg tctcctacgt aaaaaaagag atgtacaaat
caataataat 1800tacactttta
gaaactgtat catcaaagat tttcagttaa agtagcatta tgtaaaggct
1860caaaacatta ccctaacaaa gtaaagtttt caatacaaat tctttgcctt
gtggatatca 1920agaaatccca aaatattttc ttaccactgt aaattcaaga
agcttttgaa atgctgaata 1980tttctttggc tgctacttgg aggcttatct
acctgtacat ttttggggtc agctcttttt 2040aacttcttgc tgctcttttt
cccaaaaggt aaaaatatag attgaaaagt taaaacattt 2100tgcatggctg
cagttccttt gtttcttgag ataagattcc aaagaactta gattcatttc
2160ttcaacaccg aaatgctgga ggtgtttgat cagttttcaa gaaacttgga
atataaataa 2220ttttataatt caacaaaggt tttcacattt tataaggttg
atttttcaat taaatgcaaa 2280tttgtgtggc aggattttta ttgccattaa
catatttttg tggctgcttt ttctacacat 2340ccagatggtc cctctaactg
ggctttctct aattttgtga tgttctgtca ttgtctccca 2400aagtatttag
gagaagccct ttaaaaagct gccttcctct accactttgc tggaaagctt
2460cacaattgtc acagacaaag atttttgttc caatactcgt tttgcctcta
tttttcttgt 2520ttgtcaaata gtaaatgata tttgcccttg cagtaattct
actggtgaaa aacatgcaaa 2580gaagaggaag tcacagaaac atgtctcaat
tcccatgtgc tgtgactgta gactgtctta 2640ccatagactg tcttacccat
cccctggata tgctcttgtt ttttccctct aatagctatg 2700gaaagatgca
tagaaagagt ataatgtttt aaaacataag gcattcgtct gccatttttc
2760aattacatgc tgacttccct tacaattgag atttgcccat aggttaaaca
tggttagaaa 2820caactgaaag cataaaagaa aaatctaggc cgggtgcagt
ggctcatgcc tatattccct 2880gcactttggg aggccaaagc aggaggatcg
cttgagccca ggagttcaag accaacctgg 2940tgaaaccccg tctctacaaa
aaaacacaaa aaatagccag gcatggtggc gtgtacatgt 3000ggtctcagat
acttgggagg ctgaggtggg agggttgatc acttgaggct gagaggtcaa
3060ggttgcagtg agccataatc gtgccactgc agtccagcct aggcaacaga
gtgagacttt 3120gtctcaaaaa aagagaaatt ttccttaata agaaaagtaa
tttttactct gatgtgcaat 3180acatttgtta ttaaatttat tatttaagat
ggtagcacta gtcttaaatt gtataaaata 3240tcccctaaca tgtttaaatg
tccattttta ttcattatgc tttgaaaaat aattatgggg 3300aaatacatgt
ttgttattaa atttattatt aaagatagta gcactagtct taaatttgat
3360ataacatctc ctaacttgtt taaatgtcca tttttattct ttatgtttga
aaataaatta 3420tggggatcct atttagctct tagtaccact aatcaaaagt
tcggcatgta gctcatgatc 3480tatgctgttt ctatgtcgtg gaagcaccgg
atgggggtag tgagcaaatc tgccctgctc 3540agcagtcacc atagcagctg
actgaaaatc agcactgcct gagtagtttt gatcagttta 3600acttgaatca
ctaactgact gaaaattgaa tgggcaaata agtgcttttg tctccagagt
3660atgcgggaga cccttccacc tcaagatgga tatttcttcc ccaaggattt
caagatgaat 3720tgaaattttt aatcaagata gtgtgcttta ttctgttgta
ttttttatta ttttaatata 3780ctgtaagcca aactgaaata acatttgctg
ttttataggt ttgaagaaca taggaaaaac 3840taagaggttt tgtttttatt
tttgctgatg aagagatatg tttaaatatg ttgtattgtt 3900ttgtttagtt
acaggacaat aatgaaatgg agtttatatt tgttatttct attttgttat
3960atttaataat agaattagat tgaaataaaa tataatggga aataatctgc
agaatgtggg 4020ttttcctggt gtttccctct gactctagtg cactgatgat
ctctgataag gctcagctgc 4080tttatagttc tctggctaat gcagcagata
ctcttcctgc cagtggtaat acgatttttt 4140aagaaggcag tttgtcaatt
ttaatcttgt ggataccttt atactcttag ggtattattt 4200tatacaaaag
ccttgaggat tgcattctat tttctatatg accctcttga tatttaaaaa
4260acactatgga taacaattct tcatttacct agtattatga aagaatgaag
gagttcaaac 4320aaatgtgttt cccagttaac tagggtttac tgtttgagcc
aatataaatg tttaactgtt 4380tgtgatggca gtattcctaa agtacattgc
atgttttcct aaatacagag tttaaataat 4440ttcagtaatt cttagatgat
tcagcttcat cattaagaat atcttttgtt ttatgttgag 4500ttagaaatgc
cttcatatag acatagtctt tcagacctct actgtcagtt ttcatttcta
4560gctgctttca gggttttatg aattttcagg caaagcttta atttatacta
agcttaggaa 4620gtatggctaa tgccaacggc agtttttttc ttcttaattc
cacatgactg aggcatatat 4680gatctctggg taggtgagtt gttgtgacaa
ccacaagcac tttttttttt tttaaagaaa 4740aaaaggtagt gaatttttaa
tcatctggac tttaagaagg attctggagt atacttaggc 4800ctgaaattat
atatatttgg cttggaaatg tgtttttctt caattacatc tacaagtaag
4860tacagctgaa attcagagga cccataagag ttcacatgaa aaaaatcaat
ttatttgaaa 4920aggcaagatg caggagagag gaagccttgc aaacctgcag
actgcttttt gcccaatata 4980gattgggtaa ggctgcaaaa cataagctta
attagctcac atgctctgct ctcacgtggc 5040accagtggat agtgtgagag
aattaggctg tagaacaaat ggccttctct ttcagcattc 5100acaccactac
aaaatcatct tttatatcaa cagaagaata agcataaact aagcaaaagg
5160tcaataagta cctgaaacca agattggcta gagatatatc ttaatgcaat
ccattttctg 5220atggattgtt acgagttggc tatataatgt atgtatggta
ttttgatttg tgtaaaagtt 5280ttaaaaatca agctttaagt acatggacat
ttttaaataa aatatttaaa gacaatttag 5340aaaattgcct taatatcatt
gttggctaaa tagaataggg gacatgcata ttaaggaaaa 5400ggtcatggag
aaataatatt ggtatcaaac aaatacattg atttgtcatg atacacattg
5460aatttgatcc aatagtttaa ggaataggta ggaaaatttg gtttctattt
ttcgatttcc 5520tgtaaatcag tgacataaat aattcttagc ttattttata
tttccttgtc ttaaatactg 5580agctcagtaa gttgtgttag gggattattt
ctcagttgag actttcttat atgacatttt 5640actatgtttt gacttcctga
ctattaaaaa taaatagtag atacaatttt cataaagtga 5700agaattatat
aatcactgct ttataactga ctttattata tttatttcaa agttcattta
5760aaggctacta ttcatcctct gtgatggaat ggtcaggaat ttgttttctc
atagtttaat 5820tccaacaaca atattagtcg tatccaaaat aacctttaat
gctaaacttt actgatgtat 5880atccaaagct tctcattttc agacagatta
atccagaagc agtcataaac agaagaatag 5940gtggtatgtt cctaatgata
ttatttctac taatggaata aactgtaata ttagaaatta 6000tgctgctaat
tatatcagct ctgaggtaat ttctgaaatg ttcagactca gtcggaacaa
6060attggaaaat ttaaattttt attcttagct ataaagcaag aaagtaaaca
cattaatttc 6120ctcaacattt ttaagccaat taaaaatata aaagatacac
accaatatct tcttcaggct 6180ctgacaggcc tcctggaaac ttccacatat
ttttcaactg cagtataaag tcagaaaata 6240aagttaacat aactttcact
aacacacaca tatgtagatt tcacaaaatc cacctataat 6300tggtcaaagt
ggttgagaat atatttttta gtaattgcat gcaaaatttt tctagcttcc
6360atcctttctc cctcgtttct tctttttttg ggggagctgg taactgatga
aatcttttcc 6420caccttttct cttcaggaaa tataagtggt tttgtttggt
taacgtgata cattctgtat 6480gaatgaaaca ttggagggaa acatctactg
aatttctgta atttaaaata ttttgctgct 6540agttaactat gaacagatag
aagaatctta cagatgctgc tataaataag tagaaaatat 6600aaatttcatc
actaaaatat gctattttaa aatctatttc ctatattgta tttctaatca
6660gatgtattac tcttattatt tctattgtat gtgttaatga ttttatgtaa
aaatgtaatt 6720gcttttcatg agtagtatga ataaaattga ttagtttgtg
ttttcttgtc tccc 6774
* * * * *
References